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ABSTRACT 
 
Drug-induced liver injury (DILI) is a major health and economic 
problem and the leading cause of hepatic dysfunction, drug failure 
during clinical testing and post-market withdrawal of approved drugs. 
Pre-clinical testing should be able to detect potential hepatotoxins early 
in the drug development process in order to minimize health risks and 
financial losses. Several liver-derived in vitro models have been 
developed to be used in pharmacology and toxicology research to 
understand the mechanism of DILI and to evaluate potential 
hepatotoxicity of new chemical entities. Although they fail to reproduce 
the complexity of a whole organ, their low cost, high reproducibility, and 
the possibility of a human origin make them a good complement to 
traditional in vivo tests. Monoparametric strategies used in in vitro 
toxicity testing have been proved insufficient to predict human DILI. The 
application of the new 'omics' technologies allows the simultaneous 
determination of multiple parameters in a single biological sample and 
represents a more sensitive, comprehensive and powerful tool for the 
study of hepatotoxic events. Among them, metabolomics measures the 
downstream products of the 'omics cascade', thus representing a closer 
approximation to phenotype than the study of genes, transcripts or 
proteins.  
Based on the previous evidences we decided to evaluate whether 
metabolomics, in combination with in vitro cellular models and in vivo 
animal models, could be a useful tool for the disvovery of characteristic 
patterns associated to specific mechanisms of DILI.  
First, we defined a suitable framework that, thanks to a careful design 
of sample analysis and the incorporation of different internal standards 
and quality controls, allowed us to perform metabolomic analysis within 
a quality assurance environment. Then, uni- and multivariate statistical 
tools were selected in order to be able to identify mechanism-specific 
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alterations and to develop predictive/classificatory models. Finally, we 
optimized a sample processing and analysis strategy that allowed the 
differential extraction and detection of a broad range of metabolites 
ranging from highly polar to highly apolar ones thus maximizing 
metabolome coverage. 
The application of the developed tools to HepG2 cells exposed to 
subcytotoxic concentrations of model hepatotoxins acting through 
different mechanisms of toxicity allowed us to identify specific 
metabolomic patterns associated to each of the mechanisms of interest. 
Moreover, the application of multivariate data analysis techniques 
allowed the development of predictive/classificatory models able not 
only to distinguish between toxic and non-toxic compounds, but also to 
specifically classify drugs according to their mechanism of 
hepatotoxicity. The proposed strategy could be of interest for the 
identification of early markers of hepatotoxicy and for the prediction of 
mechanism of hepatotoxicity of new drug entities. 
The usefulness of the analytical strategy was also confirmed by its 
application with in vivo models using both medaka (Oryzias latipes) and 
rat. Studies in medaka revealed common liver altered pathways with 
HepG2 cells, suggesting medaka as a useful model for human 
hepatotoxicity prediction. Toxicity studies in rats allowed us to identify 
common serum markers of hepatotoxicity which could be used as 
biomarkers in pre-clinical studies or even extrapolated to humans. 
 
  
 
 
 
 
 
 
 
"Nothing is hidden so much that it 
wouldn’t be revealed through its fruit" 
 
Paracelsus 
 
 
 
“Data does not equal information; 
information does not equal knowledge; 
and, most importantly of all, 
knowledge does not equal wisdom. 
We have oceans of data, 
rivers of information, 
small puddles of knowledge, 
and the odd drop of wisdom.” 
 
Prof. Henry Nix 
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1.1 General aspects of liver structure and function 
 
The liver plays an essential role in a variety of functions to maintain 
homeostasis in the organism. This organ is able to synthesize, degrade 
or storage a wide variety of molecules in a regulated way. It is involved in 
the metabolism of substances as different as carbohydrates, lipids, 
amino acids, bile acids (BAs), vitamins, steroids or iron. The liver also 
produces most of the circulating plasma proteins, including the most 
abundant component, albumin. Moreover, the liver is the center organ in 
the detoxification of xenobiotics (1-3). 
The liver is the largest solid organ in the human body (from 1300 to 
1700 g in adults) and it is located in the abdominal cavity. Blood supply 
to the liver is performed by two different blood vessels: i) the hepatic 
portal vein, which represents about 80% of the hepatic blood supply, 
carries blood that, having already circulated through the gut, the 
pancreas and the spleen, is reduced in oxygen and enriched in nutrients, 
xenobiotics, hormones and growth factors; and ii) the hepatic artery, 
which supplies oxygen-rich blood from the aorta artery. The unusual 
pattern of blood supply in the liver is essential to understand its role in 
both nutrient and xenobiotic metabolism (2, 4). Two different efferent 
vessels coexist in the liver. On one hand, blood is drained into the 
central veins and leaves the liver through a number of hepatic veins, 
which enter the inferior vena cava. On the other hand, the bile produced 
in the liver is collected in bile canaliculi, which merge to form bile ducts. 
The basic structural unit of the liver is the hepatic lobule (Figure 
1.1.A). It has the shape of a polygon, usually a hexagon. Each corner of 
the polygonal hepatic lobule is occupied by a portal triad, consisting of 
the hepatic artery, bile duct and portal vein. At the center of each hepatic 
lobule is located the central vein. The area defined by this hexagon is 
occupied by hepatocyte plates that adopt a radial distribution from the 
central vein to the perimeter of the lobule. Hepatic plates or cords are 
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generally one hepatocyte thick and are separated from one another by 
the hepatic sinusoids (the capillaries of the liver) which are lined by 
sinusoidal endothelium (3, 5). 
The functional unit of the liver, known as the acinus, is delimited by 
the elliptical or diamond-shaped space that comprises two adjacent 
central veins, connected by the long axis, and to adjacent portal triads, 
connected by the short axis (Figure 1.1.A) (5, 6). Two different fluid 
flows take place along this axis. Blood enters the liver from the portal 
veins and hepatic arteries at the portal triads, flows through the 
sinusoids and exits from the central vein. On the other hand, bile flows 
in the opposite direction, thus going through the canaliculi along the 
hepatocyte plates to the bile ducts situated in the portal triad (3, 5). 
 
 
 
Figure 1.1. A) Diagram of the basic hepatic lobule and the acinus substructure. 
Hepatic lobules have hexagonal shape with the portal triads - formed by the 
hepatic artery, the hepatic portal vein and the bile duct - located at the corners 
and the central vein located at the center. B) Diagram illustrating the basic 
structure and composition of liver sinusoids. Liver sinusoids are lined by 
fenestrated liver sinusoidal endothelial cells (LSEC). Hepatocytes are disposed 
forming hepatic cords, with the basolateral membranes exposed to blood 
components through the space of Disse (SD), while the lateral membrane is in 
contact with adjacent hepatocytes attached by tight junctions and forms the bile 
canaliculus. Hepatic stellate cells (HSC) are located in the SD with numerous 
plasmatic extensions that allow them to be in close contact with other HSC as 
well with hepatocytes and LSEC. Finally, Kupffer cells (KC) are attached to the 
luminal surface of LSEC, in a strategic location that permits its continuous access 
to afferent blood. Figure 1.1.A adapted from reference (5). Figure 1.1.B adapted 
from reference (7).  
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1.2 Cells of the liver 
 
The liver is comprised by a rich variety of cells. The hepatocytes, the 
most abundant cell type, carry out the majority of the functions 
associated with the liver (5). They are responsible of the synthesis and 
excretion of plasma proteins, coagulation factors, lipoproteins and acute 
phase reactants. Moreover, they control the homeostasis of 
glucose/glycogen, triacylglycerides (TG), cholesterol, BAs, vitamins A and 
D, and metabolize amino acids, metals, heme, bilirubin, and xenobiotics 
(1). Nevertheless, the hepatocytes alone are not competent to perform all 
the hepatic functions, and the cohort of non-parenchymal cells are 
essential to the maintenance of the liver structure and are important 
contributors to various roles that support and regulate hepatic growth 
and function. Major liver non-parenchymal cells are bile duct epithelial 
cells (or cholangiocytes), liver sinusoidal endothelial cells (LSEC), hepatic 
stellate cells (HSC), Kupffer cells (KC), and hepatic progenitor cells (5, 8) 
(Figure 1.1.B). The liver also contains a large and diverse population of 
residing inmunocytes that in addition to KC and LSEC are essential 
components of the liver-centered immune system (2, 5, 9). 
Hepatocytes are large cells and represent about 60% of the total cell 
population and about 80% of the liver mass/volume (2, 3, 5, 8). 
Hepatocytes possess one or more nuclei, as a result of mitotic division of 
the nucleus without cytokinesis, with prominent nucleoli, indicative of an 
active transcriptional activity. As corresponds to their numerous and 
varied metabolic, storage and secretory functions, hepatocytes contain 
abundant mitochondria, lysosomes, peroxisomes and Golgi complexes, 
mainly adjacent to the bile canaliculi. The cytoplasm is rich in rough 
endoplasmic reticulum, indicative of the hepatocyte's secretory nature, 
and smooth endoplasmic reticulum, where many of the enzymes 
involved in phase I and phase II biotransformation of endogenous and 
exogenous compounds are located (2, 5). 
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Hepatocytes are highly polarized cuboidal-shaped cells. Due to the 
particular configuration of cells in the hepatic cords, each hepatocyte is 
adjacent to two neighbor hepatocytes and possess two basolateral 
domains that interface with the sinusoids on opposite sides of the cell 
plates (5, 10). The basolateral domain of hepatocytes is formed by the 
sinusoidal and lateral plasma membrane. At the sinusoidal side, 
hepatocytes are directly in contact with most of the blood substances 
thanks to the fenestrations present in the membranes of the LSEC. At the 
lateral membrane, neighbor hepatocytes are connected through gap 
junctions, thus allowing the communication of adjacent hepatocytes by 
transfer of small molecules (2, 11). The apical domain of the hepatocyte 
represents a small portion of the plasma membrane and lies between 
cells, set off from the basolateral plasma membrane by tight junctions 
and forming the bile canaliculus (10). These membrane domains show 
structural, compositional and functional differences and are essential for 
the role of hepatocytes in the uptake, metabolism and biliary elimination 
of both endogenous and exogenous substrates (5). In general, the 
basolateral plasma membrane has transporters that remove substances 
(e.g. BAs, drugs) from the portal venous blood by facilitated diffusion 
along a concentration gradient, whereas the apical plasma membrane 
has transporters that pump substances against a steep concentration 
gradient from the cell interior into the bile canaliculus (10).  
The liver architecture, cell composition and function are essential to 
understand its involvement in drug metabolism and toxicity. In 
particular, hepatocytes are the major players in biotransformation 
processes (phase I and II reactions and drug transport) and their function 
strongly impacts on the pharmacokinetic, side effects and toxicity of 
drugs. Therefore, the development of in vitro approaches for drug 
metabolism and hepatotoxicity studies is focused on the imitation of the 
functional status and disposition of hepatocytes, and other components, 
in the intact liver.  
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1.3 Drug-induced liver injury 
 
The liver is an organ specially prone to suffer toxic damage due to its 
particular anatomic location and to its involvement in drug metabolism 
and detoxification. As described above, the liver is functionally 
interposed between the site of absorption of exogenous compounds and 
the systemic circulation. Thus, through its blood supply from the portal 
vein, the liver is directly exposed to all ingested substances that are 
present in the portal blood (12-14). On the other hand, the liver is 
quantitatively and qualitatively the most important site of drug 
metabolism due to the expression in the hepatocytes of phase I and 
phase II metabolizing enzymes and drug transporters. Thus the liver, 
along with drug-metabolizing enzymes and drug transporters expressed 
in the intestinal mucosa, provides an effective barrier that prevents 
xenobiotics from entering the systemic circulation (15). However, the 
high exposure of the liver to xenobiotics, its involvement in their 
metabolism and the possibility of formation of drug-derived reactive 
species make the liver an organ specially sensitive to drug-induced 
damage (16, 17). 
Drug-induced liver injury (DILI) is a major health problem that 
challenges pharmaceutical companies, regulatory agencies and health 
care professionals and institutions (18). DILI is the most frequent basis 
for drug-related regulatory actions (19), including termination of clinical 
drug trials, failure to obtain US Food and Drug Administration (FDA) or 
European Medicines Agency (EMA) approval, restriction of use, as well as 
the major reason for post-market withdrawal of drugs (16, 20). The 
incidence of DILI in the general population has been estimated to be 10-
15 cases per 100000 patients year (21), being the responsible of one 
third to one half of cases of acute liver failure and 15% of associated liver 
transplantations (20, 22, 23). DILI mimics all forms of acute and chronic 
hepatobiliary diseases and the most frequent clinical manifestations are 
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hepatocellular damage, cholestasis, mixed hepatocellular and cholestatic 
injury, and steatosis (17). 
A major concern regarding DILI is the failure of the drug development 
process to detect potentially hepatotoxic drugs. Safety tests during drug 
development involve pre-clinical and clinical phases. Pre-clinical testing is 
based on toxicity assessments in in vitro models and in experimental 
animals. Unfortunately, these pre-clinical studies are not very predictive 
of human DILI. During clinical trials, the drug is administered to an 
increasing number of patients from phase I to phase III to reach 
approximately 3000 patients in a phase III study (24). Two of the main 
reasons leading to misdetection of DILI before drug approval are the lack 
of specific and reliable diagnostic markers or tests to verify an episode 
of DILI and the underpowered nature of clinical trials due to the limited 
number of patients involved (16). Liver function/damage monitoring 
during clinical trials includes measurement of serum liver enzyme levels. 
The discontinuation of testing is only advised in the case of finding 
frequent or severe increases in aminotransferase levels (greater than 
eight times the upper limit of normal) or accompanying increases in 
bilirubin without initial findings of cholestasis (25). In practice, it is very 
unlikely to detect those rare reactions before drug approval and most 
DILI appear post-approval. Once marketed, drugs are administered to a 
much larger and diverse group of patients than those included in 
controlled pre-approval trials, including patients at elevated risks for 
adverse effects (elderly persons, children, pregnant women, and patients 
with HIV infection or treated with multiple drugs) (13). 
DILI is commonly classified into intrinsic versus idiosyncratic 
hepatotoxicity. Intrinsic hepatotoxicity is regarded as dose-dependent 
and predictable above an approximate threshold dose, thus causing a 
reproducible liver damage that is usually detected during pre-clinical 
safety testing. Idiosyncratic toxicity occurs without obvious dose-
dependency, with a delayed onset and the participation of innate and 
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adaptive immune responses is required. Its development is strongly 
affected by the mix of unique characteristics - phase I and II drug-
metabolizing activities, transporters or immune factors - specific to an 
individual (14, 26-28).  
DILI progression involves complex multi-step mechanisms that are 
initiated by a chemical insult to cells in the liver (27). Drug exposure is 
determined by the dose and handling of the drug by the liver (phase I, II, 
III drug metabolism) (24). In phase I metabolic reactions, drugs are 
rendered more hydrophilic, primarily by oxidative pathways through the 
cytochrome P-450 (CYP) enzyme system. Phase II usually involves 
conjugation of the parent drug or its metabolites to glucuronide, sulfate 
or glutathione (GSH). Finally, the drug and/or its hydrophilic products are 
exported into plasma or bile by transport proteins located on the 
hepatocyte membrane (phase III) (13, 27). The metabolites obtained 
through biotransformation may be non-toxic, in which case drug 
metabolism and excretion is a detoxifying process, or may mediate 
toxicity, typically through the formation of chemically reactive species 
(27). Thus, the parent drug, or more often, reactive metabolites may 
cause GSH depletion, covalent binding to proteins, lipids or nucleic acids, 
induction of oxidative stress (OS), lipid peroxidation, or inhibition of the 
activity of biliary efflux transporters thus initiating the damage process 
(14, 16, 17, 27). All those have direct effects on organelles such as 
mitochondria, the endoplasmic reticulum, the cytoskeleton, or the 
nucleus. They may also have an indirect influence through the activation 
or inhibition of signaling kinases or transcription factors that may 
contribute to the protection against the damage or to its progression 
(17). The consequences of the amplification and progression of toxicity 
include hepatocellular damage and the initiation of immunological 
reactions. Innate immunity activation and inflammation seems to be a 
general feature in DILI, however some drugs have the ability to provoke 
the activation of the adaptive immune system (16, 27). The balance 
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between intracellular and cell-to-cell signaling determines the final extent 
of the damage, thus leading to an adaptation to the insult resulting in a 
mild but manageable damage or accelerating the damage leading to 
massive cell death (either through apoptosis or necrosis) and severe liver 
damage (14, 24). Figure 1.2 summarizes the events and inputs 
determining DILI initiation, development and resolution. Although the 
focus of hepatotoxicity is mainly on hepatocytes, non-parenchymal cells 
such as cholangiocytes, LSEC or KC can be involved in the process of 
drug-induced hepatotoxicity. Moreover, some drugs can induce 
cholestasis by impairing bile secretion or causing obstruction of extra-
hepatic bile ducts (26). 
 
 
 
Figure 1.2. Schematic representation of the different steps involved in the 
initiation, development and resolution of drug-induced liver damage. Drug 
exposure in the liver is determined by the dose and phase I and II drug 
metabolizing reactions. Drug metabolism is considered to be a detoxifying 
process, however, it may result in the formation of reactive species. The parent 
drug, or more often, the reactive metabolites formed may cause an initial 
damage that sets in motion a series of intracellular and extracellular processes. 
The balance between protective versus injurious pathways determines the extent 
of the hepatocellular damage. Finally, the severity, duration and progression of 
the damage versus the capacity of the liver to regenerate damaged zones will 
determine the extent of the injury. Figure adapted from references (14, 24).  
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1.4 Mechanism-based classification of DILI 
 
Several molecular mechanisms are primarily involved in hepatocyte 
injury induced by the drug itself or by any of its metabolites, and the 
manner in which the intracellular organelles, macromolecules and 
functions are affected defines the pattern of liver disease (13, 14, 24, 
29). Several mechanism-based classifications of DILI have been proposed 
according to different criteria (12, 13, 18, 24, 28-30). We have adopted 
the classification proposed by Gómez-Lechón et al (29) in which, 
independently of the initial target causing the damage, mechanisms of 
DILI are grouped according to the initial clinical manifestation provoked 
by the drug. Thus, the following mechanisms will be described below: i) 
Steatosis; ii) Phospolipidosis; iii) Cholestasis; and iv) Oxidative stress  
 
1.4.1 Steatosis 
 
Steatosis, or fatty liver disease, is characterized by an increased 
deposition of lipids, mainly TG, in hepatocytes above 5% in weight (31). 
Accumulation of TG in hepatocytes leads to micro- and macro-vesicular 
steatosis and balloon-cell degeneration (32). Steatosis is a complex 
process that has been associated to nutritional factors, genetic defects 
and drug intake. Impairment of β-oxidation leading to the accumulation 
of fatty acids (FA) as TG in the cytoplasm of hepatocytes is one of the 
major mechanisms involved in drug-induced steatosis (32, 33). Micro-
vesicular steatosis is usually due to a severe impairment of β-oxidation 
and is characterized by the presence of multiple small lipid droplets 
within the cytoplasm of hepatocytes. It is an acute condition that may be 
associated with liver failure, coma and death due to the secondary 
damages associated to lipid peroxidation and energy depletion (32-35). 
On the other hand, macro-vesicular steatosis is due to milder and 
prolonged forms of mitochondrial dysfunction. In this case fat 
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accumulates in form of a single large droplet. Although it is considered a 
benign condition it can progress to liver fibrosis or cirrhosis after several 
years (31, 32). 
Multiple drug-induced alterations can cause steatosis (29, 32): 1) 
Direct alteration of mitochondrial FA oxidation by the inhibition of any β-
oxidation enzyme; 2) Indirect impairment of β-oxidation by sequestration 
of cofactors L-carnitine or coenzyme A; 3) Inhibition of carnitine 
palmitoyl transferase-1 altering FA transport across the mitochondrial 
membrane; 4) Inhibition of long-chain acyl-CoA synthase, thus impairing 
the mitochondrial entry of long-chain FA (LCFA); 5) Increased TG 
synthesis with or without lowered cholesterol and/or phospholipid (PL) 
synthesis; 6) Reduction in lipid export by the inhibition of microsomal 
triglyceride transfer protein activity; 7) Induction of mitochondrial 
permeability transition pore opening; 8) Dissipation of the mitochondrial 
transmembrane potential; 9) Direct impairment of mitochondrial 
respiratory chain, which can secondarily inhibit mitochondrial β-oxidation 
and enhance reactive oxygen species (ROS) formation; 10) Mitochondrial 
DNA (mtDNA) depletion, which can reduce the synthesis of mtDNA-
encoded proteins, impair mitochondrial respiratory chain and increase 
ROS generation; 11) Increased de novo FA synthesis.  
 
1.4.2 Phospholipidosis 
 
Phospholipidosis is a lipid storage disorder characterized by the 
excessive accumulation of PL within cells and by the formation of 
membrane-bound cytosolic inclusions with a lamellar morphology 
(laminar bodies), predominantly of a lysosomal origin (32, 36). In toxicity 
studies, phospholipidosis has been shown to occur in various tissues, 
being the liver one of the most common targets. Most drugs inducing 
phospholipidosis belong to a group of compounds known as cationic 
amphiphilic drugs (CADs). These compounds contain a hydrophobic 
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region (usually a ring structure) and a hydrophilic side chain (a primary 
or substituted nitrogen group) that is positively charged at a 
physiological pH. This chemical structure allows a direct binding of the 
molecule with PL (32). To date, it is not clear which are the biological 
effects caused by PL accumulation, however phospholipidosis is usually 
associated to a high intrahepatic accumulation of the causing drug (or a 
metabolite), which can produce potential toxicity after chronic exposure 
(29, 32, 37). Regulatory agencies generally consider phospholipidosis an 
adverse effect and the development of a drug can be delayed or 
terminated when pre-clinical studies in animals reveal PL accumulation in 
certain organs. 
Different mechanisms have been proposed to explain the development 
of drug-induced phospholipidosis (29, 32): 1) Direct inhibition of 
lysosomal phospholipase; 2) Decreased degradation of PL due to the 
formation of degradation-resistant drug-PL complexes; 3) Decreased 
lysosomal enzyme transport; and 4) Increased synthesis of PL.  
 
1.4.3 Cholestasis  
 
Drug-induced cholestasis is characterized by impaired bile flow, which 
leads to the accumulation of BAs in the liver and the subsequent toxicity 
to hepatocytes (28, 29). BAs are major components of bile formed from 
cholesterol through various enzymatic reactions in hepatocytes. BAs act 
as detergents involved in the process of solubilization and absorption of 
dietary fats and fat soluble vitamins and they also facilitate the excretion 
of bile pigments, cholesterol and other hydrophobic molecules (38). On 
the other hand, BAs are regulatory molecules able to control not only 
their own homeostasis but also FA, lipoprotein, glucose, and energy 
metabolism (39-41) by binding specific receptors (e.g., PXR, VDR or 
TGR5) and activating several cell signaling pathways (i.e., JNK, ERK, or 
AKT) (39, 40, 42-44). Abnormal accumulation of BAs in the hepatocytes 
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not only induces several changes in gene expression, but due to its 
detergent nature it also induces damages on cellular membranes, 
mitochondrial dysfunction and ultimately necrosis and apoptosis (38, 45, 
46). It has been shown that the deleterious toxic effects of BAs depend 
on the profile of accumulated BAs, with higher toxic effects associated to 
more hydrophobic BAs (47). Thus, the rank order of BA cytotoxicity is: 
lithocholic acid (LCA) > chenodeoxycholic acid (CDCA) , deoxycholic acid 
(DCA) > cholic acid (CA) (46). 
At the hepatocyte level, cholestasis is mainly produced through 
damage to the structure and/or function of bile canaliculi, thus altering 
bile flow (29). Several transport proteins have been identified as potential 
loci for drug-induced cholestasis. These include the basolateral uptake 
transporters (NTCP and OATPs), canalicular efflux transporters (BSEP, 
MRP2, and MDR3), and basolateral efflux transporters (MRP3 and MRP4) 
(38, 45, 48). Events leading to drug-induced cholestasis include (13, 29, 
38): 1) Direct inhibition of transport proteins; 2) Altered localization of 
transport proteins; 3) Altered transport protein expression; 4) Disruption 
of actin filaments in the proximities of the canaliculus; and 5) Transport 
protein malfunction due to energy supply disruption.  
 
1.4.4 Oxidative Stress 
 
OS is produced when the generation of oxidant species (reactive 
molecules containing oxygen or nitrogen) exceeds the antioxidant 
protection of the cells (antioxidant enzymes or non-enzymatic 
scavengers/quenchers). This situation is produced by different physio-
pathological conditions, including exposure to drugs able to induce an 
excessive generation of ROS or a depletion of GSH pool. The 
mitochondrion is one of the main sources of ROS within the cell, where 
superoxide radical is produced during oxidative phosphorylation. In 
addition, ROS can be generated by CYP-dependent microsomal 
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oxidations of drugs and other xenobiotics. GSH is a strong nucleophillic 
thiol that protects cells against damage caused by a variety of 
electrophiles (free radicals, ROS, etc.). In addition, it serves as an 
essential co-factor of GSH peroxidase which removes hydroperoxides 
formed during oxidative processes. Finally, GSH is involved in the 
conjugation and inactivation of the reactive metabolites produced by 
CYP-dependent oxidations (49). Enhanced ROS levels leading to GSH 
depletion and OS may cause a wide spectrum of oxidative damage to 
intracellular biomolecules (DNA, lipids and proteins), altering the 
structure and function of key cellular constituents that result in 
mutation, cell damage and cell death (14, 29, 50). 
OS is produced by compounds that are able to undergo repeated 
oxidation and reduction cycles within the cell, or by molecules 
containing oxygen atoms that can either produce free radicals or are 
chemically activated by them (49, 51). Drugs may induce OS through 
different mechanisms (29): 1) Excessive ROS generation during drug 
oxidations catalyzed by CYPs; 2) GSH depletion due to the formation of 
GSH adducts with reactive electrophilic metabolites; 3) GSH depletion 
due to the formation of GSH conjugated metabolites catalyzed by GSH 
transferases; 4) Direct or indirect impairment of mitochondrial electron 
chain; and 5) Redox cycling inducing molecules.  
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1.5 Experimental models for the study of hepatotoxicity 
 
As mentioned, DILI is a major health and economic problem and the 
hepatotoxicity is the main cause of safety problem leading to drug 
failure during clinical testing and after being launched to the market (16, 
20). Furthermore, the limitation in the number of patients exposed to the 
drug during clinical testing hampers the detection of very low incidence 
drug-related adverse reactions (13). Pre-clinical testing should be able to 
detect potential hepatotoxins early in the drug development process in 
order to minimize health risks and financial losses. One drawback 
related to hepatotoxicity prediction is the low concordance between 
humans and commonly used experimental animals (49, 52, 53). Species 
differences in drug metabolism, target molecules and pathophysiology 
are important factors that hamper the usefulness of animal models (49). 
As an alternative to in vivo experiments, several liver-derived in vitro 
models have been developed for use in safety pharmacology and 
toxicology research to understand the mechanisms of DILI and to 
evaluate potential hepatotoxicity of new chemical entities (49, 54). Major 
advantages of in vitro models are the highly controlled environmental 
conditions in which experiments are performed, the possibility of using 
material from a human origin, the possibility of performing high-
throughput experiments, its relative low cost in comparison with in vivo 
experiments and the reduction of the number of animals needed. 
Although in vitro approaches fail to reproduce the complexity of a whole 
organ, they are a good complement to traditional in vivo tests and may 
be useful in the prediction of toxicity in early stages of drug 
development (49).  
Primary culture of freshly isolated human hepatocytes is considered 
the gold standard in vitro model for the study of DILI (55). However, 
many other liver-based models have been used in hepatotoxicity 
assessment including: immortalized tumor-derived cell lines, hepatocyte-
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like cells (HLCs) derived from pluripotent stem cells and liver tissue 
preparations (slices, microsomes and S9 fractions) (49, 54). Table 1.1 
summarizes the advantages and disadvantages of the main experimental 
models. Detailed information about the characteristics of cultured 
hepatocytes and hepatoma cell lines, the most widely used liver-derived 
cell models, is provided below.  
 
1.5.1 Hepatocytes 
 
Among in vitro systems, cultured hepatocytes are recognized as the 
closest model to the in vivo situation (5, 49, 55). Hepatocytes cultured 
under the appropriate conditions retain most of differentiated liver-
specific functions (i.e. gluconeogenesis, glycogen metabolism, urea 
formation, plasma protein synthesis and secretion, lipid metabolism...) 
and drug metabolism (phase I and phase II enzymes) and transporters 
for limited period (5, 49, 55). Many different culture conditions (medium 
formulation, cell density, extracellular matrix components and 
configuration, co-culture with other cell types, dynamic culture systems) 
have been described for the in vitro use of hepatocytes and they strongly 
influence hepatocyte's viability and functionality (5, 49, 55).  
Isolated hepatocytes in suspension are the simplest culture system 
derived from hepatocytes. They allow to perform a complete set of 
functional analysis (viability, transport, drug-metabolism, excretion of 
plasma proteins...). However, its usefulness is very limited due to their 
very short-term viability (2-4 h) and the phenotypic changes induced by 
the loss of cell-cell and cell-matrix interactions (49, 55). 
2D culture systems are the most common way of culturing 
hepatocytes. They involve the culture of the hepatocytes over a coated 
dish, what extends hepatocyte viability and functionality up to a week 
thanks to the establishment of cell-cell and cell-matrix interactions. The 
main strengths of this model are its simplicity, the extended hepatocyte 
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viability and the possibility of detecting metabolism mediated 
hepatotoxicity. However, phase I and II drug-metabolizing enzymes 
activity decay with the time in culture (5, 49, 55). An alternative to the 
classic monolayer cultures, in which transport studies cannot be 
performed due to the loss of hepatocyte polarity, is the culture of the 
hepatocytes in the commonly named 'sandwich' configuration. It involves 
the culture of the hepatocytes between two layers of matrix, thus 
reconstructing the opposing sinusoidal facing domains of hepatic plates 
in vivo. Under these conditions the hepatocytes repolarize and 
reestablish bile canaliculi and the expression of functional transporters. 
Moreover, they are characterized by an improved functionality and 
similarity to in vivo response and an increased viability (up to some 
weeks) (5, 49, 55). 
 
1.5.2 Hepatoma cell lines 
 
Hepatoma cell lines constitute a simple, readily accessible and almost 
unlimited source of cells from a human liver origin (49). Besides their 
differences with hepatocytes in many functional aspects, especially with 
respect the levels of drug-metabolizing enzymes, they represent a very 
common in vitro model used in toxicological studies. Although many 
different human hepatic cell lines have been tested (i.e. HuH7, HepaRG, 
Fa2N-4...), HepG2 cell line is the most commonly used and best 
characterized one (5, 49). 
HepG2 cells are derived from a liver tissue sample of a donor with a 
well differentiated hepatocellular carcinoma (5). HepG2 are no 
tumorogenic cells with high proliferation rates and epithelial-like 
morphology and they show many differentiated hepatic functions: 
synthesis and secretion of plasma proteins, cholesterol and TG 
metabolism, lipoprotein metabolism and transport, BA synthesis, 
glycogen synthesis or insulin signaling (5, 56-58). The main inconvenient 
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of the use of HepG2 cells in toxicological studies is the reduced 
expression of several hepatic functions, especially those related to drug 
metabolism and transport. HepG2 cell line shows substantially lower 
levels of phase I and II biotransformation enzymes when compared to 
primary hepatocytes thus leading to a possible misdetection of 
metabolic-dependent toxicity for particular compounds (5, 49). An 
alternative to circumvent the low expression of drug-metabolizing 
enzymes in HepG2 cell line is their genetic engineering to achieve stable 
or transient expression of the desired genes. HepG2 cells stably 
expressing drug-metabolizing enzymes have been successfully 
generated. However, a major limitation of this strategy is that only one 
or two enzymes can be satisfactorily transfected to cells, thus limiting 
their application to the study of the contribution of a single enzyme in 
drug metabolism and related toxicity. On the other hand, transient 
expression has been achieved for multiple enzymes in a regulated 
manner, thus being able to customize enzyme expression to reproduce 
the desired activity pattern. However, transient expression is limited to a 
maximum of 24-72 h and yet the expression or function of other several 
genes/proteins involved in drug metabolism, clearance and toxicity 
cannot be restored with this strategy (59). Despite the limitations of the 
model, HepG2, by themselves or in combination with some strategy to 
upgrade their metabolic capacity, is the most used immortalized hepatic-
derived cell line for the prediction of toxicological adverse effects. As a 
result of this widespread use, exhaustive data on the effects of a huge 
number of compounds (model hepatotoxins, drugs, chemicals) on many 
parameters indicative of toxicity to HepG2 cells (viability, membrane 
integrity, cell proliferation, ATP level, etc.) are available in the literature 
(52, 60, 61). Moreover, recent transcriptomic, proteomic and cytomic 
studies have confirmed the potential value of HepG2 cells as in vitro 
model for toxicity screenings (52, 62-64). In summary, its unlimited 
availability, easy culture and handle conditions, complete 
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characterization and wide bibliographic documentation makes HepG2 a 
very interesting option in toxicological studies, at least as a first 
approximation to the problem.  
 
Table 1.1. In vitro models for hepatotoxicity studies.  
 
In Vitro Model Advantages Limitations 
Liver Slices 
- Preserved liver architecture 
- Hepatocyte heterogeneity 
- Presence of non-parenchymal 
cells 
- Preservation of hepatocyte 
bipolarity 
- High-resemblance to the in vivo 
phenotype  
- Possibility of histological 
examination 
- Limited viability and function 
- Scarce availability (fresh human 
liver) 
- High inter-donor variability 
- High intra-assay variability 
- Technically demanding 
Primary 
Cultured 
Hepatocytes 
- Easy to use 
- Expression of inducible 
biotransformation enzymes. 
- Correct function of transporters 
(depending on the culture 
conditions) 
- Reasonable resemblance to in 
vivo liver phenotype 
- Potential use for long-term 
studies 
- High versatility of culture 
conditions 
- Limited availability (human 
tissue) 
- Early phenotypic changes  
- Loss of drug-metabolizing 
activities 
- Inter-donor variability 
- High influence of culture 
conditions (viability, transport, 
function...) 
 
HepG2 Cells 
- Unlimited availability 
- Easy to use 
- Most commonly used and best 
characterized human liver cell 
line 
- Expression of many 
differentiated hepatic functions 
- High reproducibility 
- Amenable to high throughput 
screening 
- Customizable expression of 
CYPs and phase II conjugating 
enzymes though permanent or 
transient modifications. 
- Lack/scarce expression of 
transport proteins 
- Limited/partial expression of 
some relevant drug-
metabolizing enzymes 
- No reproduction of in vivo 
hepatic phenotype 
- Low response to certain 
inducers. 
Hepatocyte 
Like Cells 
(HLCs) 
- Unlimited availability 
- Representative of phenotypic and 
genetic variation in population 
(induced pluripotent stem cells -
derived HLCs) 
- Complex culture conditions 
- Non-standardized 
differentiation procedures 
- High variability 
- Low expression of key hepatic 
functions 
- Non-complete characterization 
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1.6 Methods for the evaluation of DILI using in vitro 
models 
 
1.6.1 Conventional hepatotoxicity assays 
 
Toxicological in vitro studies have been usually performed by the 
employment of cytotoxicity assays that are based on an estimation of 
cell viability and/or functional or metabolic state of cells previously 
exposed to toxicants. Common cytotoxicity testing involves the analysis 
of cell number, membrane integrity (e.g. release of intracellular 
enzymes, membrane-impermeable DNA stain), apoptosis (e.g. activation 
of caspases), loss of critical biomolecules (e.g. ATP depletion), metabolic 
effects (e.g. tetrazolium salt assays, Alamar blue assay), or anti-
proliferative assays (e.g. inhibition of DNA or protein synthesis) (49, 65). 
These assays monitor events that occur in late stages of cell injury, when 
the cell is near to death. They are useless for mechanistic studies and 
they are more likely to miss toxicities that produce adverse but non-
lethal effects (27, 49). In contrast to this approximation, a variety of pre-
lethal mechanistic assays have been proposed to study potential 
hepatotoxic adverse effects that occur before compromising cell viability 
including: OS (e.g. ROS generation, GSH depletion, lipid peroxidation), 
mitochondrial dysfunction (e.g. inner mitochondrial membrane 
depolarization), lipid accumulation, impairment of BA transport or liver-
specific functions (e.g. plasma protein synthesis, ureogenesis...) (49, 65). 
As a general protocol, conventional in vitro hepatotoxicity studies are 
performed in two steps. First, effects in cell viability are examined by 
cytotoxicity parameters. To this end, cells are incubated with a wide 
range of concentrations of the test compound to obtain a dose-viability 
curve and to calculate IC10 or IC50 values (concentrations causing 10% 
or 50% of cell death, respectively). In a second stage, non-lethal 
concentrations of the drug (e.g., lower than IC10) are used to perform 
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functional and/or mechanistic studies (49, 65). To achieve an accurate 
and reliable in vitro evaluation of drug-induced hepatotoxicity, several 
key markers need to be analyzed. Although many of the conventional 
tests have been adapted to multi-well culture formats, contributing to 
increase screening throughput, their main limitation is that each test 
evaluates a single parameter. Thus a wide battery of traditional tests, 
each performed in a different biological replicate, needs to be performed 
in order to obtain enough information to relate one problem drug to a 
specific mechanism of hepatotoxicity. 
 
1.6.2 Multiparametric approaches 
 
The application of the new 'omics' technologies (i.e. transcriptomics, 
proteomics, cytomics and metabolomics) allows the simultaneous 
determination of multiple parameters in a single biological sample (49).  
In a general sense, transcriptomics examines the levels of all coding 
and non-coding RNA molecules (transcriptome) in a given sample (e.g. 
cell population). However, the most common application of 
transcriptomics is usually referred as gene expression profiling as it is 
based on the determination of levels of mRNAs (49, 66, 67). The premise 
beyond the application of transcriptomics to the study of toxicity is that 
after an adverse effect produced by a toxicant, the cellular homeostasis 
is altered and the cell tries to restore it by switching on/off the 
expression of specific genes (11). A fingerprint (gene expression or RNA 
levels signature) can then be deciphered and used to predict the toxicity 
of a candidate drug based on the concept that similar toxins or similar 
mechanisms of toxicity elicit comparable changes in the gene expression 
(49, 67, 68). Moreover, transcriptional profiling can be used to identify 
potential markers of DILI for diagnosis purposes. The usefulness of this 
experimental approximation has been successfully demonstrated (67, 
69-71). However, the correct interpretation of transcriptomic studies is 
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hampered by a number of experimental factors that can contribute to the 
observed changes in gene-expression data. A major difficulty is the 
differentiation of gene expression alterations related to drug toxicity 
from those associated to its pharmacological activity. Moreover, timing is 
a critical factor in the experimental design. The most valuable 
mechanistic information is obtained from early transcriptional changes 
preceding the occurrence of toxicity, because changes observed in later 
stages after drug exposure can be more related to an adaptive response 
to the toxicity (72). 
The proteome is defined as the entire set of proteins produced or 
modified by an organism or system. It varies with time and the distinct 
requirements, or stresses, that a cell or organism undergoes (73). Thus, 
from a comprehensive point of view, proteomics is the large-scale study 
of proteins, particularly their structures and functions, although a more 
simple and practical definition could be the high-throughput separation, 
display and identification of proteins (74, 75). The main theoretical 
advantage of proteomics with respect transcriptomics is that gene 
expression is not the definitive determinant of the final protein content 
and function, as not all mRNAs are transcribed into proteins and, 
moreover, post-translational modifications and final location of proteins 
(targeting, trafficking) deeply influence protein abundance and activity 
(76, 77). Chemical exposure frequently modifies proteins and 
dysregulates critical biological pathways or processes leading to toxicity. 
Therefore, the main aims of proteomics when applied to toxicity studies 
are the discovery of key modified proteins, the identification of affected 
pathways, and the development of biomarkers for the eventual 
prediction of toxicity as it is assumed that toxicants that produce similar 
effects will induce similar changes in the proteome (49). Recent 
publications support the use of proteomics to evaluate or predict 
mechanism of hepatotoxicity using in vitro models (62, 78, 79). 
However, the applicability of proteomics is limited compared to other 
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'omics' due to its relative low throughput, the need of a high amount of 
sample, the high complexity of the proteome due to post-translational 
modifications of proteins and technical problems associated to some of 
the technologies employed that hinder the detection of low-abundant, 
hydrophobic, acidic, basic, small and large proteins (49, 80-82). 
The cytomes can be defined as the heterogeneous cellular systems and 
functional components of the pluricellular organisms. Cytomics is the 
study of the heterogeneity of cytomes and aims to determine changes in 
the phenotype of single cells, which can be further related to a given 
stimulus or injury (83, 84). Within the 'omics' framework, cytomics can 
be considered as the science of single cell-based analyses that links 
genomics and proteomics with the dynamics of cell and tissue function, 
as modulated by external influences (83-85). Cytomics technology is 
based on the use of specific fluorescent probes to assess the status of 
the cell. With a suitable combination of fluorescent markers, many 
different parameters of interest in toxicological studies such as nuclear 
morphology, mitochondrial function (transmembrane potential), cell 
viability, intracellular calcium concentration, ROS generation or lipid 
accumulation may be recorded simultaneously. Among cytomic 
technologies, a new image-based technology called high content 
screening (HCS) integrates the fluorescence microscopy with image 
analysis algorithms and informatics to automate cell analysis (49, 84, 
86), what allows to record spatial information of the fluorescence signals 
while maintaining high throughput thanks to the automation (84). The 
nature of this technology makes it especially suitable for its application 
in drug toxicity as several parameters can be recorded simultaneously in 
individual cells. Many examples of the application of different 
methodological variants of cytomics applied to hepatotoxicity prediction 
or mechanistic classification can be found in the recent literature (52, 87-
93).  
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1.7 Metabolomics 
 
The term metabolome was initially defined as the quantitative 
complement of all the low molecular weight molecules present in a cell 
in a particular physiological or developmental state (94, 95). This 
definition has been updated to cover the broader range of applications 
that have arisen within this field and can be defined as the quantitative 
determination of all the low-molecular-weight (approximately below 1 
kDa) endogenous metabolites in a specified biological sample. Each cell 
type/biological fluid has specific levels of metabolites depending on the 
specific environmental conditions and fluctuate through time according 
to physiological demands (96). Two different terms were initially coined 
to name the science focused on the study of the metabolome: 
metabolomics (97) and metabonomics (98). The term metabolomics was 
defined as “the comprehensive and quantitative analysis of all 
metabolites present in a specific cellular, tissue or biological sample” and 
it was originated by semantic analogy with other 'omics' disciplines (97). 
On the other hand, the term metabonomics was defined as “the 
quantitative measurement of the time-related multiparametric metabolic 
response of living systems to pathophysiological stimuli or genetic 
modification” (98) and is derived from the Greek roots 'meta' and 'nomos' 
meaning changes and rules/laws, respectively, to describe the 
generation of pattern recognition-based models that have the ability to 
classify changes in metabolism (99). The initial discrepancy between the 
two definitions was mainly philosophical. While metabolomics aimed to 
characterize and quantify all the small molecules present in a biological 
sample, metabonomics was focused on the global changes in the 
metabolome as a response to a given stress, stimuli or genetic 
manipulation (100). Nowadays both terms are often used 
interchangeably to define those studies aimed at the untargeted analysis 
of the metabolites in a given biological system under study (100). Their 
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main applications include toxicity assessment, pharmaceutical drug 
development, cell culture monitoring, disease diagnosis, nutrition, 
oncology and transplantation (101-106). 
Metabolomics measures the downstream products of the 'omics 
cascade', thus providing information that is not accessible through other 
alternative 'omics' such as genomics, transcriptomics or proteomics (103, 
107) (Figure 1.3). Metabolites are the intermediates of biochemical 
reactions, thus their levels are determined by both the concentration and 
properties of the enzymes, these last being the result of the integration 
of transcription, translation, post-translational modifications and 
allosteric effects, thus resulting in an integrative effect between the 
capabilities of the system under study and its interaction with the 
environment (108). Therefore, thanks to amplification, as a result of 
being downstream of the activity of genes and proteins, the integration 
of intra- and extracellular signals and a more dynamic nature, the 
metabolome, and metabolomic changes, represent a closer 
approximation to phenotype than genes, transcripts or proteins (103, 
107, 109). Thus, metabolomics is more informative of functional status 
of cells than other 'omics'. 
Within the classical approximations of the 'omics cascade', each step 
closer to the phenotype represents a huge increase in the figures of 
entities of interest: from about 20000 genes to 100000 transcripts and 
1000000 proteins. However, the number of metabolites in humans is 
estimated to be around 40000 (110), although the number of major 
metabolites, those being at higher concentrations and with the most 
relevant functions, is estimated to be around 2000 (111). Moreover, 
while genes, transcripts and proteins are species specific, and therefore 
different probes have to be designed for each species, most of the 
metabolites are common to all the species and only a part of the 
metabolome is species specific (81). 
 
Introduction 
51 
 
 
Figure 1.3. Representation of the 'omics cascade' along with the figures of the 
estimated number of components belonging to each of the levels. Metabolomics 
focus is on the last step of the information cascade thus amplifying and 
integrating the signals of the preceding levels of regulation and therefore being 
the closest approximation to the actual phenotype.  
 
 
1.7.1 Basic structure of a metabolomic study  
 
The typical structure of a metabolomic study is depicted in Figure 1.4. 
The first step is to establish the hypothesis of work and define the main 
objectives to be achieved with the study, that is, the biological question 
to be answered. Closely related to this point is the definition of the 
experimental conditions in order to achieve the proposed objectives. 
This step, with regards to a toxicological study, includes the selection of 
the experimental model (e.g. in vitro vs in vivo, immortalized cell lines vs 
primary cultured cells...), the drugs to be tested (e.g., model compounds 
associated to well known mechanisms of toxicity), the concentrations 
and the schedule/pattern of the treatment, and the analytical platform. 
In addition to that, it is necessary to perform a careful selection of the 
type of sample to be analyzed (e.g., cell monolayer and/or culture 
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medium; that is endometabolome vs exometabolome) and sampling 
protocol processing methods. One key pre-requisite is that samples have 
to be representative and informative of the phenomenon under study. 
Therefore sample processing has to allow the extraction of the 
metabolites of interest while providing a correct quenching of the cell 
metabolism in order to avoid metabolite degradation or alterations in 
their levels at the time of the sampling. After the samples have been 
generated, they have to be analyzed under the appropriate analytical 
platform in an environment that ensures the quality of the generated 
results. Finally, the use of suitable data analysis techniques will allow the 
generation of biologically meaningful results that with the correct 
interpretation and validation, will answer the question of interest. The 
decisions made at every step of the workflow are crucial in obtaining 
high quality and informative results (103). 
 
 
 
Figure 1.4. Scheme of a general workflow in a metabolomics study. Figure 
adapted from reference (103)  
 
 
1.7.2 Techniques for the study of the metabolome 
 
The metabolome presents a large diversity of components 
(aminoacids, carbohydrates, lipids, organic acids...) with highly different 
chemical structures and properties (from ionic or very polar to highly 
hydrophobic compounds). It is almost impossible to determine the 
complete metabolome using a single analytical platform and thus the 
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combination of complementary techniques (covering both sample 
preparation and analysis) is required to achieve a comprehensive 
coverage of the metabolome (108). 
The most common analytical techniques used to study the 
metabolome are nuclear magnetic resonance (NMR) spectroscopy and 
mass spectrometry (MS), the later usually hyphenated to previous 
separation techniques (112). NMR and MS, in their different 
configurations, are complementary rather than opposite platforms and 
thus the use of different analytical techniques has a positive impact in 
widening the coverage of the metabolome. 
1
H-NMR spectroscopy is based on the detection of all the proton 
signals present in a given sample. The main advantages of NMR 
spectroscopy are: i) it is a non-destructive technique, therefore the 
samples may be used in further analysis; ii) it requires non or low sample 
preparation; iii) it is possible to perform analysis with solid samples; iv) it 
is an intrinsically quantitative technique; v) it is possible to perform 
structural analysis; and vi) its high robustness allows easy lab-to-lab 
comparisons. However the application of NMR is hampered by its low 
resolution and sensitivity, the difficulty in the interpretation of the 
obtained spectra and the presence of analytes deficient in protons or 
that possess protons that can be readily interchanged with the solvent 
(108, 113). 
In MS, the analytes present in the sample are ionized and characterized 
by their mass-to-charge ratio (m/z). MS detection is usually preceded by 
a separation technique in order to separate the individual components 
present in the complex biological matrices. The most popular separation 
techniques coupled to MS are: gas chromatography (GC), liquid 
chromatography (LC) and capillary electrophoresis (CE). GC is used to 
separate volatile (and no-volatile, after derivatization) metabolites. CE 
separate polar ionizable compounds based on their m/z. LC is by far the 
most popular separation technique used in metabolomics and allows the 
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separation of the metabolites based on their chemical properties as a 
function of the stationary phase of the selected chromatographic 
column. The main advantages of MS hyphenated to separation 
techniques are: i) its high sensitivity, several orders of magnitude lower 
than NMR; ii) its high resolution and selectivity; iii) the possibility of 
performing fragmentation analysis thus confirming the identity of the 
detected metabolites and the identification of unknown and unexpected 
compounds; and iv) the information is easier to handle than in the case 
of NMR spectroscopy (80, 103, 108).  
 
1.7.3 LC-MS-based metabolomics 
 
Currently two approaches are used for LC-MS-based metabolomic 
investigations: i) untargeted and ii) targeted. Although the latter may not 
be considered as a true 'omic' approach because it basically consists in a 
biased analysis which is driven usually by a hypothesis or by a priori 
knowledge of the system under study, targeted analysis may be 
considered an important part of untargeted metabolomics. Once 
potential biomarkers have been deciphered by untargeted metabolomics 
analysis, they should be validated by performing targeted quantitative 
analysis (Figures 1.4, 1.5). 
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Figure 1.5. Scheme of the proposed global metabolite profile strategy. The 
strategy is based in the combination of both untargeted and targeted 
metabolomics analysis with the workflow described in Figure 1.4 as starting 
point. Untargeted analysis is able to provide candidate biomarkers that can be 
validated by the use of targeted quantitative analysis. Moreover targeted analysis 
is a complementary tool to untargeted analysis when addressing metabolites 
belonging to a specific class. Adapted from reference (103) 
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Untargeted metabolomics 
 
Untargeted metabolomics aims to characterize the maximum possible 
number of metabolites in a given biological sample. It is focused on an 
unbiased profiling of the metabolome in order to link specific patterns of 
metabolites to a given treatment or condition (103, 108). As previously 
mentioned, the broad chemical and physical diversity of the metabolome 
renders the simultaneous analysis of all the existing metabolites in a 
given sample via a single technique impossible. In LC-MS-based 
metabolomics, this aim can be achieved with the combination of the 
right separation strategy with a detection system that covers a wide 
range of m/z in an unbiased way (103).  
Traditional LC separations have been performed using reversed phase 
(RP) chromatography (107, 114, 115). RP columns, typically C18-bonded 
silicas, are able to retain and separate medium-polar and non-polar 
metabolites and are a good option as starting point in metabolomic 
studies. However, very polar compounds elute in the void volume or with 
minimal retention. Recent advances in column technology, such as 
hydrophilic interaction chromatography (HILIC) (116), allow the detection 
of polar/ionic analytes which, typically, are poorly retained by RP phases 
or indeed are not retained at all (117-119). Stationary phases used in 
HILIC chromatography include amine, amide or free silanol groups. The 
retention of a metabolite is a combination of liquid-liquid partitioning, 
adsorption, ionic interactions, and hydrophobic retention and is heavily 
dependent on the nature of the analyte and the composition of the 
mobile phase (117). Using HILIC chromatography coupled to MS may also 
offer higher sensitivity than conventional RP phases because of increased 
ionization efficiency resulting from the use of mobile phases containing 
a high proportion of organic solvents. No single separation technique is 
able to resolve and detect the complete range of metabolites that may be 
present in a complex biological sample; therefore, achieving the most 
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comprehensive metabolome coverage may require the use of several 
column chemistries (103, 107). 
With respect to MS detection, untargeted metabolomics require 
instruments with a sensitive full scan mode and accurate mass 
measurement. The quadrupole time of flight (QTOF) mass spectrometer 
meets such requirements as it combines the stability of a quadrupole 
with the high efficiency, sensitivity and accuracy (< 5ppm) of a TOF. It 
also offers mass fragmentation capabilities for unknown metabolite 
identification. Thanks to its capabilities, the QTOF mass spectrometer 
has become the instrument of choice for untargeted analysis 
approaches, although other instruments such as Orbitrap or Fourier 
Transform Ion Cyclotron Resonance also meet high mass resolution 
capabilities (103). 
 
Targeted metabolomics 
 
Targeted metabolomics aims at the quantitative determination of a 
previously selected set or class of metabolites. The recent advances in 
MS instruments along with the development of ultra performance liquid 
chromatography (UPLC) have permitted the simultaneous quantification 
of dozens to hundreds of target metabolites in a single chromatographic 
run (103, 108). The usefulness of targeted metabolomics resides in 
mapping some metabolites of interest, instead of the whole metabolome. 
This approach is especially suitable in hypothesis-driven studies, where 
the focus is on a specific pathway or class of compounds, or to validate 
previously discovered biomarkers (Figure 1.5).  
Targeted metabolomics requires the unambiguous identification and 
the quantification of the metabolites of interest. With respect LC, the 
chromatographic separation is optimized according to the chemical 
properties of the group of metabolites of interest. Triple quadrupole (TQ) 
mass spectrometers, mostly working in multiple reaction monitoring 
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(MRM) mode, are the most common platform to perform targeted 
analysis. TQ mass spectrometers have a lower mass resolution than 
QTOF, however they have greater sensitivity, specificity, robustness, and 
a broader dynamic range. In TQ operating in MRM, the first quadrupole 
selects a parent ion that is fragmented in the second quadrupole 
(collision cell) to give specific fragments (daughter ions) that are selected 
in the third quadrupole before arriving to the detector. Thus in UPLC-TQ 
targeted metabolomics the high selectivity, that ultimately favors its high 
sensitivity, is provided by a triple filter: 1) retention time (RT) in the 
UPLC; 2) molecular formula/mass, determined by the first quadrupole; 
and 3) structure, determined by the fragmentation process and the 
selection of daughter ions in the third quadrupole (103, 120).  
 
1.7.4 Data analysis in metabolomics 
 
LC-MS untargeted analysis generates huge amounts of data in form of 
a three-dimensional matrix (RT, m/z and signal intensity). The ultimate 
goal of data analysis applied to metabolomics is to transform the raw 
data provided by the analytical platform into reliable, useful and 
intelligible biological information (103, 121). After several preprocessing 
steps, the result is a two-dimensional matrix (usually RT_m/z, signal 
intensity) in which the data from all the samples have been aligned, 
normalized, centered... and are ready to be subjected to univariate and 
multivariate data analysis (MVDA) (103).  
Univariate methods analyze only one variable at a time and they 
include tests to compare different sets of samples such as t test (or its 
non-parametric analog Mann-Whitney test) for two-group problems or 
ANOVA (analysis of variance) for multiple-class problems. Multivariate 
methods use all variables simultaneously and deal with the relationship 
among variables. (121). The MVDA workflow typically involves two 
statistical approaches comprising unsupervised and supervised methods. 
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Unsupervised multivariate data analysis 
 
Unsupervised multivariate methods, in which no a priori knowledge 
about the samples is used by the employed algorithm, are usually 
performed in order to visualize the natural interrelationship among the 
different samples thus revealing groups, trends and outliers (122). Two 
of the most commonly used tools to performed unsupervised 
multivariate analysis in metabolomics studies are hierarchical cluster 
analysis (HCA) and principal component analysis (PCA). 
In HCA, the multidimensional data obtained by untargeted 
metabolomics analysis is reduced to a correlation/distance matrix. Then, 
the samples are clustered together in a single dendogram and the 
distances between the samples reflect the similarities and differences 
between their metabolomic patterns (123). Different distance measures 
(e.g. Euclidean, Pearson, Spearman) and clustering algorithms (e.g. 
average linkage, single linkage, complete linkage, ward, centroids) can 
be used in the development of HCA models (124).  
PCA is a statistical method that reduces a great number of variables 
(usually correlated) into a smaller number of uncorrelated variables, 
which are called principal components (112, 122). This transformation is 
defined in such a way that the first principal component has the largest 
possible variance (that is, accounts for as much of the variability in the 
data as possible), and each succeeding component in turn has the 
highest variance possible under the constraint that it is orthogonal to 
(i.e., uncorrelated with) the preceding components. The goal of the 
exercise is dimensional reduction (usually to two or three components), 
while sacrificing as little accuracy as possible. The results of a PCA are 
usually discussed in terms of ‘scores’ that indicate the relationship 
between samples and 'loadings', which indicates the relationships 
(correlations) between the variables The scores represent the original 
data in the new coordinate system and the loadings are the weights 
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applied to the original data during the projection process. Each point in 
the scores plot represents one sample and each point in the loading plot 
represents one feature. Sample points that cluster together have more 
similar metabolomic patterns (and hence more similar biochemical 
composition) than those that cluster apart (112, 122). 
 
Supervised multivariate data analysis 
 
If the objective of data analysis is classification or regression, 
supervised predictive models have to be created. Several tools have been 
applied in metabolomics to achieve this purpose: random forests, 
artificial neural networks, support vector machine classification, 
discriminant analysis, SIMCA (soft independent modeling of class 
analogy)... However, partial least squares–discriminant analysis (PLS-DA) 
and orthogonal projection to latent structures-discriminant analysis 
(OPLS-DA) are the most popular ones (122, 125, 126). PLS-DA is a PLS-
based model in which the dependent variable (Y block) represents class 
membership (127, 128). OPLS-DA is a variant of the PLS method in which 
the variation in X (in metabolomics it corresponds to the intensity of the 
detected features) is divided in two parts, one that is linearly related to Y 
and one that is unrelated (orthogonal) to Y (122, 129). PLS-DA and OPLS-
DA are projection based methods, like PCA, however, they are preferred 
to PCA because the dimension reduction that PLS offers is guided 
explicitly by the among-groups variability, whereas PCA is only capable 
of identifying gross variability directions and is not designed to 
distinguish 'among-groups' and 'within-groups' variability (103, 128, 
130). A common problem with PLS-DA is its propensity to data 
overfitting. This occurs when the algorithm appears to achieve good 
separation but has done so by picking up random noise rather than real 
signals (121, 131). This problem is addressed by using double cross 
validation (2CV) (132) in combination with permutation tests (133, 134). 
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In a 2CV procedure, the data are subdivided into two different subsets 
(the size depends on the times the validation loop is performed), one is 
used for model development and the other is reserved as a validation 
set. Within the first subset a second division into two different subsets is 
performed (the usual procedure at this stage is to develop the model 
with all the samples except one, that is used for model validation) in 
order to optimize model parameters such as the number of latent 
variables (LVs) employed to develop the model (132). The samples 
included in each of the subsets are interchanged until all the samples 
have been included in each one. The developed model is an average of 
all the generated during the cross validation (CV) strategy. 
A permutation test involves randomly reassigning the class labels and 
performing PLS-DA on the newly relabeled data set. The process is 
repeated hundreds or thousands of times, and the performance 
measures are plotted on a histogram for visual assessment. From the 
resulting histogram, it is possible to determine whether the original class 
assignment is significantly different from, or a part of, the distribution 
based on the permuted class assignments (133). 
 
1.7.5 State of the art in the application of metabolomics to 
hepatotoxicity prediction 
 
Metabolomics is increasingly being used in toxicological studies and is 
now recognized as a promising technology with potential application in 
different areas of toxicology such as screening of drug-candidates, 
identification of biomarkers of toxicity and elucidating mechanisms of 
toxicity (109, 112, 135). Several recent studies have highlighted the 
usefulness of metabolomics applied to the study of hepatotoxic effects, 
usually targeting body fluids such as urine and serum, using rodents as 
in vivo models (104, 136-140). However, the presence of metabolomic 
studies associated to hepatotoxicity in humans is scarce (141-143).  
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The application of metabolomics to cells in culture is an active field of 
research and several groups have put their efforts in the optimization of 
sample processing conditions applied to different types of cells and 
metabolomic applications (103). A number of cells including human 
fibroblasts (144, 145), human induced pluripotent stem cells (146), CHO 
cells (147, 148), primary-cultured human hepatocytes (149), cancer cells 
(150, 151), INS-1 cells (152, 153), HepaRG cells (154) and HepG2 cells 
(155, 156) have been used in metabolomic studies. In spite of the 
extensive available literature about the topic, there is no general 
consensus about the harvesting, extraction or analysis methods to be 
applied to mammalian cells in adherent culture. Therefore, optimization 
of sample processing and analysis conditions is a pre-requisite prior to 
the performance of metabolomic studies. Much more limited has been 
the application of metabolomics to cell culture systems for toxicity 
purposes and, in particular, for DILI studies. In contrast to 
transcriptomics or cytomics that have been widely applied to in vitro 
hepatotoxicity assessment, relatively few studies have used 
metabolomics (154, 156-158). Moreover, previously reported 
toxicometabolomic studies using liver-derived cell models (HepG2 cells, 
HepaRG cells and primary hepatocytes) were focused in the effects of a 
single hepatotoxin (or a very reduced number of them). Therefore, the 
potential utility of cell metabolomics to identify and classify drugs able 
to induce hepatotoxicity through different mechanisms has not been 
explored yet.  
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1.8 Hypothesis of work and objectives. 
 
Based on the previous evidences our hypothesis stands that in vitro 
toxicometabolomics could be a valuable tool to study and decipher 
patterns associated to DILI. This approach may lead to high sensitive and 
specific predictions of hepatotoxicity risk to be used in drug 
development and pre-clinical safety studies as well as it could provide 
valuable information about candidate biomarkers, opening the possibility 
to discover generic and mechanism-specific biomarkers of 
hepatotoxicity. 
We propose the following objectives: 
 
1. Development of an analytical strategy for the LC-MS analysis of 
the metabolome: from sample processing and analysis to data 
analysis and biomarker validation. 
 
2. Identification of biomarkers and metabolomic patterns associated 
to drug-induced hepatotoxicity using HepG2 as in vitro cellular 
model. 
 
3. Extrapolation of in vitro biomarkers to in vivo medaka (Oryzias 
lapites) and rat models, and comparison of the molecular 
mechanisms among these models. 
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2.1 General procedures, equipment and reagents 
 
All the LC solvents (i.e. water, methanol, acetonitrile and isopropanol) 
were of LC-MS grade and were purchased from Fisher Scientific 
(Loughborough, U.K.). All the LC-MS additives (i.e. formic acid and 
ammonium acetate) and the analytical standards (when available) were 
acquired from Sigma-Aldrich (Madrid, Spain). BA (deuterium labeled BA 
included) were obtained from Steraloids (Newport, USA). Peptides were 
acquired from Xaia Custom Peptides (Göteborg, Sweden) and Bachem 
(Bubendorf, Switzerland). The rest of deuterated internal standards (IS) 
were purchased from Cambridge Isotope Laboratories (Tewksbury, USA). 
Protein determinations were performed using a 96-well adapted Lowry 
method (159, 160). 
Tissue homogenizations were performed using a Precellys 24 dual 
system equipped with a Cryolys cooler (Precellys, Saint Quentin en 
Yvelines, France) in order to maintain the samples at a controlled 
temperature during the homogenization process (Figure 2.1.A). 
Sample evaporations were performed using a Savant SPD 121P SpeeVac 
concentrator equipped with a refrigerated vapor trap (Thermo Fisher 
Scientific, Watham, USA) (Figure 2.1.B). 
 
 
 
Figure 2.1. A) Precellys 24 Dual equipped with a Cryolys cooler. B) Savant 
SpeedVac connected to an oil-free vacuum pump and a refrigerated vapor trap.  
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2.2 Instrumentation used in MS-based metabolomics 
analysis 
 
All the metabolomics analyses were performed using an LC-MS 
analytical platform. The LC separations were performed using a Waters 
Acquity UPLC system (Waters, UK), with regards to analytes detection two 
different mass spectrometers were employed: a Waters Synapt HDMS 
QToF mass spectrometer (Waters, UK) for untargeted metabolomics 
analysis and a Waters Xevo TQ-S mass spectrometer (Waters, UK) for 
targeted analysis (Figure 2.2). 
 
 
 
Figure 2.2. LC-MS metabolomic platforms employed. A) Instrument employed for 
untargeted metabolomic studies: a Waters Acquity UPLC system coupled to a 
Waters Synapt HDMS QToF mass spectrometer. B) Instument employed for 
targeted metabolomic studies: a Waters Acquity UPLC system coupled to a Waters 
Xevo TQ-S mass spectrometer. 
 
 
2.2.1 Waters Acquity UPLC system 
 
UPLC is a variant of high performance liquid chromatography (HPLC) 
that uses columns with a particle size below 2 µm (typically 1.7-1.8 µm), 
which provides significant better separations than the traditional (3-5 
µm) columns and enables much faster analysis. This technique allows the 
combination of columns with small particles and the use of higher flow 
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rates, thus obtaining an increased speed separation with superior 
resolution and sensitivity (161). This is achieved thanks to the high 
pressure (up to 15000 psi) that can be reached with the combined used 
of UPLC systems and sub 2 µm particle size columns. 
The Waters Acquity UPLC system employed to carry out the analysis is 
equipped with a binary solvent manager that enables to perform gradient 
elutions with a maximum of two eluents, a refrigerated sample manager 
that allows to keep the samples at low temperature to minimize sample 
degradation while waiting to be analyzed, and a thermostated column 
manager that allows to perform separations at a controlled temperature. 
The system requires two elution solvents which are selected to achieve 
an appropriate chromatographic separation of the components present 
in a given sample and they are selected taking into account the 
chemistry of the employed chromatographic column. Additionally, two 
wash solvents that allow the cleaning of the injection system between 
injection cycles have to be selected: the weak needle wash (WNW) solvent 
and the strong needle wash (SNW) solvent. The WNW solvent has to be as 
close as possible to the initial conditions of the chromatographic 
separation. The SNW is aimed to clean the syringe in order to avoid inter-
sample contamination. 
Information about column temperature, flow rate, elution and wash 
solvents composition and gradient will be detailed for each of the used 
analytical methods. 
 
2.2.2 Waters Synapt HDMS QToF mass spectrometer 
 
Untargeted metabolomic studies were performed using a Waters 
Synapt HDMS QToF as mass spectrometer. This instrument enables the 
scan of a wide range of masses (50-1200 Da) with a high resolution (> 
5000 full width at half maximum (FWHM)) (see Formula 2.1) and high 
mass accuracy (< 5 ppm) (see Formula 2.2).  
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𝑚𝑎𝑠𝑠 𝑟𝑒𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 (𝐹𝑊𝐻𝑀)  =  
𝑟𝑒𝑐𝑜𝑟𝑑𝑒𝑑 𝑖𝑜𝑛 𝑚𝑎𝑠𝑠
𝑚𝑎𝑠𝑠 𝑝𝑒𝑎𝑘 𝑤𝑖𝑑𝑡ℎ 𝑎𝑡 ℎ𝑎𝑙𝑓 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 
 
 
Formula 2.1. Expression to calculate mass resolution using the full width at half 
maximum (FWHM) approximation. 
 
 
𝑚𝑎𝑠𝑠 𝑒𝑟𝑟𝑜𝑟 (𝑝𝑝𝑚) = 106 𝑥 
(𝑟𝑒𝑐𝑜𝑟𝑑𝑒𝑑 𝑖𝑜𝑛 𝑚𝑎𝑠𝑠 −  𝑒𝑥𝑎𝑐𝑡 𝑖𝑜𝑛 𝑚𝑎𝑠𝑠)
𝑒𝑥𝑎𝑐𝑡 𝑖𝑜𝑛 𝑚𝑎𝑠𝑠
 
 
Formula 2.2. Expression employed to calculate mass error in parts per million 
(ppm). 
 
 
This mass spectrometer is equipped with an electro spray ionization 
(ESI) source and is able to operate in both positive and negative 
ionization modes. Moreover, mass acquisition can be recorded in MS and 
in MS/MS modes simultaneously, thus allowing to perform mass 
fragmentation to confirm identities of putative biomarkers. The data 
station operating software was Masslynx v4.1 (Waters, UK). 
To ensure reliable mass measurements, the software requires mass 
axis calibration so that the m/z values for sample peaks can be 
accurately determined. Two different kinds of calibration procedures are 
performed before and during sample analysis, that is, off line and on line 
calibrations. The objective of off line calibration is to fix the relationship 
between the m/z and the time of flight of the ions inside the TOF tube, 
while on line calibration performs a real on time correction of that 
adjustment. Off line calibration is performed using a set of known 
reference peaks (i.e. via infusion of a solution containing 10% formic 
acid/0.1 M NaOH/acetonitrile (1:1/8)) so that the software determines 
the differences between the real mass of the reference peaks and the 
observed measurement of them along the mass axis. A calibration curve 
can then be generated allowing the accurate determination of masses 
included in the calibration mass range. On the other hand, on line 
calibration relies on the measurement of a single reference mass (i.e. 
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Leucine Enkephalin, m/z 556.2771 or 554.2615, in ESI positive (+) and 
ESI negative (-), respectively, prepared at 50 pg/mL in acetonitrile/water 
(1:1) plus 0.1% formic acid) that is acquired during sample acquisition 
thanks to a dual electro spray ion source that allows the co-introduction 
of analyte and reference compounds directly into the ion source. The 
reference mass (also called lock mass) performs a real time correction of 
the calibration curve allowing to achieve a high accuracy in mass 
determination (< 5 ppm). 
 
2.2.3 Waters Xevo TQ-S mass spectrometer 
 
Targeted metabolomics analyses were performed using a Waters Xevo 
TQ-S mass spectrometer equipped with an ESI probe that allows the 
simultaneous acquisition in positive and negative ionization modes. The 
data station operating system was Masslynx v4.1 (Waters, UK). TQ mass 
spectrometers are designed for targeted analysis as they allow sensitive, 
selective and quantitative analysis of a known group of metabolites. The 
most common operational mode of TQ mass spectrometer is MRM. In TQ 
operating in MRM mode, the first quadrupole selects a parent ion that is 
fragmented in the collision cell to give specific fragments (daughter ions) 
that are selected in the second quadrupole before arriving to the 
detector. QuanOptimizer software (Waters, UK) was employed to 
optimize transitions (selection of parent and daughter ions), cone 
voltages and collision energies for each of the targeted metabolites. 
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2.3 Analytical conditions for LC-MS untargeted analysis 
 
In all the cases the temperatures of the column and the autosampler 
were set at 40 °C and 4 °C, respectively. The sample injection volume was 
5 µL and the flow rate was set at 0.4 mL/min. The ESI conditions were as 
follows: capillary was set at 3.2 kV and 2.8 kV in the positive and 
negative modes, respectively; cone voltage was set at 40 V; desolvation 
and source temperatures were set at 380 and 120 ºC, respectively; the 
flow rates of cone and nebulization gases were set at 50 and 800 L/h, 
respectively. The same parameters were applied for simultaneous MS and 
MS/MS analysis, with a collision energy ramp from 5 to 60 eV in the 
MS/MS channel. 
 
2.3.1 Generic-RP untargeted analysis 
 
LC-MS conditions for generic-RP untargeted analysis were adapted 
from reference (162). UPLC separation was performed using an Acquity 
UPLC HSST3 (1.7 µm, 2.1 × 100 mm; Waters) column. Eluent and washing 
solutions composition were: i) Solvent A: 0.1% formic acid in water; ii) 
Solvent B: 0.1% formic acid in acetonitrile; iii) WNW and seal wash (SW): 
water/acetonitrile (90:10, v/v); and iv) SNW: acetonitrile. A 26-min 
elution gradient was performed as follows: during the first 2 min, eluent 
composition was set at 99.9% A and 0.1% B, which was linearly changed 
to 75% A and 25% B in 4 min; then the proportion of B was increased to 
80% in the next 4 min, followed by a further increase to 90% B reached at 
min 12 and 100% B at min 17 and kept for 5.5 min. Finally, the initial 
conditions were recovered and maintained for 2 min for column 
conditioning.  
Mass detection was performed in the MS scan mode from 50 to 1000 
Da with a scan time of 0.1 s.  
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2.3.2 Lipidomic-RP untargeted analysis 
 
LC-MS conditions for lipidomic-RP untargeted analysis were adapted 
from reference (163). UPLC separation was performed using an Acquity 
UPLC BEH C18 (1.7 µm, 2.1 × 100 mm; Waters) column. Eluent and 
washing solutions composition were: i) Solvent A: 0.1% formic acid and 
1% ammonium acetate 1M in water; ii) Solvent B: 0.1% formic acid and 1% 
ammonium acetate 1M in acetonitrile:isopropanol (5:2); iii) WNW and SW: 
water/acetonitrile (90:10, v/v); and iv) SNW: acetonitrile:isopropanol 
(5:2). Two different chromatographic separations were performed for ESI 
(+) and ESI (-) modes, respectively. In ESI (+) mode a 18-min elution 
gradient was performed as follows: initial eluent composition was set at 
65 % A and 35% B, which was linearly changed to 20% A and 80% B in 2 
min; then the proportion of B was increased to reach 100% at min 9 and 
kept for 7 min. Finally, the initial conditions were recovered and 
maintained for 2 min for column conditioning. In ESI (-) mode a 18-min 
elution gradient was performed as follows: initial eluent composition was 
set at 85% A and 15% B, which was linearly changed to 35% A and 65% B 
in 2 min; then the proportion of B was increased to reach 100% at min 11 
and kept for 5 min. Finally, the initial conditions were recovered and 
maintained for 2 min for column conditioning. 
Mass detection was performed in the MS scan mode from 200 to 1200 
Da in ESI (+) and from 100 to 1200 Da in ESI (-), with a scan time of 0.1 s.  
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2.3.3 HILIC untargeted analysis 
 
UPLC separation was performed using an Acquity UPLC BEH Amide (1.7 
µm, 2.1 × 100 mm; Waters) column. Eluent and washing solutions 
composition were: i) Solvent A: acetonitrile; ii) Solvent B: 20 mM 
ammonium acetate pH 3 in water; iii) WNW: acetonitrile/water (90:10, 
v/v); and iv) SNW and SW: water/acetonitrile (90:10, v/v). A 18-min 
elution gradient was performed as follows: during the first 3 minutes 
eluent composition was set at 95% A and 5% B, which was linearly 
changed to 75% A and 25% B in 6 min; then the proportion of B was 
increased to reach 65% at min 13 and kept for 2 min. Finally, the initial 
conditions were recovered and maintained for 2.5 min for column 
conditioning. 
Mass detection was performed in the MS scan mode from 50 to 1000 
Da, with a scan time of 0.1 s.  
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2.4 Raw data processing and metabolite identification in 
untargeted metabolomic analysis 
 
The main goal in data processing is to correctly arrange the huge 
amount of raw data generated by the MS files into a matrix data that 
eases later data handling as MVDA. Thus, data is arranged into a 2D 
matrix in which each row represent one sample (object) and each column 
one ion detected by the MS (variable). Variables (columns) are expressed 
by the combination of three characteristics, two that define the identity 
of the ion, that is m/z and RT, and the ion intensity measured for each 
sample (164). 
Raw data was acquired using Masslynx v 4.1 software (Waters, UK) and 
was subsequently converted from *.raw format to *.cdf format using 
Data Bridge tool from Masslynx v4.1 software. Data processing was 
performed using the MZMine v.2.9.1 free software (165). The following 
steps were sequentially executed within the data processing (Figure 2.3): 
i) Peak picking/detection, it involves the detection of all signals above a 
given threshold, thus distinguishing true signals from noise; ii) 
Deconvolution of the detected signals in order to integrate mass and 
chromatographic information, as a result, the list of peaks (features) - 
characterized by RT, m/z and intensity for each sample - is obtained; iii) 
Alignment, in order to be able to compare among different samples, 
features must be matched and aligned across all the samples included in 
the sample set; iv) Gap filling, it involves gathering intensity information 
from peaks that were initially not detected in all the samples; v) Filtering, 
it consists in the elimination of those non informative features that are 
not present in a given number of samples, initial filtering was set to 
remove those features that are not present in at least 20% of the problem 
samples belonging to a common class or in 50% of a given type of 
quality control (QC) sample, once QC checking procedures have been 
performed, additional filters are applied and those features not present 
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in the problem samples or present in the blank QC samples are also 
removed (166, 167); vi) Normalization, different normalization 
approaches have been described in the bibliography (164, 168), however 
we decided to normalize data with respect the IS added to each sample 
during the homogenization and preparation processes (166, 167). As the 
response of the IS is affected by factors such as sample losses during 
preparation, volume of injection or mass detection, after IS normalization 
those confounding factors are corrected and removed from the data 
before further analysis steps. Additional normalization procedures for 
some types of samples - i.e. samples from HepG2 cultures and from liver 
tissue samples from medaka (Oryzias latipes) - include the normalization 
of the signal with respect the total amount of the biological sample, 
represented by the total amount of protein (103). 
 
 
Figure 2.3. Schematic representation of the most important steps performed 
during data processing. 
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Finally, metabolite identification was performed by the query of the 
exact mass of the detected features against on line databases within a 
certain mass range (±5 ppm). The online databases employed to perform 
metabolite identification are: the Human Metabolome Database (HMDB) 
(110), the LIPID MAPS-Nature Lipidomics Gateway (169) and the Metlin 
database (170). The identity of metabolites of interest was confirmed by 
comparing the MS/MS spectra of the selected features with those of the 
proposed metabolites on the online databases HMDB (110), Metlin (170) 
and MassBank (171). The identities of the selected metabolites were 
further confirmed by the use of authentic standards when available.  
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2.5 Data analysis 
 
All the univariate and multivariate statistical analysis as well as data 
plots were performed using R (172). The following packages were 
employed: 'pcaMethods' (173), 'mixOmics' (174), 'DiscriMiner' (175), 
'gplots' (176), 'boot' (177), 'caret' (178), 'FactoMineR' (179), 'cvTools', 
'pROC' (180), 'rgl' (181) and 'VennDiagram' (182). To perform data 
analysis, all the information for a given sample (i.e. the information 
provided by different analytical conditions) was joined into a single 
matrix comprising all the data available for each biological sample. The 
data analysis strategy is depicted in Figure 2.4 (183) 
 
 
 
Figure 2.4. Workflow of data analysis strategy. Data analysis strategy is 
developed in three different stages. I) Outlier detection and elimination is 
performed based on the examination of the intensity distribution of the samples 
and non-supervised multivariate analysis such as hierarchical cluster analysis 
(HCA) and principal component analysis (PCA). II) In order to decipher those 
metabolomic patterns associated with specific mechanisms of toxicity, data is 
split in control vs one treatment datasets and those variables showing a q value < 
0.05 (based on a Student's t test with FDR correction for multiple testing) or a VIP 
(variable importance in the projection) value > 1.2 (in PLS-DA models) are 
considered to be significantly different as a result of the mechanism of toxicity 
under study. III) Finally, predictive/classificatory models are developed based on 
PLS-DA modeling with a VIP-based selection criteria of discriminant variables.  
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2.5.1 Detection of outliers 
 
The first step in data analysis is the detection of potential outliers. 
They are defined as those samples that show a behavior that stands out 
from the average one. Abnormal sample compositions can be due to 
sample degradation, instrumental errors, changes in measurement 
conditions or faults due to human errors (131). Two different strategies 
were implemented in order to perform an early detection of outliers in 
the data analysis process. First, density and box-and-whisker plots, in 
which all the information about the intensity distribution of all the 
features for a single sample is visualized using a single graphic, were 
drawn. Those samples whose distributions considerably differed with 
respect to the rest of samples belonging to their same class (i.e. control 
samples, steatosis samples...) were considered outliers and eliminated 
from the following steps. Then, unsupervised (that is, without using any 
a priori knowledge about the samples) multivariate analyses were 
performed in order to visualize the natural interrelationship among the 
different samples and to detect outliers that have not been previously 
detected and may interfere in the subsequent analysis. In the case of 
multiclass approaches (more than two groups) this was performed 
testing one treated group with respect to its control at the time (i.e. 
steatosis vs control, phospholipidosis vs control and so on). The tools 
employed to this end were HCA and PCA. In both approaches, samples 
that cluster together are considered to have more similar metabolomic 
patterns than those that cluster apart. Data sets were mean-centered and 
unit variance-scaled before performing HCA. Data sets were log-
transformed, mean-centered and unit variance-scaled before carrying out 
the PCA. Samples whose position in the PCA scores plot is far from the 
rest of the samples of belonging to the same group (i.e. outside the 
Hotelling's T
2
 95% confidence ellipse (184)) may be considered outliers.  
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The process of outlier detection and elimination is exemplified in 
Figure 2.5 using a simulated data set. The data set used in the example 
is composed of 100 variables and 20 observations, 10 belonging to 
group A and 10 belonging to group B. For group A the first 50 variables 
follow a normal distribution with mean 80 and standard deviation 15, the 
second 50 variables follow a normal distribution with mean 120 and 
standard deviation 15. For group B, the variables share the same 
characteristics but with the means inverted. For sample B5, a value of 
160 is assigned for the mean of the first 50 variables. Figure 2.5.A 
shows that the mean value and the deviation of the intensity of the 
variables for sample B5 are greater than the ones obtained for the rest of 
samples. The PCA scores plot showes that sample B5 falls out of the 
Hotelling's T
2
 95% confidence ellipse obtained for group B (represented 
in red) (Figure 2.5.B). Finally, the dendogram drawn at the top of the 
Figure 2.5.C shows that two clusters are obtained, corresponding to 
groups A and B, respectively. However, it can be seen that within the 
cluster corresponding to group B, sample B5 shows the greater distance 
with respect to the rest of the samples and is clustered apart of the rest 
samples of the group. Moreover, a close look at the heatmap reveals that 
the reason of this distance is an increase in the intensity in a group of 
variables with respect to the rest of the samples of the group. Then, 
sample B5 is identified as an outlier and the reason of its abnormal 
behavior with respect of the rest of samples of the group is evidenced.  
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Figure 2.5. Simulated example of the application of boxplot of intensity 
distribution (A), PCA (B) and HCA (C) for the detection of outliers. A) The boxplot 
intensity distribution shows that sample B5 has a higher mean and a higher 
deviation compared to the rest of samples belonging to its same class (red 
color). Boxes denote interquartile ranges, lines denote medians, and whiskers 
denote the 10th and 90th percentiles. B) PCA scores plot. The Hotelling's T
2
 95% 
confidence ellipse is drawn for each group (green, class A, and red, class B). 
Sample B5 is out of the ellipse and far from the rest of samples of its same 
group. C) HCA, the dendogram drawn at the top of the heatmap shows the big 
distance between sample B5 and the rest of the samples of the group, which are 
clustered together. Based on this information, sample B5 would be considered to 
be an outlier. 
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2.5.2 Identification of metabolomic alterations 
 
In order to visualize the metabolomic changes provoked by each 
specific treatment with views to mechanistic elucidation, a t test with 
Benjamini-Hochberg (false discovery rate, FDR) correction for multiple 
testing was applied (185). Those variables with a q value < 0.05 were 
considered to be significantly altered as a result of the treatment. As 
univariate tests do not reflect the multivariate nature of the data and the 
relationship among the different variables, PLS-DA models were built for 
each control-treatment case and those variables with a VIP (variable 
importance in the projection) value > 1.2 were also considered to have a 
marked impact in discriminating between control and treatment groups. 
Based on those significantly altered metabolites, the pathway analysis 
tool of Metaboanalyst (186) and MBRole (187) were employed to map 
which pathways were significantly altered as a consequence of the toxic 
insult. Then, box-and-whisker plots of significantly altered 
metabolites/groups of metabolites/pathways were drawn to facilitate 
data visualization and interpretation. 
To exemplify the proposed data analysis strategy with respect to 
detection of altered variables (metabolites) a simulated data set 
consisting of 100 variables and 30 samples, split in two groups of equal 
size, was created. The variables were generated following a normal 
distribution of mean 100 and standard deviation 15. Among the 100 
variables, 10 variables were selected to have different mean between the 
two groups: V1 (A= 120, B= 100), V11 (A= 80, B= 100), V21 (A= 100, 
B=120), V31 (A= 100, B= 120), V41 (A= 140, B= 100), V51 (A= 60, B= 
100), V61(A=100, B= 140), V71 (A= 100, B= 140), V81 (A= 120, B= 100), 
and V91(A= 100, B= 120). Table 2.1 shows the results of selected 
variables using a simple t Student's test (p < 0.05), a t Student's test with 
FDR correction (q < 0.05) and using VIP value (VIP > 1.2) as criteria. FDR 
was the most restrictive criteria, with only 8 selected variables, all of 
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them belonging to those made up to be altered between the two groups. 
Similar results were obtained with respect the total number and the 
identity of the variables selected with the p value and the VIP strategies. 
In both cases all the variables with a predefined difference in the mean 
between the two classes were selected, however, a number of variables 
that were not supposed to be different between the two groups were also 
included.  
 
Table 2.1. Figures of the different strategies employed for variable selection over 
the simulated data described in Section 2.5.2. 
 
Strategy 
Number of 
selected 
variables 
Number of really 
altered variables 
selected 
Selected Variables 
FDR 8 8 
V1, V31, V41, V51, 
V61, V71, V81, V91 
p value 15 10 
V1, V4, V11, V21, 
V31, V36, V41, V42, 
V44, V51, V61, V71, 
V81, V90, V91 
VIP 16 10 
V1, V4, V11, V21, 
V31, V36, V41, V42, 
V44, V51, V61, V71, 
V75, V81, V90, V91 
FDR: variables with a q value < 0.05; p value: variables with a t Student's p value 
< 0.05; VIP: variables with VIP value > 1.2, VIP value corresponding to a PLS-DA 
model developed using 1 LV. Variables in italics represent variables with made up 
differences.  
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2.5.3 Predictive model development 
 
The main aim in the development of predictive models is to use the 
model showing maximum parsimony, that is, the one that best fits with 
the minimum possible number of predictors. To this end, a PLS-DA 
analysis using VIP-based variable ranking and selection was performed. 
 
Model validation 
 
Two different strategies with respect to model validation were 
attempted: CV and permutation testing (132, 133). While the optimum 
way of validating any model is to use an external data set, the limitations 
in the number of samples and compounds tested drove us to use CV and 
permutation testing instead. 
In a CV strategy the data is split in different subsets and depending on 
the way the CV is performed, some of the subsets are used to build the 
model and the rest are used to evaluate the capabilities of the model. 
Two different CV strategies were employed. For model development a 7-
fold CV strategy was employed (Figure 2.6.A). Using this approximation, 
the data was split into 7 different subsets. In each round of the CV, 6 of 
the subsets were used to develop the model and the last one was used 
as test set to evaluate the capabilities of the model. The process was 
repeated until all the subsets were used as test set. 
For model validation, two different parameters were employed: 
misclassification error and AUROC (area under the receiver operating 
characteristic curve), for multiclass problems the method developed by 
Hand and Till was employed (188). A randomized CV strategy was 
performed to estimate these parameters: 2/3 of the data were employed 
to develop the model and the rest 1/3 was used as test set (Figure 
2.6.B). The partitions were repeated 100 times in a randomized manner. 
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Figure 2.6. A) 7-fold CV, the data is split in 7 different subsets. 6 subsets are 
used as train set to build the model and the last one as test set to evaluate it. 
The process is repeated until all the subsets have been used as test set. B) The 
data is split in two subsets, 2/3 of the data are used as train set and the rest 1/3 
as test set. The partitions are repeated 100 times randomly. C) In permutation 
testing the classes (Y) are randomly assigned (Yp) and the model is developed 
and validated using the permuted classes. 
  
Methodology 
86
Finally, permutation testing was also employed as validation strategy. 
A permutation test involves the random reassignation of the class labels 
and the model development and evaluation based on the newly relabeled 
data set (Figure 2.6.C). Permutation testing compares the original 
model’s goodness of fit with the values obtained after class 
randomization. The model performance figures of merit can be plotted 
on a histogram for visual assessment, making possible to determine 
whether the original class assignment is significantly different from, or a 
part of, the distribution based on the permuted class assignments. An 
empirical p-value can be calculated by determining the number of times 
the permuted data yielded a better result than the one using the original 
labels (133). The process was repeated 1000 times and the performance 
results were compared to those obtained with the real classes labelling 
(133). 
 
PLS-DA 
 
PLS-DA is a PLS-based model in which the dependent variable (Y block) 
represents class membership (127, 128). The whole objective in PLS-DA 
is to model the relationship between X (the MS data set) and Y (classes). 
The fundamental equations of PLS-DA (127) are written and graphically 
represented in Figure 2.7.  
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[eq 1] 
𝑻 = 𝑿𝑾 
[eq 2] 
𝑿 = 𝑻𝑷′ + 𝑬 
 
 
[eq 3] 
𝒀 = 𝑼𝑪′ +  𝑭 
 
 
[eq 4] 
𝒀 = 𝑻𝑪′ + 𝑭∗ = 𝑿𝑾𝑪′ + 𝑭∗ = 𝑿𝑩 + 𝑭∗ 
 
 
[eq 5] 
𝑩 = 𝑾𝑪′ 
 
Figure 2.7. Fundamental equations of PLS-DA. n represents the number of 
observation, k the number of independent variables, m the number of classes in 
which the observations can be classified and a the number of LVs employed to 
develop the PLS-DA model. X is a n x k matrix of predictors, and Y a n x m matrix 
of responses. P (k x a) and C (m x a) are the matrix loadings of X and Y, 
respectively. T and U are n x a scores matrices for X and Y, respectively. E, F and 
F* represent residual (i.e. error) matrices. W (k x a) represents the X-weight 
matrix and B (k x a) represents the matrix of regression coefficients for all Ys. X 
scores (T) are calculated as a linear combination of the original predictors with 
the weights [eq 1]. X and Y can be projected in the new a dimensional space [eq 
2,3]. Y can be predicted based on X scores (T) [eq 4], which can be reformulated 
based on eq 1,5 to look as a multiple regression model in which the responses 
(Y) can be predicted based on a series of predictors (X) via the corresponding 
coefficients (B). Equations 2, 3 and 4 are graphically represented. 
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Data sets were log-transformed, mean-centered and unit variance-
scaled before carrying out the PLS-DA. The selection of the optimum 
number of LVs and the evaluation of the quality of the PLS-DA models 
was conducted by the typical CV procedure by leaving one-seventh of 
samples out of each round (Figure 2.6.A) (189). Different model 
parameters were used to evaluate model performance: i) total Y 
explained variance (i.e., R
2
); ii) predictable Y variation (i.e., Q
2
); iii) 
prediction accuracy, evaluated as misclassification error rate; and iv) 
AUROC. Different methods can be used in order to evaluate the 
importance of a variable in the output provided by a PLS-DA model (167), 
among them, we decided to employ the VIP value. The VIP score of a 
predictor summarizes the importance for the projections to find a LVs. 
Since the average of the squared VIP scores equals 1, the ‘‘greater than 
one’’ rule is generally used as a variable selection criterion (190). 
Therefore, an uninformative variable elimination process can be 
performed based on the VIP scores obtained (167). Such procedure not 
only improves model performance, but also achieves model 
simplification, a relevant issue concerning the further development of 
‘target’ MS approaches to quantitatively determine biomarkers (167). As 
overfitting is a common problem associated with PLS-DA modeling (122, 
189), a bootstrapping (191, 192) strategy coupled to VIP values 
determination was setup to select those metabolites that should be 
included in the final predictive model. 
Bootstrapping is based on random resampling with replacement to 
estimate a statistic parameter. For each of the datasets used for PLS-DA 
model building, two hundred derived datasets were obtained by random 
sampling with replacement of the observations. A PLS-DA model was 
built for each of those derived datasets and the median VIP value for 
each predictor was calculated. PLS-DA models were built with decreasing 
number of variables according to their ranked median VIP value. For each 
model, R
2
, Q
2
 and prediction accuracy were recorded. The optimum 
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predictive model was selected as the one providing the highest accuracy 
with the lowest number of retained variables. To further assess model 
consistency and performance, a response permutation test (n = 1000) 
based on R
2
, Q
2
, prediction accuracy and AUROC was applied (133, 134).  
In order to facilitate the understanding of the PLS-DA data analysis 
strategy, the whole process was applied over the simulated data 
described in Section 2.5.2. Figure 2.8 shows the values of R
2
, Q
2
 and 
misclassification error obtained for PLS-DA models built using all the 
variables and a number of LVs varying from 1 to 3. From the obtained 
results it can be concluded that the optimum number of LVs to be used 
for PLS-DA model development is 1 as it provides the highest values of 
Q
2
, which evaluates the predictive capabilities of the system, and 
accuracy. 
 
 
 
Figure 2.8. Values of R
2
, Q
2
 and misclassification error as a function of the 
number of LVs employed to build the PLS-DA model using the simulated data 
described in Section 2.5.2. The values obtained for each parameter and model 
are written over the corresponding bar. 
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After the determination of the optimum number of LVs, the next step 
is to determine the variables that should be be included in the final 
predictive/classificatory model. To this end, PLS-DA models with an 
increasing number of variables, ranked according to the previously 
described strategy, were built and their performance was evaluated. 
Following the analysis of the example, all the variables with made up 
differences were within the top 15 ranked variables, furthermore the four 
variables with the highest simulated differences (i.e. V51, V61, V71 and 
V81) were the ones with the highest median VIP value. Moreover, Figure 
2.9, shows that the model with the highest performance (i.e. AUROC = 1, 
misclassification error = 0) was achieved with only those four variables. 
 
 
 
Figure 2.9. Values obtained for the AUROC (green) and misclassification error 
(red) versus the number of retained variables using the simulated data described 
in Section 2.5.2 based on the bootstrapped resampling coupled to VIP ranking 
strategy. The data is expressed as mean ± standard deviation. The minimum 
value for the misclassification error and the maximum value for the AUROC are 
obtained with the model developed using only the four top ranked variables. 
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The scores and loadings plots corresponding to the optimum PLS-DA 
model are represented in Figure 2.10.A and Figure 2.10.B, respectively. 
The position of a variable in the loadings plot is determined by its 
relation to other variables and to the class assignments. In the example 
represented in Figure 2.10.B, variables V41 and V71 are positively 
correlated to each other and to Class A, as represented by their close 
values obtained with respect to the first LV. The same conclusion can be 
obtained with respect to variables V51 and V61and Class B.  
 
 
 
Figure 2.10. Scores (A) and loadings (B) plots corresponding to the PLS-DA model 
developed using the top 4 ranked variables and 1LV using the simulated data 
described in Section 2.5.2 and a bootstrapping coupled to VIP-based ranking and 
variable selection strategy. Class A is represented in green, class B in red and 
variables in blue. X axis represents sample order. 
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Model validation was performed by using a permutation test. The 
results are shown in Figure 2.11. Four parameters were evaluated: R
2
, Q
2
 
misclassification error and AUROC. The histograms represent the 
distribution of values obtained for the permuted models and the value 
obtained with the real classes is represented by a red dot. For all the 
parameters it can be seen that the real value is outside the distribution 
of the values obtained with the permuted classes, as 1000 permutations 
have been performed, an experimental p value < 0.001 can be assigned. 
These results indicate that the developed PLS-DA model is consistent and 
based on a real difference between the classes and does not reflect a 
chance correlation between them. 
 
 
Figure 2.11. Permutations tests (n=1000) for R
2
 (A), Q
2
 (B), misclassification error 
(C) and AUROC (D) corresponding to the PLS-DA model developed using the top 4 
ranked variables and 1LV from the simulated data described in Section 2.5.2 and 
a bootstrapping coupled to VIP-based ranking and variable selection strategy. 
Histograms represent the values provided by the PLS-DA models obtained using 
permuted classes. The red dots represent the value obtained for the PLS-DA 
model developed using the real classes, with the value written above it.  
Methodology 
93 
2.6 Culture and treatment of HepG2 cells with model 
hepatotoxic compounds 
 
Human hepatoma HepG2 cell line (ECACC 85011430) was used for in 
vitro hepatotoxicity studies. HepG2 are adherent cells with a high 
proliferation rate. They are epithelial-like cells growing as monolayers 
and forming characteristic cell clusters or islands (Figure 2.12). HepG2 
cells were routinely grown in culture grade flasks at 37 ºC under a 
humidified atmosphere 5% CO2 / 95% air in Ham’s F-12 / Leibovitz L-15 
(1:1, v/v) supplemented with 7% fetal bovine serum, 50 U/mL penicillin 
and 50 µg/mL streptomycin. Medium was renewed every 2 days. Cells 
reaching 70-80% confluence were ready to be used or passed. For 
subculturing purposes, cells were detached by treatment with 0.25% 
trypsin / 0.02% EDTA at 37 ºC. A sample of the obtained cell suspension 
was used to determine cell viability (by the trypan blue exclusion test) 
and cell number (e.g., using a cell counter) (193). For metabolomic 
studies, cells were seeded at a density of 8x10
4
 cells/cm
2
 on 3.5 cm (for 
specific-conditions analysis and processing method optimization) or 6 
cm culture dishes (for generic analysis in drug incubations). 
 
 
 
Figure 2.12. HepG2 cells cultured at low (panel A) and high (panel B) densities.  
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A total of 13 compounds were selected for the in vitro hepatotoxicity 
study based on data available in the literature (29, 69, 88, 89, 91, 92). 
Compounds with well-documented in vivo hepatotoxicity were classified 
according to the main mechanism involved in their toxicity (i.e. steatosis, 
phospholipidosis, cholestasis or OS) (Table 2.2) (29, 69, 88, 89, 91, 92). 
In addition, two compounds with no reports of hepatotoxic effects were 
used as negative controls (29). The stock solutions of the test 
compounds were prepared in DMSO and were freshly diluted in the 
culture medium to obtain the desired final concentration. Only sub-lethal 
concentrations of the compounds were used (Table 2.2) (29, 69, 88, 89, 
91, 92). HepG2 cells (70-80% confluence) were treated for 24 h with the 
compounds. After incubation, cells were processed according to the 
procedures described below. 
A specific additional culture design was applied to drugs causing 
steatosis and phospholipidosis in order to favor and accelerate the 
development of the hepatotoxic injury. Prior to being exposed to the 
model compounds, HepG2 cells were incubated for 14 h with a 62 µM 
mixture of oleate and palmitate (2:1 ratio). Then, cells were incubated 
with the test compounds for 24 h in a FA free medium (32, 193). 
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Table 2.2. Model hepatotoxins included in the HepG2 cell studies classified by 
their mechanism of hepatotoxicity. 
 
Mechanism Compound Concentrations 
Negative Control 
Culture medium 
DMSO (Solvent) 
Citrate 
Ketotifen 
 
0.5, 1.2% 
500, 1000 µM 
50, 100 µM 
Cholestasis 
Chlorpromazine 
Cyclosporine 
Troglitazone 
10, 20 µM  
10, 25, 50 µM 
10, 20 µM 
Oxidative Stress 
Cumene Hydroperoxide 
Tert-Butyl Hydroperoxide 
50, 100, 250 µM 
50, 100, 250 µM 
Phospholipidosis 
Amiodarone 
Clozapine 
Fluoxetine 
Tilorone 
Tamoxifen 
5, 10, 20 µM 
10, 20, 40 µM 
10, 20 µM 
5, 10, 20 µM 
15, 30 µM 
Steatosis 
Doxycycline 
Tetracycline 
Valproic acid 
250, 500 µM 
50, 100, 200, 400 µM 
1, 2, 4, 8 mM 
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2.7 Sample processing and analysis optimization for 
HepG2 cells 
 
Sample preparation is a crucial step in the onset of a metabolomic 
analysis involving mammalian cells in adherent culture. Different aspects 
regarding the untargeted analysis of the endometabolome of cultured 
HepG2 cells were evaluated: i) sample analysis; ii) metabolome 
extraction; and iii) sample harvesting and processing methodology 
(Figure 2.13). 
 
 
 
Figure 2.13. Schematic representation of the parameters evaluated during 
sample processing and analysis strategy optimization. 
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Each condition was tested using three biological replicates of HepG2 
cells cultured in 3.5 cm plates. The optimum condition for each of the 
evaluated parameters was selected based on the number, nature and 
intensity of the detected features and metabolites. 
In a first step, the extraction solvent and the different analytical 
conditions were tested and optimized in a combined manner. As a 
general procedure for sample processing of HepG2 cultures, the medium 
was removed and the cells were washed with phosphate buffer saline 
(PBS); then the cell monolayer was frozen using liquid N2 to halt cellular 
metabolism and prevent metabolite degradation; finally, the cells were 
scrapped by using an organic solvent and submitted to three 
freeze/thaw cycles in order to increase cell lysis and metabolite 
extraction. In a second step, and based on the optimized extraction 
solvent and analysis strategy, the different sample harvesting and 
processing methods were evaluated. 
 
2.7.1 Sample analysis 
 
Three different LC conditions, each one using both ESI (+) and ESI (-) 
MS detection, were tested in order to optimize the untargeted 
metabolomic analysis: i) Generic-RP analysis; ii) Lipidomic-RP analysis; 
and iii) HILIC analysis (Figure 2.13). 
 
i). Generic-RP analysis  
 
The analytical conditions for the untargeted LC-MS analysis using a 
generic-RP chromatographic separation are detailed in Section 2.3.1. 
For the analysis in ESI (+) mode, samples were resuspended in 75 µL of 
water:methanol (70:30) supplemented with the following IS: 
 Paracetamol, C8H9NO2, m/z 152.0712, RT 4.75 min, 10 µg/mL. 
 Caffeine, C8H10N4O2, m/z 195.0882, RT 6.74 min, 5 µg/mL. 
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 Sulfadimethoxine, C12H14N4O4S,m/z 311.0814,RT 8.11 min,1 µg/mL. 
 Val-Tyr-Val, C19H29N3O5, m/z 380.2185, RT 6.93 min, 10 µg/mL. 
 Verapamil, C27H38N2O4, m/z 455.2910, RT 8.93 min, 0.5 µg/mL. 
 Terfenadine, C32H41NO2, m/z 472.3216, RT 9.97 min, 5 µg/mL. 
 Reserpine, C33H40N2O9, m/z 609.2812, RT 9.27 min, 2.5 µg/mL. 
 
For the analysis in ESI (-) mode, samples were resuspended in 75 µL of 
water:methanol (70:30) supplemented with the following IS: 
 Lithocholic acid-2,2,4,4-D4 (LCA-D4), C24H36D4O3, m/z 379.3150, RT 
10.50 min, 4 µg/mL. 
 Deoxycholic acid-2,2,4,4-D4 (DCA-D4), C24H36D4O4, m/z 395.3099, 
RT 9.46 min, 2 µg/mL. 
 Cholic acid-2,2,4,4-D4 (CA-D4), C24H36D4O5, m/z 411.3049, RT 8.53 
min, 2 µg/mL. 
 Glycochenodeoxycholic acid-2,2,4,4-D4 (GCDCA-D4), C26H39D4NO5, 
m/z 452.3314, RT 7.98 min, 2 µg/mL. 
 Glycocholic acid-2,2,4,4-D4 (GCA-D4), C26H39D4NO6, m/z 468.3263, 
RT 7.59 min, 2 µg/mL. 
 Reserpine, C33H40N2O9, m/z 607.2656, RT 9.59 min, 2.5 µg/mL. 
 
ii) Lipidomic-RP analysis 
 
The analytical conditions for the untargeted LC-MS analysis using a 
lipidomic-RP chromatographic separation are detailed in Section 2.3.2. 
For the analysis in ESI (+) mode, samples were resuspended in 75 µL of 
methanol:chloroform (3:1) supplemented with the following IS: 
 LysoPC(13:0), C21H44NO7P, m/z 454.2934, RT 1.48 min, 25 ng/mL. 
 Terfenadine, C32H41NO2, m/z 472.3216, RT 1.89 min, 25 ng/mL. 
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For the analysis in ESI (-) mode, samples were resuspended in 75 µL of 
methanol:chloroform (3:1) supplemented with the following IS: 
 LCA-D4, C24H36D4O3, m/z 379.3150, RT 3.96 min, 4 µg/mL. 
 DCA-D4, C24H36D4O4, m/z 395.3099, RT 3.18 min, 2 µg/mL. 
 CA-D4, C24H36-D4O5, m/z 411.3049, RT 2.61 min, 2 µg/mL. 
 GCDCA-D4, C26H39D4NO5, m/z 452.3314, RT 2.55 min, 2 µg/mL. 
 GCA-D4, C26H39D4NO6, m/z 468.3263, RT 2.23 min, 2 µg/mL. 
 
iii)  HILIC analysis 
 
The analytical conditions for the untargeted LC-MS analysis using HILIC 
chromatographic separation are detailed in Section 2.3.3. 
For the analysis in both ESI (+) and ESI (-) modes, samples were 
resuspended in 75 µL of acetonitrile:water (70:30) supplemented with 
the following IS: 
 Phenylalanine-D5 (Phe-D5), C9H6D5NO2, m/z 171.1182 / 169.1020, 
RT 7.10 min, 40 µg/mL. 
 Val-Tyr-Val, C19H29N3O5, m/z 380.2185 / 378.2029, RT 6.33 min,  
10 µg/mL. 
 8-BrAMP, C10H13BrN5O7P, m/z 425.9814 / 423.9658, RT 3.96 min, 
20 µg/mL. 
 Leucine Enkephalin, C28H37N5O7, m/z 556.2771 / 554.2615, RT 6.45 
min, 10 µg/mL. 
 
2.7.2 Metabolome extraction 
 
Five different solvents, leading to seven different extracts, were tested: 
Solvent 1: 1mM Hepes, 1mM EDTA pH7.2 in water (monophasic 
extraction) (146), extract 1 (E1); Solvent 2: Water:methanol:chloroform 
(10:27:3) (monophasic extraction) (152), extract 2 (E2); Solvent 3: 
Methanol (monophasic extraction) (194), extract 3 (E3); Solvent 4: 
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Water:methanol:chloroform (1:1:1) (biphasic extraction) (195), extracts 4 
(E4, aqueous) and 5 (E5, organic); and Solvent 5: Water:methanol (1:1), 
followed by methanol:chloroform (1:3) (sequential extraction) (162), 
extracts 6 (E6, aqueous) and 7 (E7, organic) (Figure2.13). 
The volumes and specific considerations derived from the nature of 
the different combination of solvents are described below. In all the 
cases after the crude extract was obtained, it was subjected to three 
freeze/thaw cycles in order to maximize cell lysis and metabolite 
extraction. The final step in all the cases and once the clean extracts 
were obtained was to evaporate them to dryness and resuspend them in 
the suitable solvent in concordance with the analytical condition to be 
employed 
 
1. Monophasic extractions 
 
This procedure was performed with solvents 1, 2 and 3. An initial 
volume of 750 µL was used to scrap the cells, and a second volume of 
250 µL was employed (and pooled in the tube with the first one) to 
recover possible rests. After the freeze/thaw cycles, a 75 µL aliquot of 
cell extract was taken and mixed with 75 µL of 1 M NaOH to carry out 
protein quantification. Finally, the extracts were separated from the cell 
rests by centrifugation (10000 g, 10 min). 
 
2. Biphasic extraction: solvent 4 
 
Cells were scraped with 750 µL of methanol:water (1:1) and an 
additional volume (250 µL) was used to recover possible rests (and 
pooled in the tube with the first one). After the freeze/thaw cycles, a 75 
µL aliquot was taken and mixed with 75 µL of 1 M NaOH to carry out 
protein quantification. Then, 500 µL of chloroform were added to the 
rest of the extract and the tube was vortexed (3 x 10 s). After vortexing, 
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samples were allowed to rest for 20 min at -20 ºC and centrifuged 
(10000 g, 10 min). The upper aqueous phase and the lower organic 
phase were transferred to separate clean tubes. 
 
3. Sequential extraction: solvent 5 
 
750 µL of methanol:water (1:1) were used to scrap the cells, and a 
second volume of 250 µL was employed (and pooled in the tube with the 
first one) to recover possible rests. After the freeze/thaw cycles a 75 µL 
aliquot was taken and mixed with 75 µL of 1 M NaOH to carry out protein 
quantification. Then the samples were centrifuged (10000 g, 10 min) and 
the supernatants were transferred to clean tubes. The pellets were 
reextracted with 1 mL of methanol:chloroform (1:3). After centrifugation 
(10000 g, 10 min), the supernatants were transferred to clean tubes. 
 
2.7.3 Sample processing strategy optimization 
 
Three key steps are involved in adherent cells processing with respect 
to the analysis of the endometabolome: i) metabolism quenching; ii) 
metabolite extraction and iii) cell detachment from the surface of the 
plate (103). Three different configurations were tested: Method A, 
quenching, followed by simultaneous detachment and extraction; 
Method B, simultaneous quenching, extraction and detachment; and 
Method C, detachment, followed by quenching, followed by extraction 
(Figure 2.13, 2.14). 
To specifically evaluate these issues, the different cells harvesting and 
processing configurations were evaluated using the previously optimized 
sample analysis and extraction solvent conditions. In all the cases the 
first two steps regarding sample processing using HepG2 cells in culture 
consisted in the removal of the culture medium by aspiration and the 
washing of the cell monolayer with PBS. The final steps in all the cases 
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were to perform three freeze/thaw cycles in order to increase cell lysis 
and metabolites extraction, the separation of the cellular rests from the 
cellular extract and the evaporation to dryness of the clean extracts in 
order to be ready for resuspension in the suitable solvent for its analysis. 
The specific steps of each of the configurations are detailed below. 
 
 
 
Figure 2.14. Sample processing strategies tested during the development and 
optimization phase. Figure adapted from reference (103).  
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Method A 
 
After washing, cell metabolism was immediately quenched by the 
addition of liquid N2 over the cell monolayer. Frozen plates were stored 
at -80 ºC until further processing. Simultaneous metabolite extraction 
and cell detachment were performed by the addition of the extraction 
solvent over the cell monolayer followed by cell detachment with a 
rubber cell scrapper.  
 
Method B 
 
Simultaneous quenching, extraction and detachment were achieved by 
the addition of cold extraction solvent over the cell monolayer and the 
use of a rubber cell scrapper to detach the cells from the surface of the 
plate.  
 
Method C 
 
Cells harvesting was performed by treatment with 0.25% trypsin / 
0.02% EDTA at 37 ºC. Thereafter, cells were recovered in 5% fetal bovine 
serum in PBS and transferred to a clean tube. After centrifugation (3000 
g, 3 min), the supernatant was removed by aspiration and the cells were 
washed with PBS, thus repeating the centrifugation and the removal of 
the supernatant steps. The pellet was frozen in liquid N2, and stored at    
-80 ºC until further processing. Metabolites were extracted by adding the 
extraction solvent to the cell pellet and vortexing until its complete 
resuspension.  
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2.8 Optimized sample extraction protocols for untargeted 
metabolomic analysis in HepG2 cells 
 
2.8.1 Generic protocol 
 
Each experimental condition (test compound and concentration) was 
tested in triplicate using 6 cm diameter plates. After processing, each 
biological sample was split into four different fractions, one to perform 
protein quantification and three destined to be analyzed under four 
different conditions.  
After removing the medium by aspiration and washing the monolayer 
with PBS, cells were frozen by the addition of liquid N2. At this point the 
plates were stored at -80 ºC until further processing. 
Metabolite extraction and cell detachment were performed by 
scrapping the cells with 800 µL of a water:methanol:chloroform (10:27:3) 
solution containing 0.375 µg/mL reserpine and 0.075 µg/mL 
sulfadimethoxine as IS. The cell extract/suspension was transferred to a 
clean 1.5 mL tube. The possible cellular rests present in the plate were 
recovered with 400 µL of the same extraction solution and pooled with 
the previous volume. The cellular extract/suspension was submitted to 3 
freeze/thaw cycles (liquid N2, room temperature) in order to increase cell 
disruption and metabolite extraction. At this point three different 
aliquots were taken and processed independently. 
A 50 µL aliquot was mixed with 100 µL of 0.66 N NaOH and used for 
protein determination. 
A 600 µL aliquot was submitted to liquid-liquid extraction with 
chloroform. To this end, 300 µL of water and 450 µL of chloroform 
containing 0.01 µg/mL terfenadine as IS were added and the samples 
were vortexed (3 x 10 s) to put in contact both phases. Then, the 
samples were allowed to rest at -20 ºC for 20 min and centrifuged (10 
min, 10000 g, 4 ºC). Each phase (the upper aqueous phase and the lower 
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organic phase) was transferred to a clean tube and evaporated to 
dryness. The organic phase was resuspended in 75 µL of a 
methanol:chloroform (3:1) solution containing 0.5 µg/mL verapamil as IS 
and analyzed using the lipidomic-RP ESI (+) approximation. The aqueous 
phase was resuspended in 75 µL of acetonitrile:water (70:30) solution 
with IS (40 µg/mL Phe-D5, 20 µg/mL 8-BrAMP and 10 µg/mL Val-Tyr-Val) 
and analyzed using the HILIC approximation in both ESI (+) and ESI (-) 
modes. 
Finally, the rest of the volume was centrifuged (10 min, 10000 g, 4 ºC) 
and the supernatant was transferred to a clean tube and evaporated to 
dryness. The residue was resuspended in 75 µL of methanol:water (1:1) 
solution containing 4 µg/mL LCA-D4 as IS and analyzed using the 
generic-RP ESI (-) approximation. 
In all the cases the dry residue was stored at -80 ºC until its analysis, 
and, once resuspended, it was centrifuged (10000 g, 10 min, 4 ºC) 
before transferring the clean supernatant to a 96-well plate for its LC-MS 
untargeted analysis. 
 
2.8.2 Steatosis/Phospholipidosis specific protocol 
 
Each drug and concentration was tested by triplicate in 3.5 cm plates 
using a lipidomic-RP approximation adapted from reference (163). First 
of all, the medium was removed by aspiration, and the cell monolayer 
was washed once with PBS. Then the cell monolayer was frozen by the 
addition of liquid N2. At this point the plates were stored at -80 ºC until 
further processing. 
The cells were scrapped using 400 µL of cold PBS containing 0.375 
µg/mL reserpine as IS. The cell suspension/extract was transferred to a 
clean 2 mL tube. The possible cellular rests present in the plate were 
recovered with 200 µL of the solution and pooled with the previous 
volume. The cellular extract/suspension was submitted to 3 freeze/thaw 
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cycles (liquid N2, room temperature) in order to increase cell disruption 
and metabolite extraction. An aliquot of 50 µL was mixed with 100 µL of 
0.66 N NaOH and used for protein determination. The rest of the volume 
was mixed with 1100 µL of a methanol:chloroform (1:2) solution 
containing 0.01 µg/mL terfenadine as IS. After vortexing (3 x 10 s), the 
samples were allowed to rest at -20 ºC for 20 min and centrifuged (10 
min, 10000 g, 4 ºC). The lower organic phase was transferred to a clean 
2 mL tube and the aqueous phase was reextracted with 1100 µL of the 
methanol:chloroform (1:2) solution containing 0.01 µg/mL terfenadine 
as previously described. The second organic fraction was pooled with the 
first one. A 1 mL aliquot was taken and evaporated to dryness in a 
speedvac. The dry residue was stored at -80 ºC until analysis. The 
residue was resuspended in 75 µL of a methanol:chloroform (3:1) 
solution containing 0.5 µg/mL verapamil and 4 µg/mL LCA-D4 as IS and 
analyzed using the lipidomic-RP approximation in both ESI (+) and ESI (-) 
modes (Section 2.3.2). 
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2.9 In vivo hepatotoxicity studies in medakafish (Oryzias 
latipes) 
 
2.9.1 Animal handling 
 
Adult medaka (Oryzias latipes) CAB strain animals (Figure 2.15) (196) 
were kept in recirculating water 10 L aquaria at 28 °C on a 14 h light/10 
h dark daily cycle. Daily, they were fed with Artemia nauplii twice and dry 
fed once (197).  
 
 
 
Figure 2.15. Adult medaka (Oryzias latipes). 
 
 
Animals were exposed to different hepatotoxic compounds classified 
according to their mechanism of toxicity (Table 2.3). Sub-lethal 
concentrations were used based on previous in house experimental data 
and bibliographic information (198-204). Stock solutions of the drugs 
were prepared in water or methanol (according to the manufacturer's 
instructions). For treatments, the fishes were transferred to 4L aquaria 
containing either drug at the specified concentration or 0.005% methanol 
as vehicle control (Table 2.3). After a 2h treatment, the fishes were 
returned to 10 L aquaria containing clean water. The treatment was 
repeated for 5 consecutive days and the fishes were sacrificed at the end 
of treatment.  
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Table 2.3. Model hepatotoxins included in the study using Oryzias latipes. 
 
Mechanism Compound Concentration 
Negative Control Methanol (solvent) 0.005% 
Cholestasis 
17α Ethynylestradiol 
Chlorpromazine 
Cyclosporine 
3 µM 
2 µM 
2.5 µM 
Phospholipidosis 
Amiodarone 
Tilorone 
Tamoxifen 
2 µM 
2 µM 
2 µM 
Steatosis 
Doxycycline 
Tetracycline 
Valproic acid 
50 µM 
50 µM 
200 µM 
 
 
Individual adult medaka were anesthetized in cold PBS at 0 ºC and 
immediately transferred to a dry plate and sacrificed by decapitation. The 
liver was extracted, placed in a tube, flash-frozen in liquid N2, and stored 
at -80 ºC until further processing. All the experimental protocols were 
approved by the Institutional Animal Ethics Committee. 
 
2.9.2 Sample processing and analysis 
 
Frozen tissue samples (2 - 6 mg) were placed in 2 mL tubes containing 
CK14 ceramic beads and 650 µL of methanol:water (3:1) containing the 
IS reserpine (0.375 µg/mL) and sulfadimethoxine (0.075 µg/mL) were 
added. Then, livers were homogenized twice for 25 s at 6,000 rpm at 4 
ºC in a Precellys 24 Dual system equipped with a Criolys cooler. Tubes 
were centrifuged at 3000 g for 5 min at 4°C, and the supernatants were 
transferred to clean tubes. A second extraction was performed with 350 
µL of the same solvent. Finally, the two extraction supernatants were 
pooled and stored at -80 ºC until further processing. 
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An aliquot of 50 µL was mixed with 100 µL of 0.66N NaOH and used 
for protein determination. 
A 600 µL aliquot was transferred to a clean tube and evaporated to 
dryness. The dry residue was stored at -80 ºC until analysis. The residue 
was resuspended in 100 µL of water:methanol (1:1) containing 0.5 
µg/mL verapamil and 4 µg/mL LCA-D4 as IS. After centrifugation (10 
min, 10000g, 4 ºC), the clean supernatant was transferred to a 96-well 
HPLC plate and analyzed using the generic-RP analysis conditions in ESI(-) 
mode (Section 2.3.1).  
A 400 µL aliquot was transferred to a clean tube and 200 µL of 
chloroform containing 0.01 µg/mL terfenadine as IS were added. After 
vortexing (3 x 10 s), samples were allowed to rest at -20 ºC for 20 min 
and centrifuged (10 min, 10000 g, 4 ºC). The upper aqueous phase and 
the lower organic phase were separately transferred to clean tubes and 
evaporated to dryness. The organic phase was resuspended in 100 µL of 
methanol:chloroform (3:1) containing 0.5 µg/mL verapamil as IS and 
analyzed using the lipidomic-RP approximation in ESI (+) mode (Section 
2.3.2). The aqueous phase was resuspended in 100 µL of 
acetonitrile:water (70:30) solution containing 40 µg/mL Phe-D5, 20 
µg/mL 8-BrAMP and 10 µg/mL Val-Tyr-Val as IS and analyzed using the 
HILIC approximation in both ESI (+) and ESI (-) modes (Section 2.3.3). 
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2.10 In vivo hepatotoxicity studies in rats 
 
2.10.1 Animal handling 
 
Six-week-old male OFA rats (200 – 240 g) were purchased from Charles 
River (Barcelona, Spain) and acclimatized to laboratory conditions for at 
least 7 days. Animals were housed in individual cages with woodchip 
bedding in a room maintained at 21 – 25 °C, 30 – 70% humidity and a 12 
h light-dark cycle. Each animal was allowed free access to water and 
standard chow diet (Scientific Animal Food and Engineering, Augy, 
France). 
Rats were divided into three different groups: i) Tetracycline (2 
g/Kg/day); ii) Paracetamol (1 g/kg/day); and iii) Control. Drugs were 
administered orally at the indicated doses in a 0.5 % methylcellulose 
solution, control rats were administered vehicle (205). Treatments were 
repeated during 4 or 2 consecutive days for rats receiving the 
tetracycline or paracetamol treatment, respectively. The rats were 
sacrificed 24 h after the last administration.  
Rats were anesthetized with sodium thiobarbital (0.1 g/kg). Blood was 
collected by cardiac puncture. After coagulation and centrifugation (1000 
g for 10 min at 4 °C), serum samples were aliquoted and stored at -80 °C 
until their analysis by LC-MS. An aliquot was destined to perform serum 
biochemistry and enzymatic activities using standard laboratory 
procedures. Livers were removed, rinsed in PBS, divided into small 
portions, flash-frozen in liquid N2, and stored at -80 ºC until the analysis. 
Serum and liver samples were obtained from the same animals. All the 
experimental protocols were approved by the Institutional Animal Ethics 
Committee. 
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2.10.2 Sample processing and untargeted LC-MS analysis 
 
Liver tissue samples 
 
Each frozen tissue sample (around 100 mg) was placed in a 2 mL tube 
containing CK14 ceramic beads and weighted. For each 100 mg of 
tissue, 650 µL of methanol:water (3:1) containing the IS reserpine (0.375 
µg/mL) and sulfadimethoxine (0.075 µg/mL) were added. Then, tissue 
was homogenized twice for 25 s at 6,000 rpm at 4 ºC in a Precellys 24 
Dual system. After centrifugation (3000 g, 5 min, 4°C), the supernatant 
was transferred to a clean tube. A second extraction was performed with 
350 µL per 100 mg of tissue of the solvent. Finally, the two extraction 
supernatants were pooled and stored at -80 ºC until further processing. 
A 100 µL aliquot was transferred to a clean tube and evaporated to 
dryness using a speedvac. The dry residue was stored at -80 ºC until 
analysis. The residue was resuspended in 100 µL of water:methanol (1:1) 
containing 0.5 µg/mL verapamil and 4 µg/mL LCA-D4 as IS. After 
centrifugation (10 min, 10000g, 4 ºC), the clean supernatant was 
transferred to a 96-well HPLC plate and analyzed using the generic-RP 
analysis conditions in ESI (-) mode (Section 2.3.1).  
A 200 µL aliquot was transferred to a clean tube and 100 µL of 
chloroform containing 0.01 µg/mL terfenadine as IS were added. After 
vortexing (3 x 10 s), samples were allowed to rest at -20 ºC for 20 min 
and centrifuged (10 min, 10000 g, 4 ºC). Each phase (the upper aqueous 
and the lower organic) was separately transferred to a clean tube and 
evaporated to dryness in a speedvac. The organic phase was 
resuspended in 100 µL of methanol:chloroform (3:1) containing 0.5 
µg/mL verapamil as IS and analyzed using the lipidomic-RP 
approximation in ESI (+) mode (Section 2.3.2). The aqueous phase was 
resuspended in 100 µL of acetonitrile:water (70:30) containing 40 µg/mL 
Phe-D5, 20 µg/mL 8-BrAMP and 10 µg/mL Val-Tyr-Val as IS and analyzed 
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using the HILIC approximation in both ESI (+) and ESI (-) modes (Section 
2.3.3). 
 
Serum samples 
 
For lipidomic-RP analysis, a 10 µL aliquot was mixed with 40 µL of PBS 
and 250 µL of chloroform:methanol (2:1) containing 0.01 µg/mL 
terfenadine as IS. After vortexing (3 x 10 s), samples were allowed to rest 
at -20 ºC for 20 min and centrifuged (10 min, 10000 g, 4 ºC). A 100 µL 
aliquot of the lower organic phase was transferred to a 96-well HPLC and 
10 µL of the IS verapamil (5.5 µg/mL in methanol) were added. The 
analysis was performed using the lipidomic-RP approximation in ESI (+) 
mode (Section 2.3.2). 
For generic-RP analysis, a 100 µL aliquot was mixed with 300 µL of 
cold methanol containing reserpine (0.375 µg/mL) and sulfadimethoxine 
(0.075 µg/mL) as IS. After vortexing (3 x 10 s), samples were allowed to 
rest at -20 ºC for 30 min and centrifuged (10 min, 10000 g, 4 ºC). The 
clean supernatant was transferred to a clean tube and evaporated to 
dryness. The dry residue was stored at -80 ºC until analysis. The residue 
was resuspended in 100 µL of water:methanol (1:1) containing 0.5 
µg/mL verapamil and 4 µg/mL LCA-D4 as IS. After centrifugation (10 
min, 10000 g, 4 ºC), the clean supernatant was transferred to a 96-well 
HPLC plate and analyzed using the generic-RP analysis conditions in both 
ESI (+) and ESI (-) modes (Section 2.3.1). 
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2.11 Method validation for LC-MS/MS targeted analyses 
 
The bioanalytical methods described in the following sections were 
developed and validated in terms of linearity, accuracy, and precision 
following the compliance criteria described by the FDA Guidance for 
industry: bioanalytical method validation (206). 
The lower limit of quantification (LLOQ) was defined as the lowest 
concentration at which the analyte could be quantified with relative 
standard deviation (RSD) below 20% and below ± 20% deviation from the 
nominal value. The limit of detection (LOD) was determined as the lowest 
concentration at which the analyte response was at least three times the 
blank response. Calibration curves were generated by plotting the peak 
area ratio of the respective compound to the corresponding IS versus the 
nominal concentration. The line of best fit was determined by linear-
weighted (1/×) least-squares regression. The linearity acceptance 
criterion for the correlation coefficient was 0.99 or better. Each back 
calculated standard concentration should be within ± 15% deviation from 
the nominal value, except for the LLOQ, for which the maximum 
acceptable deviation was ± 20%. 
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2.12 Targeted analysis of bile acids 
 
A targeted UPLC-MS MRM method for the simultaneous quantification 
of 31 BAs, including both major and minor non-conjugated or 
conjugated forms, was developed (207). It allows the comprehensive 
quantitative profiling of BAs in different biological matrices (i.e., serum, 
liver tissue, cultured cells) from different species (i.e., human, mouse 
and rat) (103, 207, 208).  
 
2.12.1 Bile acids included in the method 
 
The following BAs were included in the analysis: lithocholic acid (LCA), 
murocholic acid (MuroCA), chenodeoxycholic acid (CDCA), deoxycholic 
acid (DCA), ursodeoxycholic acid (UDCA), hyodeoxycholic acid (HDCA), 
dehydrocholic acid (DHCA), cholic acid (CA), α-muricholic acid (αMCA), β-
muricholic acid (βMCA), ω-muricholic acid (ωMCA), hyocholic acid (HCA), 
glycolithocholic acid (GLCA), glycochenodeoxycholic acid (GCDCA), 
glycodeoxycholic acid (GDCA), glycoursodeoxycholic acid (GUDCA), 
glycohyodeoxycholic acid (GHDCA), glycodehydrocholic acid (GDHCA), 
glycocholic acid (GCA), glycohyocholic acid (GHCA), taurolithocholic acid 
(TLCA), taurochenodeoxycholic acid (TCDCA), taurodeoxycholic acid 
(TDCA), tauroursodeoxycholic acid (TUDCA), taurohyodeoxycholic acid 
(THDCA), taurodehydrocholic acid (TDHCA), taurocholic acid (TCA), 
tauro-α-muricholic acid (TαMCA), tauro-β-muricholic acid (TβMCA), tauro-
ω-muricholic acid (TωMCA), taurohyocholic acid (THCA). 
Deuterated IS: LCA-D4, DCA-D4, CA-D4) GCDCA-D4 and GCA-D4. 
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2.12.2 UPLC-MS analysis 
 
UPLC separation was performed in an Acquity UPLC system (Waters, 
UK) equipped with an Acquity UPLC BEH C18 (1.7 µm, 2.1 × 100 mm; 
Waters) column. The temperatures of the column and the autosampler 
were set at 65 °C and 4 °C, respectively. The sample injection volume was 
4 µL. Eluent and washing solutions composition were: i) solvent A: 0.1% 
formic acid in water; ii) solvent B: 0.1% formic acid in acetonitrile; iii) 
WNW and SW: water:acetonitrile (90:10, v/v); and iv) SNW: acetonitrile. 
The flow rate was set at 0.5 ml/min. A 21-min elution gradient was 
performed as follows: during the first 0.5 min, eluent composition was 
set at 95% A and 5% B, which was linearly changed to 75% A and 25% B in 
5 min; then the proportion of B was increased to 40% in the next 10.5 
min, followed by a further increase to 95% B reached at min 17.5 and 
kept for 1.5 min. Finally, the initial conditions were recovered and 
maintained for 2 min for column conditioning. 
The MS analysis was performed using a Waters Xevo TQ-S mass 
spectrometer equipped with an ESI source operating in the negative-ion 
mode working in the MRM mode. A capillary voltage of 2 kV, a source 
temperature of 120 °C and a desolvation temperature of 380 °C were 
used. Desolvation and cone gas flows were set as 800 L/h and 150 L/h, 
respectively, and the collision gas was 0.25 mL/min. Transitions, cone 
voltages, and collision energies were automatically tuned for each BA 
using the QuanOptimizer software (Waters, UK) (Table 2.4) 
Standards calibration curves prepared in methanol:water (50:50, v/v) 
with concentrations in the 0.62 – 10000 nM range for each BA. IS 
concentrations were kept constant at all the calibration points at 1 µM 
for LCA-D4 and at 0.5 µM for CA-D4, DCA-D4, GCA-D4, and GCDCA-D4. 
Figure 2.16 shows the chromatograms obtained by injecting a mix 
standard solution at 300 nM (IS concentrations: 1 µM for LCA-D4 and 0.5 
µM for CA-D4, DCA-D4, GCA-D4, and GCDCA-D4). 
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Table 2.4. Mass spectrometer setup for the quantification of selected bile acids. 
 
Bile acid 
Parent ion 
(m/z) 
Fragment 
(m/z) 
Cone  
(V) 
Collision 
energy (eV) 
Retention 
time (min) 
Internal 
standard 
LCA 375.3 375.3 90 10 17.74 LCA-D4 
MuroCA 391.3 391.3 120 10 12.69 DCA-D4 
CDCA 391.3 391.3 120 10 17.13 DCA-D4 
DCA 391.3 391.3 120 10 17.22 DCA-D4 
UDCA 391.3 391.3 120 10 14.00 DCA-D4 
HDCA 391.3 391.3 120 10 14.41 DCA-D4 
DHCA 401.2 401.2 90 10 9.14 CA-D4 
CA 407.3 407.3 120 10 13.90 CA-D4 
ωMCA 407.3 407.3 120 10 10.57 CA-D4 
αMCA 407.3 407.3 120 10 10.92 CA-D4 
βMCA 407.3 407.3 120 10 11.30 CA-D4 
HCA 407.3 407.3 120 10 12.71 CA-D4 
GLCA 432.3 73.8 80 40 17.31 LCA-D4 
GCDCA 448.3 73.8 80 40 14.61 GCDCA-D4 
GDCA 448.3 73.8 80 40 15.32 GCDCA-D4 
GUDCA 448.3 73.8 80 40 10.71 GCDCA-D4 
GHDCA 448.3 73.8 80 40 10.97 GCDCA-D4 
GDHCA 458.3 73.8 80 40 6.98 GCA-D4 
GCA 464.3 73.8 80 40 11.08 GCA-D4 
GHCA 464.3 73.8 80 40 9.71 GCA-D4 
TLCA 482.3 80 130 60 16.17 LCA-D4 
TCDCA 498.3 80 130 60 11.85 GCDCA-D4 
TDCA 498.3 80 130 60 12.55 GCDCA-D4 
TUDCA 498.3 80 130 60 8.61 GCDCA-D4 
THDCA 498.3 80 130 60 8.71 GCDCA-D4 
TDHCA 508.3 80 130 60 5.87 GCA-D4 
TCA 514.3 80 130 60 9.10 GCA-D4 
TωMCA 514.3 80 130 60 6.59 GCA-D4 
TαMCA 514.3 80 130 60 6.73 GCA-D4 
TβMCA 514.3 80 130 60 6.80 GCA-D4 
THCA 514.3 80 130 60 7.80 GCA-D4 
LCA-D4 379.3 379.3 90 10 17.74 
 
DCA-D4 395.3 395.3 120 10 17.22 
 
CA-D4 411.3 411.3 120 10 13.90 
 
GCDCA-D4 452.4 73.8 80 40 14.61 
 
GCA-D4 468.4 73.8 80 40 11.08 
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Figure 2.16. Chromatograms corresponding to the targeted LC-MS/MS analysis 
of BAs. A) Non-conjugated BAs. B) Glycine-conjugated BAs. C) Taurine-conjugated 
BAs. D) Deuterium-labeled IS. All the BAs were separated and detected in a single 
analytical run. Green: DHCA; blue: tri-hydroxylated BAs; red: di-hydroxylated BAs; 
dark blue: mono-hydroxylated BAs.  
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2.12.3 Sample processing 
 
A mixed stock solution of all the IS was prepared in methanol:water 
(50:50, v/v) at a final concentration of 100 µM, except LCA-D4, whose 
concentration was 200 µM. 
For serum samples, aliquots of 50 µL were allowed to thaw on ice and 
were subsequently spiked with 25 µL of a 1/100 dilution of the 
deuterated IS stock solution . Then, cold methanol (225 µL) was added 
for protein precipitation, and samples were vortexed (3 × 10 s) and 
allowed to rest at -20 ºC for 20 min. After centrifugation (10000 g, 10 
min, 4 ºC), supernatants were transferred to clean tubes and evaporated 
to dryness. Samples were stored at -80 ºC until analysis. 
Frozen hepatic tissue samples (5 – 100 mg) were placed in 2 mL tubes 
containing CK14 ceramic beads. For each 100 mg of tissue, 600 µL of 
cold methanol and 200 µL of a 1/100 dilution of the IS stock solution 
were added. Then, liver tissues were homogenized twice for 25 s at 6000 
rpm at 4 ºC in a Precellys 24 Dual system. After centrifugation (3000 g, 5 
min, 4 °C), supernatants were transferred to clean tubes. A second BA 
extraction was performed with 400 µl of cold methanol. Finally, the two 
extraction supernatants were pooled and 150 µL aliquots were 
evaporated to dryness and stored at -80 ºC until analysis. 
For the LC-MS analysis, dry extracts (from serum or liver) were 
reconstituted in 50 µL of methanol:water (50:50, v/v), centrifuged (1 
min, 10000 g, 4 ºC), and transferred into 350 µL volume 96-well plates 
for further analysis. 
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2.13 Targeted analysis of oxidative stress biomarkers 
 
A targeted UPLC-MS MRM method was developed in our group in order 
to evaluate the oxidative stress damage induced to proteins, DNA and 
lipids in serum, tissue liver and cultured cells samples (209).  
 
2.13.1 OS markers included in the method 
 
The markers included in the method are: GSH, oxidized glutathione 
(GSSG), ophthalmic acid, S-(5-adenosyl)-L-methionine (SAM), S-(5-
adenosyl)-L-homocysteine (SAH), phenylalanine (Phe), tyrosines (3-iodo-L-
tyrosine (I-Tyr), 3-nitro-tyrosine (N-Tyr), 3-chloro-L-tyrosine (Cl-Tyr), DL-o-
tyrosine (o-Tyr), DL-m-tyrosine (m-Tyr), L-tyrosine (p-Tyr)), 8-hydroxy-2’-
deoxyguanosine (8-OH-dG), 2-deoxyguanosine (2-dG) and 
malondialdehyde (MDA). 
 
2.13.2 UPLC-MS analysis 
 
UPLC separation was performed in an Acquity UPLC system (Waters, 
UK) equipped with an Acquity UPLC HSST3 (1.8 µm, 2.1 × 100 mm; 
Waters) column. The temperatures of the column and the autosampler 
were set at 60 °C and 4 °C, respectively. The sample injection volume was 
5 µL Eluent and washing solutions composition were: i) solvent A: 0.1% 
formic acid in water; ii) solvent B: 0.1% formic acid in acetonitrile; iii) 
WNW and SW: water:acetonitrile (90:10, v/v); and iv) SNW: 
water:acetonitrile (10:90, v/v). The flow rate was set at 0.3 mL/min. A 7-
min elution gradient was performed as follows: during the first 2 min, 
eluent composition was set at 95% A and 5% B, which was linearly 
changed to 5% A and 95% B in 1.5 min and kept for 2 min. Finally, the 
initial conditions were recovered and maintained for 1 min for column 
conditioning. 
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The MS analysis was performed using a Waters Xevo TQ-S mass 
spectrometer (Waters) equipped with an ESI source operating in the 
positive-ion mode working in the MRM mode. A capillary voltage of 3 kV, 
a source temperature of 150 °C and a desolvation temperature of 380 °C 
were used. Desolvation and cone gas flows were set as 800 L/h and 150 
L/h, respectively, and the collision gas was 0.25 mL/min. Transitions, 
cone voltages, and collision energies are shown in Table 2.5. 
 
Table 2.5. Mass spectrometer setup for the quantification of selected oxidative 
stress markers.  
 
Compound 
Parent ion 
(m/z) 
Fragment 
(m/z) 
Cone  
(V) 
Collision 
energy (eV) 
Retention 
time (min) 
GSSG 613.2 355.0 60 15 1.10 
GSH
a 
433.1 201.0 20 20 3.32 
SAM 398.9 136.0 22 17 0.74 
SAHC 385.1 136.0 35 25 1.09 
I-Tyr 308.1 291.0 40 15 3.33 
Ophthalmic acid 290.2 161.1 15 15 1.16 
8-OH-dG 284.0 168.0 30 15 2.16 
2-dG 268.0 152.0 25 15 1.60 
MDA
b 
235.0 159.0 30 30 4.08 
N-Tyr 227.1 181.0 25 10 3.21 
Cl-Tyr 216.0 170.0 30 15 2.37 
o-Tyr 182.1 136.0 20 10 2.09 
m-Tyr 182.1 136.0 20 10 1.52 
p-Tyr 182.1 136.0 20 10 1.27 
Phe 166.1 120.1 20 20 2.62 
Phe-D5  171.1 125.1 20 20 2.62 
a
 Compound quantified as the N-ethylmaleimide (NEM) derivative. 
b
 Compound 
derivatized with 2,4-dinitrophenylhydrazine (DNPH). 
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A derivatization step was required to avoid degradation of some labile 
analytes, thus improving compound stability, detection and 
quantification. Thereby, MDA and GSH were determined after reaction 
with 2, 4-dinitrophenylhydrazine (DNPH) (210-212) and N-ethylmaleimide 
(NEM) (213, 214), respectively. 
Standards calibration curves were prepared in PBS (containing 0.5 mM 
DNPH and 5 mM NEM) in the concentration range from 1.25 µg/mL to 
0.725 ng/mL. for each compound. Phe-D5 (IS) concentration was kept 
constant at 0.2 µg/mL in all calibration points. Figure 2.17 shows the 
chromatograms obtained by injecting a mix standard solution at a 
concentration of 1 µg/mL. 
 
2.13.3 Sample processing 
 
Biological samples were processed differently depending on their 
nature. Moreover, to allow optimal detection of all biomarkers in the 
different biological matrices, three different sample fractions were 
prepared : i) fraction I, obtained after a concentration step to determine 
low concentrated analytes; ii) fraction II, obtained after a dilution step to 
determine the high concentrated analytes ; and iii) fraction III, obtained 
after a basic hydrolysis and derivatization step (212), to determine MDA 
due to its instability. 
Cell monolayers (previously washed and frozen in liquid N2) were 
scraped with 1 mL of 50 mM NEM in PBS and three freeze and thawing 
cycles were applied to ensure cell lysis. Frozen tissue samples (5–100 
mg) were extracted using a Precellys 24 Dual system with a total of 1mL 
of 50 mM NEM in PBS. Culture medium and serum samples were directly 
used to prepare the different fractions. 
To obtain fraction I, 1200 µL or 600 µL of cold methanol were added 
to 400 µL of extract from cultured cells or 200 µL of liver tissue extract, 
respectively, and tubes were vortexed. For culture medium or serum 
Methodology 
122
samples, 200 µL of 10 mM NEM in PBS were added to 200 µL of sample 
and, after vortexing, 1200 µL of cold methanol were added. The 
obtained mix (from cultured cells, tissue, medium or serum) was allowed 
to rest for 20 min at -20 ºC and then centrifuged for 10 min at 10000 g 
at 4 ºC. The clean supernatant was transferred to a clean tube and 
evaporated to dryness in a speedvac. The dry residue was reconstituted 
in 50 µL of PBS containing 200 ng/mL Phe-D5, centrifuged (10 min, 
10000 g, 4ºC), and the clean supernatant was transferred to a 96-well 
HPLC plate for its analysis.  
To obtain fraction II, 115 µL or 245 µL of cold methanol were added to 
10 µL of cultured cell or 5 µL of liver tissue extract. For culture medium 
or serum samples, 15 µL of 10 mM NEM in PBS were added to 10 µL of 
sample and, after vortexing, 100 µL of cold methanol were added. Then 
the mix (from cultured cells, tissue, medium or serum) was allowed to 
rest for 20 min at -20 ºC and after centrifugation (10 min, 10000 g, 4 
ºC), 50 µL clean supernatant were transferred to 96-well HPLC plate and 
mixed with 50 µL of PBS containing 400 ng/mL Phe-D5 for its analysis. 
To obtain fraction III, 25 µL of 6 N NaOH were added to 100 µL of 
sample (cellular or tissue extract, medium or serum), and the mix was 
incubated at 60 ºC for 30 min. Then, 60 µL of 35% perchloric acid were 
added. The mix was centrifuged (10 min, 10000 g, 4 ºC). The clean 
supernatant was transferred to a clean tube and mixed with 15 µL 5 mM 
of DNPH, 2660 ng/mL Phe-D5 in PBS. The mix was incubated for 60 min 
at 37 ºC and transferred to a 96-well HPLC plate. 
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Figure 2.17. Chromatograms corresponding to the targeted LC-MS/MS analysis 
of OS markers and related compounds. A) Sulphur containing and related 
compounds; B) Markers of OS damage to proteins; C) Markers of OS damage to 
DNA; D) MDA; E) IS.  
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2.14 Targeted analysis of -glutamyl dipeptides 
 
A targeted HILIC-UPLC-MS MRM method for the simultaneous 
quantification of 32 -glutamyl dipeptides and related metabolites was 
developed. 
 
2.14.1 Compounds included in the method 
 
-Glutamyl-dipeptides: -glutamyl-glycine, -glutamyl-alanine, -
glutamyl-serine, -glutamyl-valine, -glutamyl-threonine, -glutamyl-
homoserine, -glutamyl-taurine, -glutamyl-isoleucine, -glutamyl-leucine, 
-glutamyl-asparagine, -glutamyl-ornithine, -glutamyl-aspartate, -
glutamyl-glutamine, -glutamyl-lysine, -glutamyl-glutamate, -glutamyl-
methionine, -glutamyl-histidine, -glutamyl-phenylalanine, -glutamyl-
arginine, -glutamyl-citrulline, -glutamyl-tyrosine, -glutamyl-triptophan, 
-glutamyl-cysteine, -glutamyl-homocysteine. Related compounds: 
pyroglutamic acid, glutamine, glutamic acid, GSSG, GSH, cysteinyl-
glycine, bis-cysteinyl-glycine. Phe-D5 was used as IS. 
 
2.14.2 UPLC-MS analysis 
 
UPLC separation was performed in an Acquity UPLC system (Waters, 
UK) equipped with an Acquity UPLC BEH Amide (1.7 µm, 2.1 × 100 mm; 
Waters) column. The temperatures of the column and the autosampler 
were set at 40 °C and 4 °C, respectively. The sample injection volume was 
4 µL. Eluent and washing solutions composition were: i) solvent A: 
acetonitrile; ii) solvent B: ammonium acetate pH3 200 mM in water; iii) 
WNW and SW: water:acetonitrile (10:90, v/v); and iv) SNW: 
water:acetonitrile (90:10, v/v). The flow rate was set at 0.3 mL/min.  
A 12-min elution gradient was performed as follows: initial conditions 
were set at 85% A and 15% B and maintained for 1 min, the proportion of 
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B was increased to 35% in 5 min and then increased to 55% at min 9 and 
maintained for 0.5 min. Finally, the initial conditions were recovered and 
maintained for 2 min for column conditioning. 
The MS analysis was performed using a Waters Xevo TQ-S mass 
spectrometer (Waters) equipped with an ESI source operating in the 
positive-ion mode working in the MRM mode. A capillary voltage of 3 kV, 
a source temperature of 120 °C and a desolvation temperature of 380 °C 
were used. Desolvation and cone gas flows were set as 800 L/h and 150 
L/h, respectively, and the collision gas was 0.25 mL/min. Transitions, 
cone voltages, and collision energies were automatically tuned for each 
compound using the QuanOptimizer software (Waters, UK) (Table 2.6) 
A derivatization step was required to avoid degradation of some labile 
analytes, thus improving compound stability, detection and 
quantification. Thereby, GSH, -glutamyl-cysteine, -glutamyl-
homocysteine and cysteinyl-glycine were determined as NEM derivates 
(213, 214). 
Standard calibration curves (ranging 1.14 – 20000 nM for each 
compound) were prepared by serial half dilutions of a 100 µM stock 
solution in acetonitrile:ammonium acetate pH3 100 mM in water (7:3). 
Phe-D5 (IS) concentration was kept constant at 1 µM. Figure 2.18 shows 
the chromatograms obtained by injecting a 625 nM mix standard 
solution. 
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Table 2.6. Mass spectrometer setup for the quantification of selected -glutamyl 
dipeptides and related compounds.  
 
Compound 
Retention time  
(min) 
Parent ion 
(m/z) 
Cone  
(V) 
Fragment 
(m/z) 
Ce  
(eV) 
Pyroglutamate 3.94 130 30 84 20 
Glutamine 5.77 147.1 40 84 15 
Glutamate 6.17 148.1 40 84 15 
γ-Glu-Gly 7.03 205.1 40 84 10 
γ-Glu-Ala 6.59 219.1 40 90.1 10 
γ-Glu-Ser 7.35 235.1 40 106.1 10 
γ-Glu-Val 5.79 247.1 40 118.1 10 
γ-Glu-Thr 7.00 249.1 40 120.1 10 
γ-Glu-HomoSer 7.13 249.1 40 120.1 10 
γ-Glu-Tau 6.84 255.1 40 126 15 
γ-Glu-Leu 5.25 261.1 40 132.1 10 
γ-Glu-Ile 5.34 261.1 40 132.1 10 
γ-Glu-Asn 7.51 262.1 40 133.1 10 
γ-Glu-Orn 7.83 262.1 40 133.1 10 
γ-Glu-Asp 7.36 263.1 40 134 10 
γ-Glu-Gln 7.32 276.1 40 147.1 10 
γ-Glu-Lys 7.74 276.2 40 147.1 10 
γ-Glu-Glu 7.16 277.1 40 148.1 10 
γ-Glu-Met 5.81 279.1 40 150.1 10 
γ-Glu-His 7.65 285.1 40 156.1 10 
Ophthalmic acid 6.47 290.1 40 161.1 10 
γ-Glu-Phe 5.34 295.1 50 166.1 10 
Cys-Gly
a 
4.11 304.1 40 158 25 
γ-Glu-Arg 7.65 304.2 40 175.1 10 
γ-Glu-Citr 7.27 305.1 40 176.1 15 
γ-Glu-Tyr 5.99 311.1 50 182.1 10 
γ-Glu-Trp 5.22 334.1 50 205.1 15 
(H-Cys-Gly-OH)2 8.32 355.1 50 177 20 
γ-Glu-Cysa 5.58 376.1 50 247.1 10 
γ-Glu-HomoCysa 5.29 390.1 60 261.1 10 
GSH
a
 5.64 433.1 50 304.1 10 
GSSG 8.64 613.2 60 484.1 15 
Phe-D5 (IS) 3.34 171.1 40 125 20 
a
 Compounds quantified as the N-ethylmaleimide (NEM) derivative.  
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Figure 2.18. Chromatograms corresponding to the targeted LC-MS/MS analysis 
of γ-glutamyl dipeptides and related compounds. A) IS Phe-D5; B) Aminoacids; C) 
Ophthalmic acid; D) γ-Glutamyl dipeptides; E) Compounds detected as NEM 
derivates; F) Oxidized compounds.    
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2.14.3 Sample processing 
 
Biological samples were processed differently depending on their 
nature. Moreover, to allow optimal detection of all biomarkers in the 
different biological matrices, different dilutions and/or concentrations 
were used. 
For hepatic tissue and cultured cells samples, the extracts were 
obtained as previously described in Section 2.13.3. 
To obtain a 2x concentrated extract, 600 µL of cold methanol were 
added to 200 µL of extract. After vortexing, the mix was allowed to rest 
for 20 min at -20 ºC, centrifuged (10 min, 10000 g, 4 ºC) and the clean 
supernatant was transferred to a clean tube and evaporated to dryness in 
a speedvac. The dry residue was reconstituted in 100 µL of 
acetonitrile:100 mM ammonium acetate pH3 in water (7:3) containing 1 
µM Phe-D5, centrifuged (10 min, 10000 g, 4 ºC) and the clean 
supernatant was transferred to a 96-well HPLC plate for its analysis.  
To obtain 1/10 and 1/100 diluted samples, 120 µL of cold methanol 
were added to 30 µL of extract. After vortexing, the mix was allowed to 
rest for 20 min at -20 ºC. The extract was centrifuged (10 min, 10000 g, 
4 ºC). To prepare a 1/10 dilution, 50 µL clean supernatant were 
transferred to 96-well HPLC plate and mixed with 50 µL of 
acetonitrile:100 mM ammonium acetate pH3 in water (7:3) containing 
Phe-D5 2 µM. To prepare a 1/100 dilution, 5 µL clean supernatant were 
transferred to 96-well HPLC plate and mixed with 95 µL of 
acetonitrile:100 mM ammonium acetate pH3 in water (7:3) containing 
1.05 µM Phe-D5. 
For serum samples, to obtain a non-diluted sample, 100 µL of 50 mM 
NEM in were added to 100 µL of serum. After vortexing, 600 µL of cold 
methanol were added. The mix was vortexed, allowed to rest for 20 min 
at -20 ºC, centrifuged (10 min, 10000 g, 4 ºC) and the clean supernatant 
was transferred to a clean tube and evaporated to dryness in a speedvac. 
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The dry residue was reconstituted in 100 µL of acetonitrile:100 mM 
ammonium acetate pH3 in water (7:3) containing 1 µM Phe-D5, 
centrifuged (10 min, 10000 g, 4ºC) and the clean supernatant was 
transferred to a 96-well HPLC plate for its analysis.  
To obtain 1/16 and 1/80 dilutions, 30 µL of 50 mM NEM were added 
to 30 µL of serum. After vortexing, 240 µL of cold methanol were added. 
After vortexing, the mix was allowed to rest for 20 min at -20 ºC and 
centrifuged (10 min, 10000 g, 4 ºC). To prepare a 1/16 dilution, 50 µL 
clean supernatant were transferred to 96-well HPLC plate and mixed with 
50 µL of acetonitrile:100 mM ammonium acetate pH3 in water (7:3) 
containing 2 µM Phe-D5. To prepare a 1/80 dilution, 10 µL of clean 
supernatant were transferred to a 96-well HPLC plate and mixed with 90 
µL of acetonitrile:100 mM ammonium acetate pH3 in water (7:3) 
containing 1.11 µM Phe-D5. 
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3.1 Quality assurance strategy in untargeted 
metabolomic analysis 
 
The main premise in a metabolomics study is that the levels of the 
detected metabolites reflect the biological status of the system under 
study. Thus, a quality assurance strategy was implanted in sample 
preparation and analysis in order to ensure the quality of the results and 
to minimize and detect any sources of variation unrelated to the 
biological nature of the samples (166, 167). This was accomplished by 
the addition of IS to the problem samples, the inclusion of QC samples, a 
careful design of the sample acquisition process and a thorough 
equipment cleaning and maintenance before starting a batch analysis. 
Different IS were incorporated to the samples at different steps of 
sample processing (i.e. sample homogenization and sample preparation 
for the LC-MS analysis). These IS have a dual function, on one hand the 
levels of the IS are used to evaluate the efficiency of the metabolome 
extraction along the different samples and to account for any possible 
sample loss; on the other hand, the IS also assists to monitor, within the 
problem samples, the robustness of the analysis regarding both 
chromatography (RT and peak shape) and detection (mass accuracy and 
peak area) aspects. Detailed information about the IS employed for each 
type of sample and analytical condition is provided in Methodology. 
Here, different QC samples were used: i) Blank QC samples; ii) 
Pooled/commercially available QC samples; and iii) Class/treatment-
specific pooled samples. Blank QC samples were processed like problem 
samples, but without the addition of the biological matrix; their purpose 
was to detect any contaminant ions coming from both sample processing 
and sample analysis. Pooled/commercially available samples QC were 
employed, when possible, to check the performance of the LC-MS 
analysis with samples of equal nature to the problem samples. In this 
sense, different QCs have been used: i) commercially available pooled 
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serum (Sigma Aldrich, Spain); ii) a pool of liver tissue from Liver Bank at 
the Hospital La Fe (UHE-LAFE / CIBERehd, Valencia, Spain); and iii) pooled 
control samples from cellular cultures. These QC were spiked with 
different IS specifically selected to cover both a wide m/z and RT ranges 
for each analytical condition. Thus LC-MS performance was not only 
checked with respect to the metabolomic pattern, but also with respect 
to a few known peaks. Finally, class/treatment-specific pooled samples 
were also included in each batch analysis to perform simultaneous MS 
and MS/MS acquisition to facilitate feature identification. 
The following considerations were taken into account with respect to 
each batch analysis or sample queue: i) As mass accuracy and response 
reproducibility may be compromised for long batch analysis times, total 
analysis time was limited to 48 h (215); ii) Pooled/commercially available 
QC sample was injected six times before starting the analysis of the 
problem samples, not only to condition the column but also to check 
system performance; iii) QC samples were alternated throughout the 
analysis batch sequence as follows: 1 pooled/commercially available QC 
every 15 problem samples and 1 blank QC every 10 problem samples; iv) 
Problem samples were analyzed in a random order but divided in 
representative blocks (e.g. blocks of the same number of samples 
belonging to different classes) (216); and v) Class/treatment-specific 
pooled samples were analyzed per triplicate at the end of the batch. The 
design of sample queue analysis is exemplified in Figure 3.1. 
To test instrument’s performance, the RSD of RT, peak area and mass 
accuracy of each IS was calculated for both problem samples and QCs. 
Acceptable RSD cutoffs for the peak area and RT were set at 15% and 1% 
respectively, while the threshold for mass error was set at 5 ppm. These 
figures were selected following the criteria described by the FDA 
Guidance for industry: bioanalytical method validation (206). Moreover, 
the analytical performance was evaluated with respect to the whole 
metabolomic pattern by using PCA. The relative position of a sample in 
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the principal component scores plot is determined by the metabolomic 
pattern obtained, that is, the sum of its composition and the response 
obtained by the analytical platform. Samples that cluster together have a 
more similar metabolic pattern than those that cluster apart. Therefore, 
all the samples belonging to a given class (i.e. pooled QC, blank QC, 
problem samples...) are supposed to cluster together and apart from the 
samples belonging to a different class. Thus, a correct clustering of the 
samples is an indicative of a good performance of the UPLC-QToF 
system. 
 
 
Figure 3.1. Analysis queue example in LC-MS untargeted metabolomic study. 
Problem samples are distributed in representative blocks and randomized within 
those blocks. Pooled quality control (QC) is injected 6 times before starting the 
analysis of problem samples in order to condition the column and to check 
system's performance. Blank QC is injected every 10 problem samples and 
pooled QC every 15 samples. 
 
 
By way of example, Figure 3.2 shows the values for area, mass 
accuracy and RT for the IS sulfadimethoxine and reserpine, under the 
generic RP in ESI (+) conditions, for all the samples included in the 
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example study. Figures 3.3-3.5 show the values for area, mass accuracy 
and RT for all the IS added to the pooled QC analyzed under the same 
conditions. All the recorded values, in both the QC and the samples, met 
the acceptance values.  
 
 
 
Figure 3.2. The peak area (upper panel), mass error (middle panel) and retention 
time (RT, lower panel) for the IS sulfadimethoxine and reserpine spiked in the 
problem samples. Each plot shows the values for all the problem samples 
analyzed under the generic-RP analysis in ESI (+) conditions. The red lines in the 
plots indicate the acceptance criterion for each parameter: 15% deviation for 
area, 1% deviation for RT and 5 ppm for mass error. 
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Figure 3.3. Peak area (arbitrary units) variation along sample batch analysis for 
the different IS spiked in the pooled QC. Each plot shows the values for the 11 
analytical replicates of the pooled QC analyzed throughout the batch in the 
generic RP analysis in ESI (+) conditions. At the top of each plot, the relative 
standard deviation (RSD as a percentage) for the 11 measures is shown. The red 
lines indicate the ±15% accepted deviation for the area. 
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Figure. 3.4. Mass error (ppm) variation along sample batch analysis for the 
different IS spiked in the pooled QC. Each plot shows the values for the 11 
analytical replicates of the pooled QC analyzed throughout the batch in the 
generic RP analysis in ESI (+) conditions. The red lines indicate the ±5 ppm 
acceptance criterion as specified in the text. 
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Figure. 3.5. Retention time (RT, expressed in minutes) variation along sample 
batch analysis for the different IS spiked in the pooled QC. Each plot shows the 
values for the 11 analytical replicates of the pooled QC analyzed throughout the 
batch under the generic RP analysis in ESI (+) conditions. At the top of each plot, 
the relative standard deviation (RSD, percentage) for the 11 measures is shown. 
The red lines indicate the ±1% accepted deviation for the RT. 
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To investigate the natural sample relationship among the different QC 
and samples, a PCA was conducted (Figure 3.6). All the replicates of a 
given QC type were clustered together and separate from other QC 
samples or problem samples, thus indicating a good performance of the 
UPLC-QToF system throughout the batch analysis in terms of not only the 
targeted IS compounds, but the whole metabolomic profile. 
 
 
 
Figure 3.6. PCA scores plot showing the natural interrelationship among the 
different QC and problem samples included in the example study. Each point in 
the scores plot represents all the information provided by the generic-RP analysis 
in ESI (+) conditions for a given sample. Blue: problem samples; Green: Pooled 
QC; Red: Blank QC. 
 
 
The present quality assurance strategy constitutes a straightforward 
method to evaluate system performance before, during and after 
problem samples acquisition. Pre-batch checks are designed to ensure 
that the system is in optimal conditions before starting the analysis, or 
before finishing the preparation of the problem samples. All the 
parameters (IS peak area, RT, peak symmetry, mass accuracy, QC global 
profile…) are checked during sample acquisition. Therefore, if a trouble 
is detected, the analysis can be halted and the samples can be stored 
(preventing sample injection or degradation). Finally, post-injection 
checks are the final evaluation previous to data analysis, thus preventing 
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to waste time processing samples or batches that did not meet the 
quality standards. Moreover, the incorporation of analysis-specific IS is a 
helpful tool in the normalization data analysis stage as the IS levels 
reflect inter-samples differences in aspects such as injection volume, 
volume losses while preparing the sample, detection sensitivity...(133). 
Recent publications have highlighted the importance of quality 
assurance strategy in metabolomic studies (133, 162, 215, 217). 
Common strategies to check systems performance in LC-MS based 
metabolomics include the use of QC samples and the addition of IS. 
However, previously reported strategies focused on checking the system 
performance before the start of the analysis and once it has finished. The 
strategy described here has the added value of carrying out live 
instrument performance checking as the parameters can be evaluated 
during the acquisition, what is especially important when the sample size 
is limited as it prevents samples to be injected (and consumed) or 
degraded while waiting or after being injected. 
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3.2 Optimization of metabolome coverage for mammalian 
cells in adherent culture by using LC-MS 
 
Untargeted metabolomics aims to detect the maximum possible 
number of metabolites in a given biological sample. In order to avoid 
metabolite degradation or alterations in their levels at the time of the 
sampling, sample processing has to allow the extraction of the 
metabolites of interest while providing a correct quenching of the cell 
metabolism. After the samples have been generated, they should be 
analyzed under the appropriate analytical conditions to achieve optimal 
chromatographic separation and detection of both polar and lipidic 
metabolites and maximize the information about their metabolomic 
profiles. 
Several examples of the application of metabolomics to different 
cellular models are available in the literature (reviewed in reference 
(103)). However, there is no general consensus about the harvesting, 
extraction or analysis methods. Therefore, we evaluated different sample 
analysis and processing conditions in order to determine the best sample 
processing (including metabolism quenching, cell harvesting and 
metabolite extraction) and analysis protocol using HepG2 cells as cellular 
in vitro model (Figure 2.13). 
 
3.2.1 Optimization of endometabolome analysis by LC-MS 
 
First, we evaluated the metabolome coverage offered by six different 
analytical conditions using three different chromatographic separations 
and each one tested in both ESI (+) and ESI (-) modes. Based on our 
previous experience in human liver tissue metabolomic profiling analysis 
(166), we decided to evaluate both HILIC and RP stationary phases. With 
respect to RP chromatography, two different approximations were used, 
one directed to detect the lipidome (lipidomic-RP) (163), and one 
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intended to cover a wider set of metabolites from different polarities 
(generic-RP) (162). The seven HepG2 cells extracts (E1 to E7) obtained by 
the use of five different extraction solvents (solvent 1 to solvent 5) were 
analyzed by the six proposed analytical configurations (Figure 2.13). In 
all the cases the same cell harvesting and processing configuration (i.e. 
the way metabolism quenching, cell harvesting and metabolite extraction 
were applied) was performed based on a previously published one (152).  
Results are summarized in Table 3.1, a detailed analysis of the figures 
revealed that a total of 103 polar and 492 lipidic unique metabolites 
were detected. As expected, no polar compounds were detected using 
the lipidomic-RP approximation, and no lipidic species were detected by 
using the HILIC conditions, however the generic-RP approximation was 
able to identify a range of polar and lipidic metabolites. Actually, polar 
metabolites could be detected using the lipidomic approximation and 
lipids using the HILIC one, however, the chromatographic signal, in 
terms of RT, peak shape and reproducibility, was not adequate and 
therefore those peaks were not considered for further analysis. As 
expected based on the characteristics (stationary and mobile phases) of 
the separation methods, lipidomic-RP approximation provided a broad 
coverage of lipidic species, with most of them being detected in ESI (+), 
although part of them were detected in ESI (-) mode as 
phosphatidylserine (PS), phosphatidylglycerol (PG), phosphatidic acid 
(PA).... On the other hand, although HILIC analysis did not provide a 
complete polar metabolite coverage, this approach rendered an 
acceptable number of polar compounds. Finally, the generic-RP 
approximation provided a complementary detection of both polar and 
non-polar compounds (i.e. FA and PL) thanks to the combined use of a RP 
column designed to enhance the retention of polar compounds and a 
chromatographic gradient set up to properly resolve both polar and 
lipidic metabolites.  
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Table 3.1. Summary of the metabolites detected by each extract under the 
different analytical conditions. 
  
E1 E2 E3 E4 E5 E6 E7 
Lipidomic-RP 
ESI(+) 
ChE 10  11 16 0 17 4 15 
Cer 7 8 11 0 12 5 12 
DG 13 20 22 0 22 11 20 
FA 3 4 8 0 10 5 8 
LysoPC 11 12 16 0 18 9 18 
LysoPE 6 6 12 0 12 3 12 
PC 46 52 63 0 64 46 64 
PE 40 45 47 0 47 39 47 
PG 14 18 22 0 25 5 25 
PI 6 6 7 0 7 5 7 
PS 11 14 16 0 19 11 19 
SM 15 17 20 0 21 14 21 
TG 87 93 107 0 108 73 105 
Lipidomic-RP  
ESI(-) 
Cer 3 3 3 0 3 2 2 
FA 3 6 6 0 5 3 5 
LysoPE 5 11 12 0 12 9 10 
PC 3 9 8 0 9 7 8 
PE 17 18 17 0 17 17 15 
PG 3 11 11 0 11 9 9 
PI 4 8 10 0 10 7 8 
PS 13 21 20 0 20 17 16 
Generic-RP  
ESI(+) 
Polar 4 2 2 4 0 4 0 
DG 9 12 17 2 23 12 15 
LysoPC 1 7 7 0 8 4 5 
LysoPE 0 5 5 0 6 2 3 
MG 1 2 2 1 15 2 5 
PC 14 30 32 0 33 15 23 
PE 2 24 24 0 24 3 15 
PS 0 8 8 0 8 0 3 
SM 1 11 11 0 11 2 6 
Generic-RP  
ESI(-) 
Polar 12 21 16 21 0 21 0 
FA 5 12 11 7 15 13 11 
LysoPA 0 3 3 2 3 3 0 
LysoPE 0 7 7 0 7 2 1 
LysoPG 0 1 1 0 0 1 4 
LysoPI 0 2 2 0 0 1 0 
PG 0 9 9 0 9 2 4 
PI 0 12 12 0 12 1 7 
PS 0 5 5 0 5 1 3 
HILIC ESI(+) Polar 59 42 34 52 0 39 0 
HILIC ESI(-) Polar 44 34 25 41 0 37 0 
 
E1-E7 refer to the different extracts obtained (see Figure 2.13). Color code refers 
to by-row centered and normalized mean intensity from the lower (blue) to 
higher (red) values. ChE: cholesterol ester, Cer: ceramides, DG: diacylglyceride, 
FA: free fatty acid, LysoPA: lysophosphatidic acid, LysoPC: 
lysophosphatidylcholine, LysoPE: lysophosphatidylethanolamine, LysoPG: 
lysophosphatidylglycerol, LysoPI: lysophosphatidylinositol, MG: 
monoacylglyceride, PC: phosphatidylcholine, PE: phosphatidylethanolamine, PG: 
phosphatidylglycerol, PI: phosphatidylinositol, Polar: polar metabolites, PS: 
phosphatidylserine, SM: sphingomieline, TG: triacylglyceride  
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To graphically assess the relationship and the overlap between the 
metabolites extracted and detected by each analytical condition Venn 
diagrams were drawn (Figure 3.7).  
 
 
 
Figure 3.7. Venn diagrams showing the overlap between the different analytical 
conditions with respect to polar (A) and lipidic metabolites (B).  
 
 
From the total 151 polar metabolites detected, the HILIC conditions 
provided the highest coverage detecting 113 species with 92 unique 
identifications. Generic-RP detected a total of 38 polar metabolites, 31 of 
them detected by using ESI (-), where 9 metabolites were not detected by 
any other analytical condition (Figure 3.7.A).  
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With respect to the lidipidome (Figure 3.7.B), a total of 661 lipids were 
detected. Generic-RP was able to achieve a good chromatographic 
separation of high to medium polar lipids as FA, PL, LysoPL… (Table 
3.1), detecting a total of 143 metabolites with 138 unique metabolites. 
The lipidomic-RP approximation extended the coverage to highly apolar 
lipid species (e.g. TG and ChE) covering a total of 518 metabolites with 
451 unique metabolites (Figure 3.7.B). Due to the diversity of the lipids, 
differences were obtained between ESI (+) and ESI (-) ionization modes 
that provided complementary information. Results showed that 
lipidomic-RP ESI (+) showed the highest lipidome coverage and no 
important complementary information was provided by generic-RP ESI 
(+), although using ESI (-) further information was obtained. 
The overall analysis of the results revealed that using the combination 
of HILIC, lipidomic-RP with ESI (+) and generic-RP with ESI (-) the 90% of 
the total unique metabolites were covered. 
LC-MS based metabolomics have been usually performed based on RP 
chromatography (107, 114, 115). However, the combination of HILIC and 
RP chromatographies has been satisfactory employed by our group (166, 
183) and others (218-220) as an analytical strategy suitable to expand 
the coverage of the metabolome. The added value of the strategy 
described herein resides not only in the combination of RP and HILIC 
stationary phases, but also in an experimental design that allows a 
comprehensive characterization of the entire lipidome. It has been 
recently suggested the use of HILIC chromatography to perform 
lipidomic analysis, mainly to cover highly to medium polar lipids such as 
PL, LysoPL and SM (221-223). Therefore, in our opinion, it is more 
appropriate to use a RP-based lipidomic as the one developed by the 
group of Professor Matej Orêsic (163), whose usefulness and robustness 
have been extensively proven in many studies (224-226). Recently, Fei et 
al proposed an analytical strategy in which both polar and lipidic species 
were simultaneously analyzed using an HILIC-based chromatographic 
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separation, thus reducing analysis time per sample (227). However, the 
usefulness of such approach might be limited by the fact that highly 
apolar lipids (i.e. FA, ChE, TG...) were not detected and the co-elution of 
polar and lipidic species, what could lead to ion suppression differences 
between samples and thus to misunderstanding of the results. 
 
3.2.2 Optimization of endometabolome extraction  
 
Five different extraction solvents that generated seven extracts were 
evaluated (Figure 2.13). Huge differences were obtained both in the 
nature, number and intensity of metabolites efficiently covered by each 
solvent combination (Table 3.1). A PCA analysis was performed in order 
to analyze the natural interrelationship between the different extracts 
(Figure 3.8).  
 
 
 
Figure 3.8. The PCA scores plot showing the natural interrelationship among the 
different extracts. Each cluster is represented by a different color and the lines 
denote 95 % confidence interval Hotelling's ellipse each one.  
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Three different clusters were identified): i) E4, formed by extracts 
composed exclusively of polar metabolites; ii) E1, E2, E3 and E6, 
composed by extracts that achieved the extraction of both polar and 
lipidic compounds; and iii) E5 and E7, grouping extracts composed 
exclusively by lipidic metabolites. The direction along the first 
component is driven by an increased extraction of lipidic compounds, 
while the second component separated those extracts containing polar 
and/or lipidic compounds from those containing only lipidic metabolites 
(Figure 3.8). 
With respect to the extraction of polar metabolites, extracts E1 and E4 
provided the highest number and intensity of metabolites detected using 
HILIC conditions. With respect to lipids, extracts E3 and E5 were the ones 
providing the highest performance in lipidomic-RP ESI (+) conditions with 
a total of 367 and 382 detected compounds, respectively. However in 
general terms, and particularly for highly apolar lipids (i.e. ChE and TG), 
E5 provided higher extraction yields. Extracts E1, E2, E3 and E6 were 
able to extract both polar and lipidic metabolites. Among them, extract 
E1 was the one that achieved the best coverage of polar metabolites and 
E3 of lipids. However extract E2 was the one that provided the highest 
combined coverage of both polar and lipidic metabolites both in terms of 
detected metabolites (21 and 51, respectively in generic-RP ESI (-) 
conditions) and intensity (Table 3.1). 
The overall review of these results showed that the combined analysis 
of E4 (HILIC), E5 (lipidomic-RP/ESI (+)), and E2 (generic-RP/ESI (-)), 
covered 90% of the metabolites comprised in the seven extracts. 
Extraction with methanol alone or combined with other solvents (i.e. 
water or water and chloroform) is usually employed as a first 
approximation to metabolomic studies as a wide range of polar to 
medium apolar metabolites are extracted (103, 108). However, when the 
objective is to achieve a wider metabolome coverage and to exploit the 
capabilities of the analytical platform employed, different combinations 
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of extraction solvents can be tested. For example, with respect to the 
characterization of the lipidome, methanol extracts represent a good 
option to perform metabolomics studies covering the phospholipidome, 
while the addition of more apolar solvents (i.e. chloroform or 
dichloromethane) is needed when the focus is also put in highly apolar 
lipids such as TG or ChE (228). Our sample processing strategy, in which 
the combination of extraction solvents has been performed in a joint 
manner with respect the selection of the analytical conditions, allows to 
maximize the detection of metabolites of interest in each condition while 
minimizing the interferences provided by other groups of metabolites.  
 
3.2.3 Optimization of cell harvesting and processing 
 
Sample processing for adherent cells needs to overcome the following 
aspects: i) metabolism quenching; ii) cell detachment; and iii) 
metabolome extraction (103). These steps can be performed 
simultaneously or sequentially (103).  
Three different approaches were tested to optimize cell harvesting and 
processing (Figures 2.13, 2.14). To focus on the influence of these 
specific factors on the metabolome coverage, the rest of operational 
variables were kept constant and all the samples were processed and 
analyzed based on the above mentioned results. All the methods showed 
similar figures in terms of the number of detected lipids (around 380 
and 50 in lipidomic-RP ESI (+) and generic-RP ESI (-) conditions, 
respectively), although lower total intensities were obtained for method 
C with a mean decrease around 20% with respect to methods A and B 
(Table 3.2). An important decrease in both the intensity and number of 
identified polar metabolites was observed for method C: a total of 124 
and 123 polar metabolites were identified using method A and B, 
respectively, while only 93 polar metabolites an a mean decrease in the 
total intensity near to 30% were detected using method C (Table 3.2).  
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Table 3.2. Summary of the metabolites detected with each sample processing 
strategy under each analytical condition. 
 
  
 Method A Method B Method C 
Lipidomic-RP 
ESI(+) 
ChE  17 15 16 
Cer  12 12 12 
DG  22 19 21 
FA  10 8 8 
LysoPC  18 17 17 
LysoPE  12 13 12 
PC  64 65 64 
PE  46 46 46 
PG  25 27 28 
PI  7 7 7 
PS  19 19 17 
SM  21 20 21 
TG  108 110 112 
Generic-RP  
ESI(-) 
Polar  21 18 13 
FA  12 13 11 
LysoPA  3 3 3 
LysoPE  7 7 7 
LysoPG  1 2 0 
LysoPI  2 2 2 
PG  9 7 9 
PI  12 11 12 
PS  5 5 5 
HILIC ESI(+) Polar  59 59 45 
HILIC ESI(-) Polar  44 46 36 
 
Color code refers to fold of change with respect the mean value: blue = 0.5, 
white = 1, red = 2. ChE: cholesterol ester, Cer: ceramides, DG: diacylglyceride, 
FA: free fatty acid, LysoPA: lysophosphatidic acid, LysoPC: 
lysophosphatidilcholine, LysoPE: lysophosphatidilethanolamine, LysoPG: 
lysophosphatidilglycerol, LysoPI: lysophosphatidilinositol, MG: 
monoacylglyceride, PC: phosphatidylcholine, PE: phosphatidylethanolamine, PG: 
phosphatidylglycerol, PI: phosphatidylinositol, Polar: polar metabolites, PS: 
phosphatidylserine, SM: sphingomieline, TG: triacylglyceride.  
 
 
Method C involves the use of trypsin to detach the cells from the plate 
surface and metabolism quenching is delayed with respect to the other 
two methods. It has been reported that trypsinization may compromise 
the cellular membrane integrity, leading to the loss of intracellular 
metabolites (150, 229, 230). Moreover, the delay in metabolism 
quenching may contribute to the enzymatic degradation of some 
metabolites (103). No significant differences were found with respect to 
methods A and B. However, from a practical point of view, an important 
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advantage of method A is that several samples can be simultaneously 
generated and stored at -80 ºC after metabolism quenching without the 
need of processing them just after their collection. This is especially 
useful when a high number of samples are generated at the same time, 
allowing to focus on time sensitive biological transformations, and when 
performing complex extraction procedures (152). Moreover, it has been 
previously shown an increased stability if the cells are stored previously 
to be extracted (as frozen plates), rather than the cellular extracts (152). 
Therefore, metabolism quenching with liquid N2 followed by the 
simultaneous cells detachment and metabolite extraction was selected as 
the optimum strategy to perform sample processing when analyzing the 
endometabolome of cultured adherent cells. 
 
3.2.4 Assembling an appropriate protocol for  sample processing and 
analysis 
 
The optimized sample processing and analysis strategy is depicted in 
Figure 3.9. The first step in sample processing involves the removal of 
the culture medium followed by cell washing with PBS. Then, metabolism 
is quenched by the addition of liquid N2 over the cell monolayer. At this 
step the cells can be stored at -80 ºC, thus delaying the rest of sample 
processing steps. Cell detachment and metabolite extraction are 
performed simultaneously by scrapping the cells in 
water:methanol:chloroform (10:27:3) (152). The cell extract/suspension 
is submitted to three freeze/thaw cycles (liquid N2/room temperature) in 
order to increase cell disruption and metabolite extraction. The extract is 
then split in two different aliquots for untargeted metabolomic analysis 
plus an additional one for protein quantification. The first aliquot is 
destined to be analyzed using generic-RP ESI (-) conditions. The second 
aliquot is extracted with chloroform thus generating two different 
fractions: an aqueous fraction, that will be analyzed using HILIC 
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separation coupled to both ESI (+) and ESI (-) detection, and an organic 
fraction, that will be analyzed using lipidomic-RP ESI (+) conditions. Then, 
three different aliquots are generated for each biological sample, which 
will be analyzed using four analytical conditions (Figure 3.9). 
 
 
 
Figure 3.9. Workflow of the optimized sample processing and analysis strategy 
for the analysis of the endometabolome of HepG2 cells.  
 
 
Few studies have evaluated different aspects of sample processing for 
mammalian adherent cell cultures (150-152, 227, 229, 231). These 
studies focused on the optimization of sample processing for a particular 
cell line, however, a series of conclusions can be extracted. Most of them 
focused on the detection of polar metabolites. The only study that 
evaluated some lipidic metabolites is the one performed by Fei et al 
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(227). In all of them the decisions were taken on the basis of the levels of 
a set of metabolites and the total number/intensity of detected features. 
This strategy could lead to misunderstandings in results interpretation 
and decision making.  
Our results agree with respect to the basic operational steps (i.e. 
metabolism quenching, cell detachment and cell disruption) described in 
the literature (103). It is not possible to compare our results with the 
previous ones in terms of metabolome extraction and analysis as our 
protocol aims to cover a wider range of metabolites, from highly polar 
(e.g. aminoacids, nucleotides, cofactors...) to lipidic (e.g. lysoPLs, PLs, 
TGs...) metabolites, compared to the previously mentioned studies. To 
analyze the extent of the improvement of metabolome coverage reached 
by each protocol modification, we decided to evaluate only those 
features that were matched with a known identity. This strategy allows a 
more accurate and reliable evaluation of the capabilities of the sample 
processing and analytical procedures. 
The main strength of our study approach was the simultaneous 
optimization of sample processing and analysis, this allows to evaluate 
the capabilities of each analytical modification in combination with the 
extraction properties of each solvent mixture, thus maximizing the 
information that can be obtained from each biological sample. Our aim 
was to set up a sample processing and analysis strategy that allowed the 
determination of the widest possible number of metabolites. This 
approximation allows to get a more comprehensive information about 
the events that are occurring within the cell, which supposes a crucial 
advantage to the metabolic phenotyping of the cells and the possibility 
of the discovery of biomarkers. Moreover, as several different aliquots 
can be extracted from a single biological sample, it supposes an 
important saving of economic, biological and time resources. While the 
strategy described here provides a thorough mapping of the 
metabolome, it has some disadvantages. The proposed extraction 
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method involves more complex sample manipulations compared to the 
extractions using aqueous:methanolic mixtures (103). Moreover, the 
analytical strategy involves the analysis of each biological sample under 
four different conditions. That supposes a considerable increase in the 
analysis time and the time and complexity of data analysis, and therefore 
a reduction in the efficiency compared to those methods that perform 
the analysis of the samples using a single analytical condition.  
No comprehensive sample processing and analysis optimization has 
been previously performed using liver-derived cells although some 
metabolomic studies are available in the literature (154-157, 232). After 
the evaluation of several parameters regarding sample processing (i.e. 
metabolism quenching, cell harvesting and metabolome extraction) and 
analysis, we propose a strategy that allows a comprehensive coverage of 
the metabolome ranging from polar metabolites (e.g. aminoacids, 
nucleotides, cofactors, organic acids...) to the whole spectra of lipidic 
species (i.e. LysoPL, PL, FA, TG...). This strategy can be applied to any 
study involving the use of mammallian cells and mass spectrometry 
analysis. 
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3.3 Metabolomic analysis of HepG2 cells exposed to 
model hepatotoxic compounds 
 
The main objective of the present thesis was the identification of 
mechanism-specific biomarkers, metabolomic patterns and altered 
pathways associated to drug-induced hepatotoxicity using HepG2 cells as 
in vitro model. HepG2 is the most commonly used and best 
characterized human liver-derived cell line. The main strengths 
associated to the use of HepG2 cells in pre-clinical testing are its human 
origin, unlimited availability, high reproducibility, easy culture and 
handle conditions, complete characterization and wide bibliographic 
documentation (5, 49). Their limited drug metabolizing and transport 
capabilities are the main drawbacks associated to their use.  
The optimized analytical strategy described in Section 3.2 was applied 
to unravel the metabolomic changes associated to hepatotoxicity in 
general and to specific mechanisms of hepatotoxicity in HepG2 cells. 
Model hepatotoxins and concentrations were selected based on 
previously published studies (Table 2.2) (29, 69, 88, 89, 91, 92). Four 
different mechanism of toxicity were tested: i) OS; ii) phospholipidosis; 
iii) steatosis and iv) cholestasis (29). 
Figure 3.10 shows the scores plots corresponding to the PCA analysis 
performed by comparing the metabolic profile of cells treated with 
control (i.e. non-hepatotoxic) compounds vs cells treated with 
compounds corresponding to each of the different mechanisms of 
hepatotoxicity included in the study.  
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Figure 3.10. PCA scores plots corresponding to data obtained from HepG2 cells 
treated with hepatotoxins acting through different mechanisms of toxicity and 
analyzed using the generic metabolomic strategy. The lines denote 95 % 
confidence interval Hotelling's ellipse. PCA models were developed using two 
principal components. A) Control vs OS. B) Control vs Steatosis. C) Control vs 
Cholestasis. D) Control vs Phospholipidosis. Green: Control; Orange: OS; Purple: 
Steatosis; Blue: Cholestasis; Red: Phospholipidosis.  
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The scores plots corresponding to the comparison of non-hepatotoxic 
compounds vs OS (Figure 3.10.A), steatosis (Figure 3.10.B) and 
phospholipidosis (Figure 3.10.D) show that the samples corresponding 
to cells treated with control compounds were clustered together and 
separated from those corresponding to hepatotoxic compounds. This 
trend indicates that the toxic insult induced changes in the metabolome 
that were detected by using our sample processing and analysis strategy. 
The PCA scores plot in Figure 3.10.C reveals that the changes induced in 
the metabolome by the three drugs from the cholestasis group were not 
homogeneous. While the samples corresponding to the treatment with 
cyclosporine were located far from the cluster of control samples in the 
scores plot, those corresponding to troglitazone and chlorpromazine 
were located within the 95% confidence interval Hotelling's ellipse 
corresponding to the control samples. This finding suggests no 
detectable changes in the HepG2 metabolome after treatment with 
troglitazone and chlorpromazine, at least at the concentrations and 
analytical conditions used in our study. 
 
3.3.1 Identification of markers of hepatotoxicity 
 
The PCA analyses shown in Figure 3.10 revealed that the observed 
metabolome alterations were strong enough to be able to differentiate 
between control and hepatotoxic compounds using a non-supervised 
multivariate analysis. Thus, the next step in the data analysis workflow 
was to identify which metabolites and pathways were altered as a 
consequence of the different treatments. First, a general comparison 
between non-hepatotoxic and hepatotoxic compounds was performed in 
order to identify non-specific markers of hepatotoxicity. Then, the 
analysis was focused on the identification of specific markers and 
patterns associated to each of the studied mechanisms of toxicity. Two 
different strategies were performed to select those altered metabolites 
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with the aim of capturing both the alterations reflecting uni- and 
multivariate dependencies (121). Those metabolites showing a q value < 
0.05 (p value using a Student's t test corrected using FDR) or a VIP value 
> 1.2 (based on a PLS-DA model discriminating between control and the 
treatment of interest) were considered to be significantly altered as a 
result of the exposure to the toxicant. 
 
Non-specific metabolome changes triggered by hepatotoxic compounds 
 
Those metabolites which were altered by all the hepatotoxic 
compounds may be considered as general biomarkers of toxicity. With 
respect to polar metabolites the most important changes were related to 
aminoacids (i.e. glutamine, histidine, methionine, phenylalanine, 
threonine, tyrosine, tryptophan, citrulline...), glycolysis (i.e. glucose-6-
phosphate), OS markers (i.e. GSH/GSSG, cysteine-GSH disulfide (CSSG) 
and -glutamyl-glutamine), metabolism of purines (i.e. adenine and 
xanthine) and intermediates in PL metabolism (i.e. phosphocholine, 
glycerophosphocholine, LysoPL...). With respect to the lipidic species, 
several changes were observed in PL, FA, TG and acylcarnititines (Figure 
3.11). 
From a general point of view these results suggest that the 
hepatotoxic insult affected some of the most basic metabolic functions. 
Pathways such as glycolysis, urea cycle and metabolism of FA, 
aminoacids, nitrogen, purines and PL, that were revealed to be 
significantly altered using pathway enrichment analysis, are among the 
most important ones controlling energy production and maintaining 
cellular integrity and homeostasis. Moreover, the appearance of OS 
markers in conjunction with the alteration of metabolites related to the 
metabolism of FA suggests that the mitochondrion is a common target in 
hepatotoxic damage (34, 35).  
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Figure 3.11. Boxplots showing the most important changes associated to generic 
hepatotoxicity in HepG2 cells analyzed following the generic untargeted 
metabolomic analysis strategy. Values are expressed as relative intensity. Boxes 
denote interquartile ranges, lines denote medians, and whiskers denote the 10th 
and 90th percentiles. 
 
 
Metabolomic changes provoked by OS inducers  
 
Among the hepatotoxic compounds used in our study, cumene 
hydroperoxide and tert-butyl hydroperoxide were selected as pure OS 
inducers (Table 2.2). A total of 66 metabolites were significantly altered 
in HepG2 cells exposed to these model toxicants. A pathway enrichment 
analysis revealed that FA and TG metabolism, PL metabolism, glutamate 
and GSH metabolism, nitrogen and aminoacid metabolism and 
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nucleobases metabolism were the pathways suffering the greatest 
impact. The most important metabolic changes are shown in Figure 
3.12. As expected, a characteristic increase in well-known low-molecular-
weight OS markers was found. Moreover, noteworthy changes in the 
lipidome, that can be interpreted as a secondary damage associated to 
the oxidative insult, were also observed (Figure 3.12).  
 
 
 
Figure 3.12. Boxplots showing the most important changes associated to OS 
treatment in HepG2 cells analyzed using the generic untargeted strategy. Values 
are expressed as relative intensity. Boxes denote interquartile ranges, lines 
denote medians, and whiskers denote the 10th and 90th percentiles. 
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The most common change associated to OS damage is a decrease in 
the GSH/GSSG ratio. GSH is the predominant low-molecular-weight thiol 
(0.5 – 10 mmol/L) in animal cells, mainly located in the cytosol (85 – 
90%), but also in many organelles (233, 234). Its high intracellular 
concentration, compared to other redox systems (i.e. NADP
+
/NADPH and 
thioredoxin (TrxSS/Trx(SH)2), makes the GSH/GSSG pool the principal 
redox buffer of the cell (50, 235). As seen in Figure 3.12, an important 
reduction in GSH levels and GSH/GSSG ratio was observed in HepG2 cells 
treated with OS-inducers, in agreement with previous in vitro studies in 
liver-based cellular models (236, 237). The shift of GSH/GSSG toward the 
oxidizing state activates several signaling pathways which, in 
conjunction with GSH efflux, has been associated to increased apoptosis 
in liver cells (234, 238, 239). 
According to the observed changes in GSH and GSH/GSSG, increased 
levels of CSSG were also found (Figure 3.12). CSSG is a marker of 
oxidative damage to GSH (240). CSSG, usually assessed in serum, is the 
result of the reaction between cystine (the oxidized form of cysteine, 
which constitutes the major thiol pool in blood) and GSH, supplied from 
the cells to preserve the cysteine to cystine ratio (241). Nevertheless, 
CSSG is ubiquitously found in mammalian cells and under OS conditions 
its production is enhanced (240). Increased levels of CSSG have been 
reported in the liver of rats treated with paracetamol (140).  
Tightly related, several compounds belonging to the -glutamyl cycle 
(i.e. -glutamyl-glutamine, -glutamyl-glutamate, glutamine and 
glutamate) showed altered levels as a result of the oxidative damage. 
The -glutamyl cycle (Figure 3.13) was postulated by Meister in the mid-
seventies (242, 243) and accounts for the biosynthesis and degradation 
of GSH. GSH is synthesized from its constituent amino acids in two 
consecutive reactions (Figure 3.13) (233, 244). The first step, considered 
rate limiting, is catalyzed by glutamate cysteine ligase (GCL). GCL is 
specific for the glutamyl moiety and is regulated physiologically by 
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inhibition by GSH and availability of its precursor, L-cysteine (243). The 
second step is catalyzed by GSH synthase (GS). In addition, the rate of 
GSH biosynthesis in the hepatocyte is balanced by its rate of export, 
mainly into plasma and bile (233, 244).  
 
 
 
Figure 3.13. -glutamyl cycle. Enzymes are denoted in italics. Square boxes 
denote transmembrane transporters. GGT: -glutamyl transpeptidase. DP: 
dipeptidase. Figure adapted from references (233, 245). 
 
 
Storage of cysteine is one of the most important functions of GSH 
because extracellular cysteine is extremely unstable and rapidly auto-
oxidizes to cystine, in a process that produces potentially toxic oxygen 
free radicals (242). The -glutamyl cycle describes how GSH can be used 
as a continuous source of cysteine. GSH is released from the cell by 
carrier mediated transporter(s) and then -glutamyl transpeptidase (GGT) 
transfers the -glutamyl moiety of GSH to an amino acid, forming -
glutamyl amino acid and cysteinylglycine which can be further 
metabolized to retrieve their constitutive amino acids. (233, 242, 244) 
(Figure 3.13).  
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Two different theories can explain the appearance of -glutamyl 
dipeptides as a result of OS. Soga et al found increased serum levels of 
different -glutamyl dipeptides in different forms of liver disease (246). 
They hypothesized that -glutamyl dipeptides are synthesized via the 
ligation of glutamate with various amino acids and amines by GCS, and 
are indicative of the amount of GSH production (Figure 3.14) (246). 
 
 
 
Figure 3.14. Hypothesis postulated by Soga et al (246) to explain the 
accumulation of -glutamyl dipeptides under OS conditions. Under reducing 
conditions, GCS is feedback inhibited by GSH and small amounts of -glutamyl 
dipeptides are synthesized (left panel). During OS, GSH is consumed, leading to 
GCS activation, which could result in biosynthesis of -glutamyl dipeptides. GCS: 
-glutamyl-cysteine synthetase; GS: glutathione synthetase. Figure adapted from 
reference (246). 
 
 
However, not only -glutamyl dipeptides, but other components of the 
-glutamyl cycle were altered as a result of the oxidative damage. Under 
OS conditions, the flux of GSH to the -glutamyl cycle is enhanced to 
restore reduced thiol status of the cell (mainly as reduced cysteine) what 
could be an alternative theory to explain the observed metabolomic 
alterations (Figures 3.12, 3.13). Additional studies (measurement of 
enzyme activities and metabolic fluxes) would be required to clarify the 
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contribution of each of the aforementioned pathways in the protection of 
the cell under OS conditions and the appearance of -glutamyl 
dipeptides. 
With respect to the alterations in the lipidome, the most remarkable 
changes were a decrease in the levels of free FA and an increase in the 
levels of acylcarnitines and TG (Figure 3.12). Although the oxidative 
insult can induce damage in different molecules and cell organelles, the 
oxidative processes that take place in the mitochondria (along with the 
presence of an unprotected mtDNA) make them sensitive targets of 
oxidative damage (32-34). A consequence of mitochondrial damage is 
the inhibition of metabolic pathways in the mitochondria, including FA β-
oxidation. This situation results in an accumulation of FA and 
intermediates of FA oxidation such as acylcarnitines. FA can either be 
esterified into TG or remain as a free form, this later reinforcing 
mitochondrial dysfunction and increasing OS (32-34, 247). 
 
Metabolomic alterations induced by steatogenic drugs 
 
Three model drugs causing steatosis as main mechanism of toxicity 
were included in the study (Table 2.2): doxycycline, tetracycline and 
valproic acid. Drug-induced steatosis resulted in the alteration of 91 
metabolites in HepG2 cells. A functional enrichment analysis revealed 
that FA and TG metabolism, aminoacid metabolism, urea cycle and 
nitrogen metabolism, PL metabolism and glutamate, cysteine and GSH 
metabolism were the most altered pathways. 
The main alterations related to lipidic species were the increase in the 
levels of TG, DG, PL and LysoPL and the decrease in FA (Figure 3.15). 
With respect to polar metabolites, although several compounds were 
altered as a result of drug-induced steatosis, it is worthy to remark the 
changes in several OS markers (Figure 3.15). 
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Figure 3.15. Boxplots showing the most important changes associated to 
steatosis treatment in HepG2 cells analyzed using the generic untargeted 
metabolomic analysis strategy. Values are expressed as relative intensity. Boxes 
denote interquartile ranges, lines denote medians, and whiskers denote the 10th 
and 90th percentiles. 
 
 
The accumulation of TG inside the hepatic cells is the hallmark of 
hepatic steatosis. Increased TG deposits has been previously observed in 
the liver of patients suffering steatosis (106, 166, 248), in animal models 
of diet-induced (249-252) or drug-induced (253-255) steatosis and in 
cellular models of in vitro hepatosteatosis (88, 154, 256). Different 
mechanisms leading to drug-induced hepatic steatosis have been 
identified (29, 32). Among them, impairment of FA β-oxidation due to 
mitochondrial disturbances is of special relevance (29, 32, 34, 35). There 
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is substantial evidence that FA can directly cause toxicity by increasing 
OS and through the activation of inflammatory pathways (247); therefore, 
the accumulation of FA as TG is thought to be an adaptive and protective 
response of hepatocytes to excessive availability of free FA to the liver 
and its associated liver toxicity (257-259). Impairment of TG synthesis 
has been shown to improve of hepatic steatosis but increase cytotoxicity 
and liver damage (252, 260). 
While TG are considered to be a non-lipotoxic counterpart in steatosis, 
the list of possible lipotoxic metabolites include FA, PA, LysoPA, LysoPC, 
ceramides, and DG (257, 259). Among them, the levels of LysoPL and DG 
were found to be elevated in cells treated with steatogenic drugs (Figure 
3.15). The levels of LysoPL have been previously found to be elevated in 
liver biopsies and serum samples from patients suffering hepatic 
steatosis (166, 248, 261, 262), in palmitate-loaded HepaRG cells (154) 
and in mouse models of fatty liver disease and obesity (251, 263). 
LysoPL are generated through the action of phospholipases. LysoPC, 
produced by phospholipase A2 (PLA2), which catalyzes the hydrolysis of 
the fatty acyl ester bond at the sn-2 position of glycerophospholipids 
(Figure 3.16), have been implicated in several types of cell death (264-
266). One recent study related elevated LysoPC content in the liver with 
the genesis and progression of necroinflammatory injury of hepatocytes 
(267). A direct role of LysoPC in lipotoxic liver injury was then 
demonstrated using human liver cell lines, mouse hepatocytes in primary 
culture, and in mice. Consistently, induction of phospholipase A2 genes 
has been found in non-alcoholic steatohepatitis (NASH) (106, 267). 
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Figure 3.16. Main lipidic pathways showing alterations as a result of drug-
induced steatosis. See the text for a detailed explanation of the consequences 
derived of the blockade and enhancement of specific routes. The glycerol 
backbone is highlighted in blue, the polar groups of the different PL are 
highlighted in different colors. 
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Together with TG accumulation, increased levels of DG is the most 
common lipidomic pattern associated to hepatic steatosis and has been 
described in both liver (106, 248, 268) and serum (261, 262, 269) 
samples from patients with steatosis and in palmitate-loaded HepaRG 
cells (29). DG are intermediates in the synthesis of TG and their elevated 
levels may be a consequence of the elevated traffic of FA from its free 
form to MG, DG and finally TG (Figure 3.16). However, DG species are 
well-known activating ligands of most protein kinase C (PKC) isoforms 
and increases in DG species have been suspected as a major contributor 
to hepatic lipotoxicity (259). Moreover, DG signaling through PKC has 
been shown to be an important event in cancer progression (270, 271) 
and specific DG transferases have been implicated in the progression of 
non-alcoholic fatty liver disease (NAFLD) and liver fibrosis (272, 273). 
The increased levels of DG in combination with the increased levels of 
phosphocholine could lead to higher rates of PC biosynthesis via the 
CDP-choline pathway (i.e. Kennedy pathway) (274, 275), thus resulting in 
increased levels of PL as observed (Figures 3.15, 3.16).  
Impairment of FA β-oxidation by steatogenic drugs can lead to an 
enhancement of extramitochondrial FA oxidation, thus promoting higher 
rates of ROS production and lipid peroxidation (276). Accordingly, a 
decrease in GSH levels and GSH/GSSG ratio, and an increase of CSSG 
levels were observed in HepG2 cells exposed to steatosis-inducing drugs 
(Figure 3.15). GSH depletion and oxidative damage to macromolecules 
have been reported in liver biopsies from patients with steatosis (166, 
268). Increased ROS levels have also been described in palmitate-loaded 
HepaRG (154) and H4IIEC3 (277) cells and in primary cultured human 
hepatocytes and HepG2 cells treated with steatogenic drugs (88, 92). 
  
Results & Discussion 
169 
Metabolomics changes associated to cholestatic damage 
 
Chlorpromazine, cyclosporine and troglitazone, three compounds 
reported to induce cholestasis, were included in the study (Table 2.2). 
The PCA scores plot shown in Figure 3.10.C revealed that 
chlorpromazine and troglitazone did not induce any detectable changes 
at the employed concentrations. Therefore, we decided to exclude those 
samples from the data analysis and focused on the alterations induced in 
HepG2 cells as a consequence of the incubation with cyclosporine.  
A total of 92 metabolites were altered in cyclosporine-treated cells. 
Aminoacid metabolism, urea cycle and nitrogen metabolism, FA and TG 
metabolism, PL metabolism and glutamate and GSH metabolism were 
revealed as the most affected pathways using enrichment analysis. The 
altered metabolites and pathways did not suggest an obvious relation to 
the expected mechanism of toxicity through a cholestatic effect. 
However, the results suggest that cyclosporine was able to induce 
changes that were consistent with OS and steatosis mechanisms of 
hepatotoxicity. Figure 3.17 shows increased levels of GSSG, CSSG and -
glutamyl-glutamine and a decreased GSH/GSSG ratio as previously 
observed for OS (Figure 3.12). On the other hand, the increase in 
acylcarnitines, DG, TG, phosphocholine and PL (Figure 3.17) is similar to 
the pattern previously observed for steatosis-inducing compounds 
(Figure 3.15). Cyclosporine is not only a cholestasis-inducing drug, but 
has also been reported as being able to induce OS and lipid 
accumulation (89, 92, 278, 279) and inhibit β oxidation of FA, thus 
resulting in the accumulation of FA and TG (280, 281). Cyclosporine is an 
immunosuppressant drug widely used in organ transplantation to 
prevent rejection, accumulation of free FA has been described in post-
transplant recipients after the treatment with cyclosporine (282). 
Moreover, a recent study comparing the effect of steatotic compounds in 
the expression profile of 47 transcription factors revealed that the 
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pattern induced by cyclosporine was similar to the obtained with a set of 
well-defined steatotic drugs (69). 
 
 
 
Figure 3.17. Boxplots showing the most important changes associated to HepG2 
cells exposed to cyclosporine A and analyzed using the generic untargeted 
metabolomic strategy. Values are expressed as relative intensity. Boxes denote 
interquartile ranges, lines denote medians, and whiskers denote the 10th and 
90th percentiles. 
 
 
The development of drug-induced cholestasis is based on the direct or 
indirect effect that the drugs induces in the function of BA transporters 
such as the basolateral uptake transporters (NTCP and OATPs), the 
canalicular efflux transporters (BSEP, MRP2, and MDR3), and the 
basolateral efflux transporters (MRP3 and MRP4) (38, 45, 48). Therefore, 
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the study of cholestasis requires the choice of an experimental model in 
which those transporters are active and correctly located. Unfortunately 
the loss of native cell polarization in HepG2 cells affects the correct 
expression, location and activity of transporters (49). Hilgendorf et al 
compared the expression profile of 36 transporters (related or relevant 
for drug transport) in HepG2 and human liver and both qualitative and 
quantitative differences were found (283). A study performed by 
Ulvestad et al revealed decreased levels of mRNA for BSEP, MDR1, NTCP 
and OATP1B1 in HepG2 cells and other hepatocellular models with 
respect to the levels observed in primary cultured human hepatocytes 
(284). Moreover, OATP1B1 and NTCP showed low levels of activity in 
HepG2 cells that were correlated with a cytoplasmic localization instead 
of a membrane localization of the transporters (284).  
In contrast to HepG2 cells, hepatocytes cultured in a collagen sandwich 
configuration reestablish cell polarity and tight junctional complexes, 
leading to the formation of sealed bile canaliculi (285, 286). Therefore, 
sandwich-cultured hepatocytes are the most commonly used cellular 
model for BA uptake and efflux studies and to identify hepatotoxicity 
associated to drugs that cause iatrogenic cholestasis (287, 288). As an 
alternative to the use of primary cultured hepatocytes, HepaRG cell line 
has shown its potential in the study of the mechanisms involved in the 
development of drug-induced cholestasis (289-291). However, although 
no consistent results were obtained with the selected drugs and no 
characteristic pattern associated to cholestasis in HepG2 cells was 
defined, our analytical conditions were able to identify metabolomic 
alterations besides the ones directly associated to cholestatic injury and 
consistent with the information available in the literature. 
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Metabolomic changes associated to phospholipidogenic insult 
 
Five model hepatotoxic drugs causing phospholipidosis as main 
mechanism of toxicity were used in the study (Table 2.2): amiodarone, 
clozapine, fluoxetine, tilorone and tamoxifen. Phospholipidogenic drugs 
induced changes in 65 identified metabolites. A pathway enrichment 
analysis showed that PL metabolism, unsaturated FA metabolism, urea 
cycle, aminoacid metabolism and glutamate and GSH metabolism were 
the most affected pathways as a result of the treatment with 
phospholipidogenic drugs (Figure 3.18).  
 
 
 
Figure 3.18. Boxplots showing the most important changes associated to HepG2 
cells treated with phospholipidogenic drugs and analyzed following the 
untargeted metabolomic strategy. Values are expressed as relative intensity. 
Boxes denote interquartile ranges, lines denote medians, and whiskers denote 
the 10th and 90th percentiles. 
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A slight increase in the PL levels and a slight decrease in the LysoPL 
levels in the phospholipidosis group were observed. However, it is 
noteworthy to point out the decrease in the most abundant LysoPE, 
LysoPE(18:1), and the decrease in the LysoPL/PL ratio. Moreover, a slight 
increase in the amount of TG was also detected (Figure 3.18). With 
respect to polar metabolites, the most remarkable changes were 
associated with the appearance of OS markers (i.e. increased levels of 
CSSG and decreased levels of GSH and the ratio GSH/GSSG) (Figure 3.18). 
The most characteristic alteration associated to phospholipidosis is an 
excessive accumulation of PL; however, such hallmark was not 
reproduced under our experimental conditions (24h incubation with sub-
lethal concentrations of the drugs) and only slight but non-significant 
increases in PL were observed in HepG2 cells. Phospholipidosis is a 
chronic process and PL accumulation in the liver is only observed after 
long-term/repeated treatments with the drug (32). The observed 
decrease in LysoPL and in the LysoPL/PL ratio can be interpreted as an 
inhibition of the degradation of PL that ultimately would lead to their 
excessive accumulation (Figure 3.16). It is well known that drugs 
inducing phospholipidosis, especially CADs, inhibit lysosomal 
phospholipase activity (292, 293). Indeed, inhibition of phospholipases 
A1, A2 and C by CADs has been observed both in vitro and in vivo (294, 
295) and a dose dependent inhibition has been reported in the case of 
amiodarone (296, 297). The mechanism responsible of this inhibition is 
unknown. It has been suggested that the drug can bind to PL, thus 
resulting in the formation of complexes that are either resistant to 
breakdown or can act as enzyme (phospholipase) inhibitors (294). As an 
alternative mechanism, the accumulation of phospholipidosis-inducing 
drugs (usually cations) can neutralize the anionic surface charge in 
lysosomal lipid bilayers required by phospholipase activity (298). Besides 
this simple and attractive view of the problem, recent studies have 
suggested that not only impaired phospholipase activity, but also 
Results & Discussion 
174 
alterations in lysosomal enzyme transport and PL or cholesterol 
biosynthesis are mechanisms likely involved in the development of drug-
induced phospholipidosis (71). 
Besides the alterations in PL and LysoPL levels, increases in TG and OS 
markers were also observed in HepG2 cells treated with 
phospholipidosis-inducing drugs (Figure 3.18). It is known that some 
drugs that cause phospholipidosis (especially CADs) can also induce 
mitochondria damage and steatosis (299, 300) and manifestations such 
as impaired lysosomal protein degradation, decreased pinocytosis and 
endocytosis, and increased free radical formation have also been 
reported in studies using in vitro models (37, 301, 302). Alakoskela et al 
suggested that drug (CAD)-lipid interactions may lead to changes in lipid-
dependent protein activities not only in lysosomes, but also in other 
cellular compartments (303). In particular, the complex structure and 
physicochemical characteristics of mitochondria (e.g., double membrane, 
mitochondrial membrane potential) facilitate the progressive 
accumulation of CADs, thus damaging their function (32, 303).  
 
3.3.2 Development of a metabolomic approximation focused on the 
detection of lipidomic alterations induced by steatogenic and 
phospholipidogenic drugs 
 
Our general untargeted metabolomic analysis strategy allowed us to 
detect metabolic alterations in HepG2 cells treated with drugs inducing 
steatosis or phospholipidosis (Figures 3.15, 3.18). These results showed 
that although the drugs induced important alterations in the 
metabolome which can be directly associated to a particular mechanism 
of toxicity, only early markers of toxicity were detected. For example, in 
the case of phospholipidosis a decrease in the LysoPL/PL ratio (Figure 
3.18) was observed, which can be directly related to the mechanism of 
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toxicity, however, no significant increases in the total content of PL, or 
particular classes of PL, were detected.  
Steatosis and phospholipidosis-inducing drugs usually require chronic 
treatments to show their characteristic clinical manifestations (32). 
Therefore, we decided to apply a new experimental design that favored a 
faster development of the toxic events associated to phospholipidosis 
and steatosis. Gomez-Lechón et al studied the fat accumulation dynamics 
in HepG2 cells as a function of the concentration and composition of free 
FAs in the culture medium (193). Donato et al adapted this strategy to 
develop an experimental design in which a low concentration of free FAs 
is provided to cultured cells to serve as an external source of FA that 
facilitates and accelerates the evolution of the toxic insult (88). Palmitic 
(FA(16:0)) and oleic (FA(18:1)) acids are the most abundant free FAs in 
the liver in both normal subjects and patients with NAFLD (268). Thus, 
HepG2 cells were pre-incubated for 14 h with a mixture of FA (62 µM 2:1 
ratio of oleate and palmitate) before being exposed to drugs (88). As the 
main alterations associated to phospholipidosis and steatosis were found 
in the lipidome (Figures 3.15, 3.18), our new analytical strategy was 
focused on the analysis of lipidic species (see Section 2.8.2 for detailed 
information). 
Figure 3.19.A-B show the scores plots corresponding to the PCA 
analysis performed by comparing the lipidomic profiles of HepG2 cells 
treated with control compounds vs HepG2 cells treated with 
phospholipidogenic or steatogenic drugs, respectively. The clear 
separation in the PCA scores plots between control and treated cells 
suggests that the experimental design and analytical strategy were 
appropriate for the detection of phospholipidosis and steatosis-induced 
alterations. Moreover, Figure 3.19.C shows the PCA scores plot 
corresponding to the three groups included in the study. Three different 
clusters are observed, one corresponding to each different class (i.e. 
control, phospholipidosis and steatosis). The first component seems to 
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be describing the differences caused by steatogenic drugs, while the 
second component describes the separation of the phospholipidogenic 
ones. Therefore, the proposed experimental design seems to be suitable 
to differentiate not only between control and treated samples, but even a 
non-supervised analysis such a PCA was able to detect that steatosis and 
phospholipidosis-inducing drugs provoked different alterations in the 
lipidome of HepG2 cells previously incubated with a mixture of free FAs. 
 
 
Figure 3.19. PCA scores plots corresponding to the lipidomic analysis of HepG2 
cells preloaded with a mixture of free FAs and treated with phospholipidogenic 
and steatogenic compounds. A) Control (green) vs phospholipidosis (red). B) 
Control (green) vs steatosis (purple). C) All groups together. All the PCA analysis 
were performed using only two PCs. The lines denote 95 % confidence interval 
Hotelling's ellipse..  
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Alterations in the lipidome  
 
The new experimental conditions (cells pre-incubated with a FA 
mixture) reproduced all the changes previously observed in the lipidome 
of cells treated with the drugs in absence of an external source of FAs 
(Figures 3.15, 3.18), but additional metabolite alterations were observed 
(Figures 3.20, 3.21). In general, the differences found in cells cultured in 
standard medium (without FA) were subtle and indicative of a very early 
stage of hepatotoxicity, whereas the changes observed in cells pre-
incubated with FA were more extensive and indicative of a more 
advanced damage. 
The supplementation of culture medium with FA facilitated PL 
accumulation (the hallmark of phospholipidosis) in HepG2 cells treated 
with phospholipidosis-inducing drugs. Increased levels of PC, PE and PS 
were observed as well as a subtle increase in the levels of PI and PG 
(Figure 3.20). The decrease in LysoPL content was more evident with 
lowered levels of both LysoPC and LysoPE, thus resulting in a decrease in 
the LysoPC/PC and LysoPE/PE ratios. Besides these changes in the 
phospholipidome, increases in TG, ceramides and SM levels were also 
produced (Figure 3.21). The increased levels of different lipids, and PL in 
particular, are in agreement with previous reports found in the literature. 
Baronas et al found several types of PL altered in urine from rats treated 
with different compounds inducing phospholipidosis (304). Notable 
increase in PC and PE, primary substrates for PLA2, as well as PS were 
described in MDCK cells treated with amiodarone or D-threo-1-phenyl-2-
decanoylamino-3-morpholino-propanol, whereas no changes in PI levels 
were found (297). These changes were consistent with the known 
substrate specificity of PLA2 (297). Our results showing decreased levels 
of LysoPC, LysoPE, LysoPC/PC and LysoPE/PE (Figure 3.20) are also in 
concordance with a diminished hydrolytic activity of PLA2, although 
other potential mechanism explaining PL over accumulation cannot be 
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discarded (32, 37). Finally, a previous study in HepaRG cells exposed to 
amiodarone for 2 weeks showed strong increases in PE and PC levels and 
moderate increases in SM, PI, PS and TG (107). Interestingly, by using our 
experimental strategy a similar pattern of PL alterations was detected in 
HepG2 cells shortly exposed to amiodarone and other phospholipidosis 
inducers (Figures 3.20, 3.21), evidencing the utility of this approach to 
the study the early stages of drug-induced phospholipidosis.  
 
 
 
Figure 3.20. Boxplots showing the changes induced in the levels of PLs and 
LysoPLs as a result of the treatment with steatosis and phospholipidosis-inducing 
drugs in HepG2 cells previously incubated with a mixture of free FAs. Values are 
expressed as relative intensity. Boxes denote interquartile ranges, lines denote 
medians, and whiskers denote the 10th and 90th percentiles. Green: control; 
Red: phospholipidosis; Purple: steatosis.  
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Figure 3.21. Boxplots showing the changes induced in the lipidome (except 
phospholipids) as a result of the treatment with steatosis and phospholipidosis-
inducing drugs in HepG2 cells previously incubated with a mixture of FA. Values 
are expressed as relative intensity. Boxes denote interquartile ranges, lines 
denote medians, and whiskers denote the 10th and 90th percentiles. Green: 
control; Red: phospholipidosis; Purple: steatosis. 
 
 
In relation to steatogenic drugs, the presence of an external source of 
free FA in combination with a lipidomic focused analysis allowed the 
detection of changes not previously observed in the generic analysis 
(cells cultured in absence of FA supplement). Thus, besides the increase 
in TG and DG, an increase in the levels of MG, acylcarnitines, ChE, 
ceramides and SM was also observed (Figure 3.21). A detailed analysis of 
the phospholipidome revealed that only the levels of PC (the most 
abundant PL inside the cells) were increased by steatosis inducers, while 
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the levels of the rest of PL did not show any significant change (Figure 
3.20). This suggests a contribution of de novo synthesis of PC via the 
CDP-choline pathway as a result of the elevated levels of DG and 
phosphocholine (274, 275) (Figures 3.15, 3.16). A higher increase in the 
levels of both LysoPC and LysoPE was also found (Figure 3.20). Drug-
induced steatosis is characterized by TG accumulation, mainly, but not 
exclusively, due to FA oxidation impairment as a result of mitochondrial 
disturbances (29, 32, 34, 35). The result of this situation is the 
accumulation of both intermediates of FA oxidation, such as 
acylcarnitines, and of TG synthesis, such as MG, and DG (Figures 3.16, 
3.21). Similar results have been previously reported in humans, animal 
and cell-based models of steatosis (106, 154, 248, 250, 268). Besides 
the expected alterations related to FA metabolism and TG synthesis, 
increased levels of ceramides and SM were also observed (Figure 3.21). 
Ceramides are complex lipids composed of sphingosine and a FA. 
Ceramides further combine with phosphocholine forming SM, the major 
sphingophospholipid in humans. Ceramides can also be rapidly 
generated from SM by sphingomyelinase induced hydrolysis (305, 306). 
Previous reports have found elevated hepatic levels of ceramides in fatty 
liver disease (248, 307, 308) and increased levels of sphingosine, the 
precursor in ceramide synthesis, in FA overloaded HepaRG cells (154).  
It is well described that the degree of saturation of free FAs has a 
strong effect on the tendency of the cells to store them as TG, while 
unsaturated FAs are more likely incorporated into TG, their saturated 
counterparts are channeled towards other cellular fates (258). Thus 
steatosis- and cytotoxicity-inducing properties of palmitic and oleic acids 
are different, while the steatogenic capacity of oleic acid is higher, 
palmitic acid induces a higher cytotoxicity as it remains as a free FA 
(193). Our results showed that when HepG2 cells pre-treated with the 
oleic and palmitic acids mixture were exposed to model steatogenic 
drugs, there was an intracellular accumulation of palmitic acid (FA(16:0)), 
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whereas a decrease in the levels of oleic acid (FA(18:1)) was observed 
(Figure 3.22). Accordingly, the levels of SM and TG containing only 
FA(16:0) and FA(18:1) moieties showed a higher increase for those 
species incorporating a higher proportion of oleate (Figure 3.22). Thus, 
the fold of change for SM follows the tendency SM(d36:2) > SM(d34:1) > 
SM(d32:0). With respect to TG, the same tendency was observed: 
TG(54:3) > TG(52:2) > TG(50:1) > TG(48:0) (Figure 3.22).  
 
 
 
Figure 3.22. Boxplots showing the differences in palmitic and oleic acid 
distribution in lipidic species as a result of drug-induced steatosis in HepG2 cells 
pre-incubated with a mix of palmitic and oleic acids and analyzed using a 
lipidomic strategy. Boxes denote interquartile ranges, lines denote medians, and 
whiskers denote the 10th and 90th percentiles. Green: control; Purple: steatosis. 
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The combined use of a lipidomic-specific chromatographic separation 
in combination with high mass-resolution MS allowed us to describe not 
only changes in the total amount of lipids or TG, as is the case of 
enzymatic- or fluorescence-based methods, but to provide a more 
detailed description and a deeper understanding of the changes induced 
in specific species of lipids. 
 
Alterations in the levels of lipidic species containing only FA(16:0) and/or 
FA(18:1) moieties  
 
The follow up of the compounds provided to the cells represents an 
appealing option to the development of target analyses to evaluate the 
evolution of the hepatotoxic damage. Palmitic and oleic acids can be 
directed to different cell metabolic pathways. They can be converted into 
other FA by desaturases and elongases (248, 269) or can be incorporated 
into the different lipid classes that compose the lipidome (Figure 3.16). 
This information could be obtained by deuterium-labeled FA incubations 
or acyl-CoA desaturase/elongase activity measurement. We propose a 
simpler approximation based on the comparative analysis of the 
different types of lipids containing only palmitic or oleic acid moieties. 
Table 3.3 shows a good concordance between the changes in the total 
levels of each of the lipidic species detected and the changes observed 
for those species containing only palmitic and oleic acid moieties. While 
the fold of change for specific species (i.e. those containing only palmitic 
or only oleic acid as moieties) might differ, the average value for all the 
species containing only palmitic and/or oleic acid as components 
provided similar results than the average of all the different 
combinations of FA for a given lipid class. Therefore, the evaluation of 
those lipidic species containing only palmitic and/or oleic acid as 
moieties constitutes a good option for the development of targeted 
analysis that would result in the generation of quantitative results and 
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the save of both time and economical resources, while providing a 
representative snapshot of the alterations produced in the lipidome. 
 
Table 3.3. Values of fold of change for control vs treated cells for each of the 
lipid classes and treatments indicated. The values correspond to the lipidomic 
analysis of HepG2 treated either with steatogenic or phospholipidogenic 
compounds in the presence of an external source of FA. 16:0 column 
corresponds to lipidic species containing only the FA(16:0). 18:1 column 
corresponds to lipidic species containing only the FA(18:1). Mean column 
correspond to the mean value obtained for those lipidic species containing only 
FA(16:0) and/or FA(18:1) moieties. Total corresponds to the mean value obtained 
for all the species of a given class. 
 
 
Phospholipidosis Steatosis 
 
16:0 18:1 Mean Total 16:0 18:1 Mean Total 
Acylcarnitine 0.99 0.95 0.97 0.86 2.70* 2.69* 2.7* 2.45* 
ChE 1.03 1.1 1.08 1.1 2.08** 1.99* 2.03** 1.64* 
Cer n.d. 0.89 2.09*** 1.75*** n.d. 3.74*** 2.28* 1.15* 
DG 1.24 1.47 1.31 1.11 1.40* 1.38* 1.33* 1.3** 
FA 1.46** 0.33*** 0.88 1.05 1.56** 0.31*** 0.92 1.08 
LysoPC 0.73* 0.82 0.77* 0.80* 1.45* 1.43* 1.44* 1.56* 
LysoPE 1.18 1.02 1.07 0.93 1.54 1.25 1.33 1.23 
MG 0.65* 0.79 0.74 0.77 1.57* 1.69* 1.65* 1.96* 
PC 1.85** 1.19* 1.25** 1.20** 1.7* 1.42** 1.54** 1.28** 
PE 2.38*** 2.78*** 2.59*** 2.25*** 1.1 1.2 1.16 0.64 
PG 1.99*** 2.12* 1.9* 1.83* 1.57 0.87 1.11 0.79 
PI n.d. 2.53** 2.45** 1.14 n.d. 0.81 0.9 0.66 
PS n.d. 2.52*** 2.52*** 2.17*** n.d. 1.28 1.28 0.73 
SM 1.1 1.17 1.42* 1.35* 1.13 1.94*** 1.73*** 1.26** 
TG 1.69 1.28** 1.31** 1.40*** 1.31 1.76** 1.67* 1.45** 
Comparisons between control and each treatment were performed using a 
Student t test. *: p value < 0.05; ** p value < 0.01; *** p value < 0.001. 
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3.3.3 Targeted analysis of OS markers 
 
The untargeted analysis of HepG2 exposed to hepatotoxic compounds 
(Section 3.3.1) revealed that the presence of OS markers is a common 
hepatotoxicity event, even in the case of hepatotoxins whose primary 
mechanism of toxicity is not directly related to OS (29, 88, 89, 92). In 
order to achieve a deeper insight in the involvement of OS in 
hepatotoxicity, a quantitative targeted analytical method aimed to 
determine a set of well-known OS biomarkers was developed in our 
laboratory (209). The markers included in the method are: i) sulfur-
containing substances, as GSH, GSSG, SAM and SAH (214, 309); ii) 
phenylalanine (310) and tyrosines I-Tyr, N-Tyr, Cl-Tyr, o-Tyr, m-Tyr and p-
Tyr as markers of oxidative protein damage (311, 312); iii) 8-OH-dG and 
2-dG, which indicate DNA damage (313), iv) MDA, which indicate 
peroxidation (314); and v) ophthalmic acid, that indicates GSH 
consumption (138). 
The targeted analysis was applied to a set of four compounds that 
induce hepatotoxicity through different mechanism (tert-butyl 
hydroperoxide (OS), amiodarone (phospholipidosis), tetracycline 
(steatosis) and cyclosporine (cholestasis)) and with previous reports of 
OS and mitochondrial impairment (29, 88, 89, 91, 92, 291). Among the 
OS markers analyzed, GSH/GSSG ratio, ophthalmic acid and MDA were 
significantly altered following a dose-dependent tendency Figure 3.23. 
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Figure 3.23. Boxplots showing the results obtained with the targeted analysis of 
OS markers (GSH/GSSG, upper panel; ophthalmic acid, middle panel; and MDA, 
lower panel) for HepG2 cells treated with control compounds (green), tert-butyl 
hydroperoxide (orange), amiodarone (red), tetracycline (purple) and cyclosporine 
(blue). Boxes denote interquartile ranges, lines denote medians, and whiskers 
denote the 10th and 90th percentiles. The value in the x-axis denotes the 
concentration at which the indicated compound has been employed. 
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As expected, all compounds induced a concentration-dependent 
decrease in the GSH/GSSG ratio (Figure 3.23). These results confirm the 
tendency of a decreased GSH/GSSG ratio observed in the untargeted 
analysis (Figures 3.12, 3.15, 3.17, 3.18) and are in agreement with those 
previously reported for both OS as a primary (209, 236, 237) and 
secondary (88, 140, 279, 315) hepatotoxic damage both in vivo and in 
liver-based cellular models.  
An increase in the levels of ophthalmic, in parallel to the decrease in 
the GSH/GSSG ratio, was also observed for the four compounds (Figure 
3.23). Ophthalmic acid was not detected using the untargeted analysis 
strategy, however the increased sensitivity provided by the UPLC/MS-MS 
targeted method allowed its detection and quantification. Ophthalmic 
acid (-glutamyl-2-aminobutyrate-glycine) is a nonsulfur-containing 
analog of GSH in which the cysteine moiety has been substituted by 2-
aminobutyric acid. It shares the same biosynthetic pathway than GSH: 
the first step in the synthesis of ophthalmic acid is the linking of 2-
aminobutyrate to glutamate, a step catalyzed by GCS; subsequently, 
glycine is linked to this dipeptide via GS (138, 316, 317) (Figure 3.13, 
3.14). Under OS conditions, the activity of the enzyme GCS is enhanced 
thus leading to an increased synthesis of ophthalmic acid (Figure 3.14). 
However, due to the lack of a thiol group, ophthalmic acid is not further 
metabolized under OS conditions and thus accumulates (138). 
Ophthalmic acid was first proposed as a marker of OS and GSH depletion 
by Soga et al (138). They found increased levels of ophthalmic acid in the 
liver and serum of mice treated with acetaminophen following a pattern 
that correlated with GSH depletion (138). Increased levels of ophthalmic 
acid have also been reported in THLE-2E1 cells and in the liver of rats 
treated with acetaminophen (140, 318). More recently, we have reported 
increased levels of ophthalmic acid in primary-cultured rat hepatocytes 
incubated for 24 h with 500 µM cumene hydroperoxide and in the serum 
of patients suffering non-alcoholic steatohepatitis (209). It is not clear 
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whether ophthalmic acid has any meaningful physiological role or it is 
simply a byproduct associated to GCS activation during OS (138, 316). 
Nevertheless, it has been shown that ophthalmic acid is able to 
competitively inhibit and trans-stimulate GSH transport in liver 
canalicular membranes (319), which can be interpreted as an adaptive 
mechanism to minimize GSH efflux during OS. Therefore, it has been 
hypothesized that it can act as a GSH analog for functions that do not 
require the presence of the thiol group (138).  
Increased levels of MDA, a marker of lipid peroxidation, were observed 
in HepG2 cells treated with amiodarone, tetracycline or cyclosporine but 
not with tert-butyl hydroperoxide (Figure 3.23). Increased MDA levels 
have been reported in hepG2 cells shortly (3 h) treated with tert-butyl-
hydroperoxide and hydrogen peroxide (211) but not after longer 
incubation (24 h) with the OS inducer cumene hydroperoxide (209). High 
MDA levels have been previously reported in HepG2 cells exposed to 
amiodarone (320), in the liver of rats administered cyclosporine (321, 
322) and in the liver of patients with steatosis (209, 268). Moreover, 
increased lipid peroxidation has been previously described in liver 
mitochondria of rats previously administered amiodarone (315). 
Interestingly, amiodarone, tetracycline and cyclosporine have been 
previously described to induce mitochondrial impairment while tert-butyl 
hydroperoxide is considered a pure OS inducer (32, 88, 92). Amiodarone 
inhibits β-oxidation of FA (30, 323-325), inhibits complexes I, II, and III in 
the respiratory chain (315, 325, 326), uncouples oxidative 
phosphorylation (324, 327) and decreases mitochondrial membrane 
potential (325, 328). Tetracycline has been reported to inhibit β-
oxidation (323, 329, 330) and cyclosporine inhibits β-oxidation (280, 
281) and complexes I and II (331). Therefore, the oxidative damage 
produced by amiodarone, tetracycline or cyclosporine is secondary to 
other hepatotoxic effects, thus resulting in a delayed appearance of the 
OS markers and a situation that is more likely to become chronic and 
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amplified. In contrast, tert-butyl hydroperoxide is able to induce OS by 
itself and its effects are detected shortly after exposure (209). 
 
3.3.4 Development of predictive/classificatory models of 
hepatotoxicity 
 
One of our goals was to develop a model able to predict and classify 
the potential hepatotoxicity of new drug candidates. Thus, firstly, we 
considered the development of a model aimed to discriminate between 
non-toxic and hepatotoxic compounds. Secondly, we tried to develop a 
more sophisticated model aimed to discriminate among the different 
mechanisms of toxicity included in our study. Cholestasis was not 
considered to develop the model and finally four different classes (i.e. 
control, OS, phospholipidosis and steatosis) were used. 
Predictive models were built using PLS-DA and a bootstrapped strategy 
coupled to VIP ranking to order and select variables according to their 
importance in the model, fitting and predictive (predictability) capacity. 
The optimum number of variables was selected as the one that provided 
the highest figures or merit (accuracy and AUROC).  
 
Predictive model for the discrimination between non-toxic and 
hepatotoxic compounds 
 
Here the objective was to develop a mathematical model able to 
classify between non-toxic and hepatotoxic compounds. CV was used to 
select the optimum number of LVs in the PLS-DA model. Based on the 
values of R
2
, Q
2
 and misclassification error, two LVs were selected (Figure 
3.24.A). After fixing the number of LVs, the variables were ranked 
according to their importance in the model. The results of model 
performance (evaluated based on AUROC and misclassification error) vs 
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the number of retained variables included in the model are shown in the 
Figure 3.24.B. 
 
 
 
Figure 3.24. A) Values of R
2
 (blue), Q
2
 (red) and misclassification error (green) as 
a function of the number of LVs employed to build the PLS-DA model using all 
the variables from the data obtained with the generic untargeted metabolomic 
analysis of HepG2 treated with either non-toxic or hepatotoxic compounds. The 
values obtained for each parameter and model are written over the 
corresponding bar. B) Values obtained for the AUROC (green) and 
misclassification error (red) vs the number of retained variables for the top-20 
ranked variables using PLS-DA models with two LVs. The data is expressed as 
mean ± standard deviation.  
 
 
A perfect classification (AUROC = 1, misclassification error = 0) was 
obtained using only 8 variables (i.e. adenine, FA(20:4), LysoPC(18:2), 
FA(22:6), phosphocholine, GMP, FA(20:3) and LysoPE(24:1). The PLS-DA 
scores and loadings plot corresponding to the model developed using 
2LV and 8 retained variables are shown in Figure 3.25. A clear 
separation was observed between non-toxic and hepatotoxic 
compounds, with no overlap between the 95 % confidence interval 
Hotelling's ellipse drawn for each of the classes (Figure 3.25.A). The 
loadings plot revealed that only 2 of the 8 variables included in the final 
model showed a positive correlation with the onset of hepatotoxicity (i.e. 
adenine and phosphocholine) (Figure 3.25.B), whereas the remaining 6 
variables correlated with the assignment to the non-toxic group. The 
model retrieved good figures of performance based on CV: R
2
 = 0.82, Q
2
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= 0.81, misclassification error = 0.00 and AUROC = 1. Moreover, a 
permutation test was also performed in order to further validate model 
consistency and performance (133). No overlap was obtained between 
the actual figures estimated using CV and the distribution of values 
calculated for the permuted models (Figure 3.25.C-D).  
 
 
 
Figure 3.25. Summary of the results provided by the PLS-DA model built using 2 
LVs and the top-ranked 8 variables based on the data obtained with the generic 
untargeted metabolomic analysis of HepG2 treated with either non-toxic or 
hepatotoxic compounds. A) Scores plot. The lines denote 95 % confidence 
interval Hotelling's ellipse for each class. Green: non-toxic; Grey: hepatotoxic B) 
Loadings plot. Green: non-toxic; Grey: hepatotoxic; Blue: metabolites. C) 
Permutation test for the misclassification error. D) Permutation test for the 
AUROC. In both cases the histograms represent the values obtained using the 
permuted classes. The actual value obtained with the real classes is indicated by 
the red dot and the value written above it.  
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The results obtained for the PLS-DA model suggest that our 
experimental and data analysis strategies represent a good option to 
discriminate hepatotoxic and non-hepatotoxic drugs. However, the 
validation methods were based only on CV and permutation testing and 
only a limited number of model hepatotoxins were included in the study, 
what would result in overoptimistic results. 
The present model, constitute the first metabolomic-based strategy to 
discriminate hepatotoxic compounds in human hepatic cells in culture. 
Several examples of the development of predictive models of 
hepatotoxicity are available in the literature. Both in vivo and in vitro 
assays based on the analysis of traditional cytotoxicity end points (e.g. 
ATP content, lactate dehydrogenase (LDH) release, urea syntesis...) (332), 
transcriptomics/gene expression (64, 333, 334), proteomics (62, 78, 
335) and HCS (52, 87, 90, 93, 336, 337) have been proposed. Among 
them, the combined used of in vitro liver-based cellular models and HCS 
is the most popular strategy. HCS assays are usually performed in 96-
well or 386-well formats, what allows for high throughput analyses and, 
therefore, large lists of compounds have been tested. Cell count, ROS 
generation, mitochondrial damage, lipid accumulation and intracellular 
calcium are the most commonly parameters analyzed by HCS assays 
(338). With respect to their predictive capabilities, high specificity values 
(~90%) but sensitivity values ranging from 50 to 90% have been reported 
(338). This low sensitivity, specially associated to drugs that do not 
induce cell death or even in the case of non-proliferative cellular models, 
constitute an important drawback (338).  
An important advantage of metabolomics, compared to other 
screening methods, is the detection of early metabolic alterations that 
occur in absence of cell death. However, to be competitive with respect 
to techniques such as HCS a higher number of hepatotoxins must be 
tested in order to identify a set of highly reliable markers of toxicity. 
Then, the development of quantitative targeted analysis of selected 
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markers would considerably increase sample throughput and minimize 
sample requirements. 
 
Predictive model for the discrimination of specific mechanisms of 
hepatotoxicity 
 
After the development of a classificatory model to discriminate 
between hepatotoxic and non-hepatotoxic compounds, our next goal 
was to develop a model able to discriminate among the different 
mechanism of toxicity. Using a CV strategy the optimum number of LV to 
develop the PLS-DA model was set to three (Figure 3.26.A). Then the 
model performance (evaluated based on AUROC and misclassification 
error) vs the number of retained variables included in the model was 
assessed (Figure 3.26.B).  
 
 
 
Figure 3.26. A) Values of R
2
 (blue), Q
2
 (red) and misclassification error (green) as 
a function of the number of LVs employed to build the PLS-DA model using all 
the variables from the data obtained with the generic untargeted metabolomic 
analysis of HepG2 treated with either non-toxic or hepatotoxic compounds acting 
through different mechanism of hepatotoxicity (i.e. OS, phospholidosis and 
steatosis). The values obtained for each parameter and model are written over 
the corresponding bar. B) Values obtained for the AUROC (green) and 
misclassification error (red) calculated using CV vs the number of retained 
variables for the top-30 ranked variables using PLS-DA models with three LVs. 
The data is expressed as mean ± standard deviation. 
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The maximum value of AUROC and minimum value of misclassification 
error were obtained using the top 22 ranked variables (i.e. adenine, GSH, 
LysoPC(20:0), GSH/GSSG, LysoPC(18:2), phosphocholine, -glutamyl-
glutamine, LysoPC(22:1), LysoPC(20:1), LysoPC(24:0), SM(d44:2), 
LysoPC(24:1), LysoPC(22:6), PC(44:11), LysoPC(26:1), FA(20:4), aspartic 
acid, carnitine(5:0), SM(d32:2), LysoPC(18:1), TG(60:8), and AMP). The 
final PLS-DA model rendered the following figures using CV: R
2
 = 0.73, Q
2
 
= 0.72, misclassification error = 0.06 ± 0.08, AUROC = 0.96 ± 0.05. The 
good values obtained with respect the AUROC and the misclassification 
represent good indicators of the capabilities of the PLS-DA model.  
 
 
Figure 3.27. Summary of the results provided by the PLS-DA model built using 3 
LVs and the top-22 ranked variables based on the data obtained with the generic 
untargeted metabolomic analysis of HepG2 treated with either non-toxic or 
hepatotoxic compounds acting through different mechanism of hepatotoxicity 
(i.e. OS, phospholipidosis and steatosis). A) Scores plot. The lines denote 95 % 
confidence interval Hotelling's ellipse for each class. Green: non-toxic; orange: 
OS; red: phospholipidosis; purple; steatosis. B) Permutation test for the 
misclassification error. C) Permutation test for the multiclass AUROC. In both 
cases the histograms represent the values obtained using the permuted classes. 
The actual value obtained with the real classes is indicated by the red dot and the 
value written above it.  
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A good separation between the different groups is observed in the PLS-
DA scores plot (Figure 3.27. A), and there is almost no overlap between 
the 95 % confidence interval Hotelling's ellipses drawn for each class. 
The model was further validated using a permutation test strategy with 
excellent results, as no overlap was obtained for values obtained using 
the permuted classes and the real values obtained with the actual PLS-DA 
for the misclassification error (Figure 3.27. B) and the AUROC (Figure 
3.27. C) 
As previously discussed for the model aimed at the discrimination 
between non-hepatotoxic and hepatotoxic compounds, although the 
results obtained for the present PLS-DA model were very encouraging, 
they must be carefully analyzed as only a limited number of compounds 
were evaluated and no external validation was performed. 
Only a few studies aimed at the classification/prediction of different 
mechanisms of toxicity have been reported in the literature (92, 332). 
The HCS-based assay developed by Tolosa et al aimed to screen and 
classify drugs according to their hepatotoxicity mechanism (apoptosis, 
genotoxicity, OS, mitochondrial damage and bioactivation) (92). To this 
end, cell viability, morphological nuclear changes, mitochondrial 
membrane potential, intracellular calcium concentration and OS were 
measured in HepG2 cells and a mean sensitivity of 90 % was obtained 
when evaluating the different mechanisms of toxicity (92). On the other 
hand, Germano et al employed sandwich-cultured rat hepatocytes and a 
combination of different techniques in order to distinguish between 
steatosis, phospholipidosis and cholestasis. The assay included 
biochemical assays (i.e. ATP content, LDH release, urea synthesis and 
albumin secretion), HCS (i.e. Mrp-2 mediated transport, neutral lipid 
accumulation and PL accumulation) and gene expression quantification 
(i.e. nuclear receptors, transporters and CYPs). Their results suggested 
that the strategy might be a suitable tool for the evaluation of 
phospholipidosis and cholestasis but not for steatosis (332).  
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Our method was able to distinguish between non-toxic compounds 
and compounds inducing OS, steatosis and phospholipidosis. However, it 
failed in the evaluation of cholestatic drugs. As indicated above, 
identification of drug-induced cholestasis would require the use of liver-
based cellular models that correctly express the transporters of interest 
(i.e. HepaRG or sandwich-cultured hepatocytes). However, and besides its 
limitations, our method supposes a valuable alternative to detect 
mechanism-specific alterations at subcytotoxic concentrations. Moreover, 
while the number of parameters evaluated simultaneously using other 
strategies such as HCS is highly limited (338), untargeted metabolomics 
allows to measure hundreds of signals that could be later ranked and 
selected. Similarly, targeted analysis allows the simultaneous 
quantification of dozens up to hundreds of compounds (103, 108). 
Finally, the applicability of the present strategy to routine toxicological 
evaluation and compound screening would be conditioned to the 
definition of set of reliable mechanism-specific markers to be quantified 
by the use of a LC-MS/MS targeted method. 
 
Predictive model for steatosis and phospholipidosis based on lipidic 
species containing only FA(16:0) and/or FA(18:1) moieties  
 
As seen above, the changes induced in lipidic species containing only 
FA(16:0) and/or FA(18:1) were representative of the general changes 
induced in the lipidome by treatment with drugs inducing either 
phospholipidosis or steatosis (Table 3.3). Then, we decided to develop a 
predictive/classificatory model based on those lipidic species composed 
only by FA(16:0) and/or FA(18:1) moieties.  
Using a CV strategy, the optimum number of LV to develop the PLS-DA 
model was set to two based on the values of R
2
, Q
2
 and misclassification 
error (Figure 3.28.A). The results of model performance (evaluated based 
on multiclass AUROC and misclassification error) vs the number of 
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retained variables included in the model retrieved a maximum value of 
AUROC and minimum value of misclassification error for the model built 
using the top 8 ranked variables (i.e. Cer(d36:2), FA(18:1), SM(d36:2), 
LysoPC(16:0), PE(32:0), PE(36:2), PC(36:2), PC(34:1)) (Figure 3.28.B). 
 
 
Figure 3.28. A) Values of R
2
 (blue), Q
2
 (red) and misclassification error (green) as 
a function of the number of LVs employed to build the PLS-DA model using all 
the variables from the data obtained with the lipidomic analysis of HepG2 treated 
with either non-toxic or hepatotoxic compounds inducing steatosis or 
phospholipidosis in the presence of an external source of FA. and using those 
lipididc compounds containing only FA(16:0) and/or FA(18:1) moieties. The 
values obtained for each parameter and model are written over the 
corresponding bar. B) Values obtained for the AUROC (green) and 
misclassification error (red) calculated using CV vs. the number of retained 
variables for the top-20 ranked variables using PLS-DA models with two LVs. The 
data is expressed as mean ± standard deviation. 
 
 
The final PLS-DA model rendered the following figures using CV: R
2
 = 
0.76, Q
2
 = 0.73, misclassification error = 0.03 ± 0.08, AUROC = 0.98 ± 
0.03. A good separation between the different groups was observed in 
the PLS-DA scores plot (Figure 3.29.A), with only a few overlap between 
the 95 % confidence interval Hotelling's ellipses drawn for steatosis and 
phospholipidosis. The first component was driven by the differences 
induced by steatogenic compounds and the second component 
described the separation between non-toxic and hepatotoxic compounds 
(in particular between phospholipidosis and control samples). The 
contribution of each of the variables included in the final model can be 
evaluated by their position in the loadings plot (Figure 3.29.B). FA(18:1) 
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was associated to the assignment to control class, PE(32:0) and PE(36:2) 
to phospholipidosis, LysoPC(16:0), SM(d36:2) and Cer(d36:2) to steatosis 
and PC(34:1) and PC(36:2) to both steatosis and phospholipidosis. These 
results are in concordance with the alterations shown in Table 3.3. The 
model was further validated using permutation testing (Figure 3.29.C-D). 
No overlap was obtained between the values obtained using the 
permuted classes and the real values obtained with the actual PLS-DA for 
the misclassification error (Figure 3.29.C) and the AUROC (Figure 
3.29.D) thus pointing the excellent consistency of the developed model. 
 
 
Figure 3.29. Summary of the results provided by the PLS-DA model built using 2 
LVs and the top-ranked 8 variables based on the data obtained with the lipidomic 
analysis of HepG2 treated with either non-toxic or hepatotoxic compounds 
inducing steatosis or phospholipidosis in the presence of an external source of 
FA. A) Scores plot. The lines denote 95 % confidence interval Hotelling's ellipse 
for each class. Green: control; Red: phospholipidosis; Purple: steatosis. B) 
Loadings plot. Green: control; Red: phospholipidosis; Purple: steatosis; Blue: 
metabolites. C) Permutation test for the misclassification error. D) Permutation 
test for the AUROC. In both cases the histograms represent the values obtained 
using the permuted classes. The actual value obtained with the real classes is 
indicated by the red dot and the value written above it.  
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The results reinforce the idea that the development of a targeted 
quantitative analysis of those species containing only palmitic and oleic 
acids as moieties (in cells pre-incubated with a palmitate/oleate mixture) 
might constitute a straightforward strategy for the prediction of drug-
induced phospholipidosis and steatosis.  
Different examples are available in the literature with respect to the 
prediction of drug-induced steatosis (69, 88, 89), phospholipidosis (71, 
339-341) or both simultaneously (300, 332).  
Two different approximations have been applied to the study of drug-
induced steatosis in cultured cells, Donato et al performed an HCS 
analysis using HepG2 cells as model (88, 89). Among the different 
evaluated parameters, the combination of lipid accumulation (measured 
using BODIPY) and ROS generation was the one that provided the best 
performance (88, 89). On the other hand, Benet et al identified a series 
of transcription factors (i.e. FOXA, HEX and SBREP1C) whose expression 
levels in HepG2 cells might be used to predict drug-induced steatosis 
(69). 
The gold standard confirmatory method for the detection of 
phospholipidosis is electron microscopy (342). However, the method is 
expensive, time consuming, and not dedicated to medium and high-
throughput screenings. In addition, drug-induced phospholipidosis 
detected by electron microscopy could be discovered only after 
subchronic/chronic intake of compounds (343). Two alternative 
techniques, feasible to be adapted to high throughput, have arisen as an 
alternative: HCS and gene expression. HCS methods are usually based on 
the incorporation of fluorescent PL analog or a lipid-specific fluorescent 
dye (i.e. NBD-PE, NBD-PE, LipidTox, Nile red...) (339-341, 344, 345). Gene 
expression methods (71, 339, 341, 343) are based on the measure of 
the expression of 17 genes associated to phospholipidosis and 
previously identified by Sawada et al (71). Both methods provided high 
values of sensitivity and specificity (~90 %), however, it has been 
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reported that HCS based assays allow multiplexing and a higher 
throughput (341). 
The few studies that simultaneously evaluated steatosis and 
phospholipidosis (300, 332) reported unsatisfactory results with respect 
their capabilities to accurately classify steatogenic drugs. 
In summary, our strategy based on the pre-incubation of the cells with 
a mixture of free FA achieved to accelerate the development of the 
hepatotoxic damage. Moreover the metabolomic analysis of the lipidomic 
alterations was able to detect events that occur in early stages of the 
toxic insult thus being able to differentiate between control, steatogenic 
and phospholipidogenic drugs. This fact represents an advantage with 
respect the methods available in the literature and after the suitable 
validation and development of a targeted quantitative analysis might 
represent a real alternative to the established methods. 
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3.4 Extrapolation of in vitro results to in vivo models 
 
After exploring the capabilities of HepG2 cells coupled to MS-based 
metabolomics to predict DILI, we decided to test whether the results 
obtained using a simple in vitro model could be extrapolated to in vivo 
models. First we evaluated the usefulness of medaka fish (Oryzias 
latipes) to predict human hepatotoxicity using a study design 
comparable to that performed in HepG2. Then, the changes were 
compared with those obtained using rats, an in vivo animal model 
widespreadly used in hepatotoxicity studies (137, 140, 205, 304). 
Finally, the rat model was used to search for non-invasive serum markers 
of hepatotoxicity. 
 
3.4.1 Differential metabolomic profiling analysis of medaka  
 
Medaka fish (Oryzias latipes) allows to use a high number of 
individuals with minimum requirements and provides information of 
relevance to human metabolism. The main advantages of medaka are its 
high reproductive rate, rapid maturation, and little cost in terms of 
rearing space and daily maintenance owing to their small size (203, 346). 
Moreover, the use of small fishes like medaka is in line with the 3R’s 
(reduce, refine, and replace) approach of animal use for scientific 
purposes by replacing higher order animals with lower order ones (347). 
Physiologically, medaka are omnivores and metabolize sugars and 
lipids in a manner analogous to that of mammals (348, 349). With the 
exception of some structural and anatomical differences, the general 
cellular composition and function of a healthy medaka liver is virtually 
the same as in mammals (350). It is worthy to mention that significant 
differences exist in the lipid composition between medaka and human 
liver. The most abundant FA in healthy human liver are palmitate 
(FA(16:0), 28%) and oleate (FA(18:1), 35%), and polyunsaturated FA 
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represent around 19% of the total (106, 268, 351). The most abundant 
FA in medaka liver are palmitate (FA (16:0), 27% ), oleate (FA(18:1), 16%) 
and docosahexaenoate (FA(22:6), 24%), with a 39% of the FA being 
polyunsaturated (352, 353). With respect to xenobiotic metabolism, 
medaka metabolize drugs using similar pathways as humans as they 
possess a wide range of CYPs, enabling metabolic reactions including 
hydroxylation, conjugation, oxidation, demethylation and de-ethylation 
(202, 203, 354, 355). 
Small fish models (mainly medaka and zebrafish) are being 
increasingly used as an in vivo model system for the evaluation of novel 
drug candidates for efficacy and safety testing (201, 203, 356) and 
recent literature has confirmed that mammalian and small fish toxicity 
profiles are strikingly similar (203, 357, 358). It is worthy to mention the 
contribution of small fish models in the understanding of diet-induced 
steatosis and steatohepatitis development (346, 359). 
The hepatic metabolomic profiles of medaka fish treated with model 
hepatotoxic compounds were compared with those obtained using 
HepG2 cells and with the data available in the literature regarding 
toxicity in humans and other animal models. The compounds were 
administered once a day for five consecutive days. This dosing protocol 
is closer to drug dosage in humans than treatment protocols in in vitro 
experiments in which the cells are exposed uninterruptedly to the drug 
for a given period of time (e.g., 24 h).  
The analytical strategy was equivalent to that applied to unravel the 
metabolomic changes in HepG2 cells. Figure 3.30 shows the scores plots 
corresponding to the PCA analysis comparing the hepatic metabolic 
profile of medaka exposed to vehicle vs medaka treated with compounds 
inducing cholestasis, phospholipidosis or stetatosis. Samples from 
control group clustered together and separated from those 
corresponding to hepatotoxic compounds. These results suggest that 
the treatments induced marked changes in the hepatic metabolome. 
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Figure 3.30. Scores plots corresponding to the PCA performed using the data 
obtained from the metabolomic analysis of liver of medaka treated either with 
control (i.e. non-toxic) or hepatotoxic compounds acting thorugh different 
mechanisms of toxicity (i.e. cholestasis, phospholipidosis and steatosis). The 
lines denote 95 % confidence interval Hotelling's ellipse drawn for each class. 
PCA models were developed using two principal components. A) Control vs 
cholestasis. B) Control vs Phospholipidosis. C) Control vs Steatosis. Green: 
Control; Blue: Cholestasis; Red: Phospholipidosis; Purple: Steatosis. 
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Identification of markers of hepatotoxicity 
 
First, a general comparison between untreated medaka (control group) 
and those treated with hepatotoxic compounds was performed in order 
to identify non-specific markers of hepatotoxicity. Then, the analysis was 
focused on the identification of specific markers and patterns associated 
to each of the studied mechanisms of hepatotoxicity. 
A total of 9 compounds acting through different mechanism of toxicity 
were included in the study (Table 2.3). The generic changes observed in 
medaka were comparable to those observed for HepG2 cells (Figure 
3.11). With respect to the lipidic species, several changes were observed 
in PLs, FAs, TG and acylcarnititines. With respect to polar metabolites the 
most important changes were related to glycolysis (i.e. glucose-6-
phosphate), pentose phosphate pathway (i.e. ribose-5-phosphate), OS 
markers (i.e. GSH/GSSG and ophthalmic acid) and intermediates in PL 
metabolism (i.e. choline and glycerophosphoethanolamine) (Figure 
3.31). Besides the similarities between HepG2 and medaka models, some 
differences were also observed as no relevant changes were detected in 
the metabolism of purines or aminoacids in the case of medaka. A main 
reason for these differences could be the proliferative nature of HepG2 
cells compared to the normal non-proliferative state of hepatocytes (5). 
From the detected alterations it can be concluded that the generic 
changes induced by hepatotoxic insults in medaka are directed to key 
aspects of lipid metabolism (i.e. PL, TG, FA and TG) and that 
mitochondrial damage is likely to be implied as suggested by the altered 
energetic metabolism and the appearance of markers of OS (34, 35).  
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Figure 3.31. Boxplots showing the most important changes associated to generic 
hepatotoxicity in the liver of medaka analyzed following the generic untargeted 
metabolomic analysis strategy. Values are expressed as relative intensity. Boxes 
denote interquartile ranges, lines denote medians, and whiskers denote the 10th 
and 90th percentiles. 
 
 
Liver's metabolome changes triggered by cholestatic drugs 
 
Three compounds classified as cholestatic were included in the study 
(Table 2.3): 17α-ethynylestradiol, chlorpromazine and cyclosporine. Up 
to 197 metabolites were altered in the liver of medaka treated with 
cholestatic drugs, with impact on FA, TG and PL, urea cycle, nitrogen 
metabolism, aminoacid metabolism, and glutamate and GSH metabolism 
revealed by pathway enrichment analysis (Figure 3.32). 
Results & Discussion 
205 
  
Figure 3.32. Boxplots showing the most important changes associated to 
cholestasis treatment in the liver of medaka analyzed following a generic 
untargeted analysis strategy. Values are expressed as relative intensity. Boxes 
denote interquartile ranges, lines denote medians, and whiskers denote the 10th 
and 90th percentiles. 
 
 
The altered pathways and metabolites (Figure 3.32) were similar to 
those obtained as a result of drug-induced OS in HepG2 cells (Figure 
3.12) with no characteristic alterations indicative of a specific cholestasis 
hepatotoxicity mechanism. Our results are in agreement with the 
reported ability of these compounds to induce OS and mitochondrial 
impairment both in vitro and in vivo (29, 89, 91, 92). 
Five different species of BAs were found in the liver of medaka: 
trihydroxycholic acid, tauro-trihydroxycholic acid, tauro-dihydroxycholic 
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acid, trihydroxycholestanoic acid and tauro-trihydroxycholestanoic acid. 
These results are in concordance with the data available in the literature 
(360-362). No significant differences were found in the levels of total or 
a particular BA in the liver of medaka treated with cholestatic drugs. 
These results are in agreement with previous studies in medaka and 
zebrafish. Driessen et al compared the changes in gene expression 
induced in zebrafish embryos incubated with hepatotoxicants, including 
three cholestatic drugs (cyclosporine, 17α-ethynylestradiol and 
chlorpromazine) (200). Their results showed alterations in genes and 
pathways that could be related to hepatotoxic responses in general, but 
not specifically to cholestasis (200). Similar results were obtained in a 
study that compared the changes in gene expression in zebrafish 
embryos treated with cyclosporine with those occurring in other models 
(i.e. HepaRG and mouse liver) (357). In a study of α-
naphthylisothiocyanate-induced hepatobiliary toxicity in medaka, a 
similar response at both cellular and systemic levels was obtained in 
comparison with previous studies in rodents, however, no alterations to 
bile transport were found (363). 
The alterations observed are consistent with an OS damage due to 
mitochondrial impairment, although a diminished canalicular efflux may 
play a role. The main alterations in the lipidome include increased levels 
of acylcarnitines, TG and PC (Figure 3.32). With respect to polar 
metabolites, it is worthy to highlight the appearance of OS markers 
related to GSH metabolism: increase in the levels of GSSG, ophthalmic 
acid, glutamate and glutamine and decreased levels of taurine. 
Interestingly, the increases in GSSG and ophthalmic acid are not 
accompanied by a decrease in the levels of GSH or GSH/GSSG ratio 
(Figure 3.32). This could be due to a diminished canalicular efflux of 
GSH by an inhibition of the corresponding transporters by the cholestatic 
drugs. Accordingly, PC, that are usually released into bile, showed 
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increased levels and it cannot be discarded a contribution of decreased 
canalicular efflux to explain it. 
As previously discussed, mitochondrial impairment may result in 
decreased FA oxidation thus leading to the over accumulation of FA 
oxidation intermediates as acylcarnitines, and ultimately of TG as a 
protective response to prevent free FA accumulation (34, 259) (Figure 
3.16). The mitochondrial impairment exacerbates the production of ROS 
that may be accompanied with other mechanisms of ROS production 
and/or GSH depletion, thus leading to OS. As previously discussed, 
increased levels of some OS markers such as GSSG, glutamate, glutamine 
and ophthalmic acid (Figure 3.32) can be related to GSH oxidation, 
synthesis and recycling (Figures 3.13, 3.14). The observed decrease in 
taurine levels could also be due to an oxidative insult. Previous studies 
have reported decreased levels of taurine associated to oxidative damage 
and GSH depletion (138, 140), suggesting that under that circumstances 
cysteine is shunted to GSH production at the expense of taurine 
biosynthesis (140).  
 
Hepatic metabolic alterations induced by phospholipidogenic drugs 
 
Amiodarone, tilorone and tamoxifen were studied as model 
phospholipidosis inducers (Table 2.3). 117 metabolites showed 
significant changes in the liver of medaka fish treated with these drugs. 
The alterations were mainly focused in PL, glutamate and GSH 
metabolism (Figure 3.33).  
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Figure 3.33. Boxplots showing the most important changes associated to 
phospholipidosis treatment in the liver of medaka analyzed following a generic 
untargeted analysis strategy. Values are expressed as relative intensity. Boxes 
denote interquartile ranges, lines denote medians, and whiskers denote the 10th 
and 90th percentiles. 
 
 
These metabolic changes showed a great concordance with those 
obtained in HepG2 cells (Figure 3.18). As observed in HepG2, only a 
discrete (non-significant) increase in the levels of PL was obtained. This 
feature was accompanied by a decrease in the levels of LysoPL thus 
resulting in a lower LysoPL/PL ratio suggestive of a reduction in PL 
degradation (292, 293). An increase in the GSSG levels and a decrease in 
the GSH levels and GSH/GSSG ratio were also observed, indicative of OS 
damage, as previously found for HepG2 cells (Figures 3.18, 3.33). 
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Hepatic metabolomic markers of drug-induced steatosis 
 
Three compounds classified as steatotic were included in the study 
(Table 2.3): doxycicline, tetracycline and valproic acid. A total of 295 
metabolites were altered as a consequence of drug-induced steatosis, 
thus impacting several metabolic pathways: metabolism of unsaturated 
FA, PL metabolism, FA and TG metabolism, pentose phosphate pathway, 
glutamate and GSH metabolism and BA metabolism as revealed by 
pathway enrichment analysis (Figure 3.34). 
 
 
 
Figure 3.34. Boxplots showing the most important changes associated to 
steatosis treatment in the liver of medaka analyzed following a generic 
untargeted analysis strategy. Values are expressed as relative intensity. Boxes 
denote interquartile ranges, lines denote medians, and whiskers denote the 10th 
and 90th percentiles. 
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The main changes in the lipidome included increased levels of 
acylcarnitines, FA, DG, TG, SM, PL, LysoPL and 
taurotrihydroxycholestanoic acid (the main BA in the liver of medaka 
fish). With respect to polar metabolites, the most remarkable alteration 
was the decrease in the GSH/GSSG ratio (Figure 3.34). These changes 
were more similar to those observed in lipid-loaded HepG2 cells (Figures 
3.20, 3.21) than those obtained without an external source of free FA in 
the medium (Figure 3.15). 
In mammals, short-chain FA (SCFA) and medium-chain FA (MCFA) 
absorbed by intestinal epithelial cells are released directly into the portal 
vein without esterification, while most LCFA form TG and are released 
into lymph ducts as chylomicron particles (4, 346). In fish, a two-step 
absorption model for dietary lipids has been proposed. Immediately after 
feeding, a fraction of dietary FA are found in the plasma, either as 
unbound FA (SCFA) or bound to carrier proteins (LCFA) and only later 
LCFA are resynthesized as TG and released as chylomicron particles into 
the blood thus performing an inter-organ transport of lipids that 
resembles the one occurring in mammals (346, 348, 352). The way the 
free FA are delivered into the liver from the intestine is similar to the 
phenomena that takes place in steatotic patients in which an exacerbated 
flux of free FA from adipose tissue to liver occurs (31, 259, 276, 364, 
365). This may be the cause why NAFLD and NASH are developed more 
easily in medaka than in other animal models of high fat diet-induced 
steatosis (346, 366) and the reason of the fast development of NAFLD in 
our experimental conditions compared to HepG2. As observed for 
HepG2, the impairment in FA β-oxidation induced by the steatotic drugs 
resulted in the alteration of the levels of lipidic species not only directly 
related to TG and FA metabolism, but also to PL and SM metabolism 
(Figures 3.20, 3.21, 3.34). Moreover an induction of OS, represented by 
the decrease in the GSH/GSSG ratio, was also observed (Figure 3.34), in 
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concordance with previous results and the known hepatotoxic 
mechanism of action of the employed molecules. 
Finally, an increase in the intrahepatic levels of 
taurotrihydroxycholestanoic acid was observed after treatment with 
steatogenic drugs (Figure 3.34). This finding, not observed in the HepG2 
model, has been reported in the literature as a consequence of diet or 
drug-induced steatosis either in humans or in animal models (140, 166). 
 
Development of predictive/classificatory models of hepatotoxicity based 
on medaka metabolite profiling 
 
After the identification of generic and mechanism-specific markers of 
hepatotoxicity, the next step was the development of 
predictive/classificatory models of hepatotoxicity.  
As an initial approximation, a predictive model centered only in the 
discrimination of hepatotoxic compounds was developed. Using a CV 
strategy the optimum number of LV to develop the PLS-DA model was set 
to two based on the values of R
2
, Q
2
 and misclassification error (Figure 
3.35.A). Once the number of LVs was set, the number of variables to be 
included in the final model was selected based on model performance 
(Figure 3.35.B). The lowest value of misclassification error and the 
highest value of AUROC were obtained with the model developed using 
only the top ranked 6 variables (i.e. PE(40:0), DG(34:3), DG(38:7), 
PC(42:2), TG(46:4), PC(40:1) 
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Figure 3.35. A) Values of R
2
 (blue), Q
2
 (red) and misclassification error (green) as 
a function of the number of LVs employed to build the PLS-DA model using the 
data obtained with the generic untargeted metabolomic analysis of the liver of 
medaka treated with either non-toxic or hepatotoxic compounds. B) Values 
obtained for the AUROC (green) and misclassification error (red) calculated using 
CV vs. the number of retained variables for the top-20 ranked variables using 
PLS-DA models with two LVs. The data is expressed as mean ± standard 
deviation. 
 
 
The PLS-DA scores and loadings plot corresponding to the model 
developed using 2LV and 6 retained variables are shown in Figure 3.36. 
Some overlap can be observed between 95 % confidence interval 
Hotelling's ellipse drawn for each of the classes (Figure 3.36.A). The 
poor separation between the classes was also confirmed by the bad 
results obtained for performance parameters of the model: R
2
 = 0.61, Q
2
 
= 0.60, misclassification error = 0.05 ± 0.03 and AUROC = 0.81 ± 0.14. 
Although the permutation testing rendered good results (Figure 3.36.C-
D), the information provided by the parameters evaluated by CV and the 
PLS-DA scores plot pointed the limited utility of the developed model. 
The results provided by the PCA scores plot suggested that the pattern 
generated by hepatotoxins acting through a specific mechanism can be 
distinguished independently from the control samples (Figure 3.30). 
Therefore, it can be concluded that no useful common pattern can be 
deducted with classificatory or predictive perspectives and each 
mechanism of toxicity has to be evaluated as an independent entity. 
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Figure 3.36. Summary of the results provided by the PLS-DA model built using 2 
LVs and the top-ranked 6 variables based on the data obtained with the generic 
untargeted metabolomic analysis of livers from medaka treated with either non-
toxic or hepatotoxic compounds. A) Scores plot. The lines denote 95 % 
confidence interval Hotelling's ellipse for each class. Green: non-toxic; Grey: 
hepatotoxic. B) Loadings plot. Green: non-toxic; Grey: hepatotoxic; Blue: 
metabolites. C) Permutation test for the misclassification error. D) Permutation 
test for the AUROC. In both cases the histograms represent the values obtained 
using the permuted classes. The actual value obtained with the real classes is 
indicated by the red dot and the value written above it.  
 
 
Following the data analysis workflow, the next step was to develop a 
model focused on the discrimination between specific mechanisms of 
toxicity (i.e. non-toxic, cholestasis/OS, phospholipidosis and steatosis). 
Using a CV strategy the optimum number of LV to develop the PLS-DA 
model was set to three (Figure 3.37.A). The maximum value of AUROC 
and minimum value of misclassification error were obtained for the 
model built using the top 23 ranked variables (i.e. 
glycerophosphoethanolamine, PE(36:0), PE(44:5), PE(44:6), PC(44:12), 
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LysoPA(18:2), LysoPC(20:1), LysoPE(20:4), PE(42:4), PE(44:8), cytidine, 
LysoPC(20:0), ophthalmic acid, carnitine(18:1), FA(20:2), PE(40:0), GSH, 
DG(38:7), carnitine(18:2), DG(40:8), methylhistidine, carnitine(4:0) and 
FA(20:4)) (Figure 3.37.B). 
 
 
 
Figure 3.37. A) Values of R
2
 (blue), Q
2
 (red) and misclassification error (green) as 
a function of the number of LVs employed to build the PLS-DA model using the 
data obtained with the generic untargeted metabolomic analysis of liver from 
medaka treated with either non-toxic or hepatotoxic compounds acting through 
different mechanism of hepatotoxicity (i.e. cholestasis, phospholidosis and 
steatosis). B)Values obtained for the AUROC (green) and misclassification error 
(red) calculated using CV vs. the number of retained variables for the top-30 
ranked variables using PLS-DA models with three LVs using. The data is 
expressed as mean ± standard deviation. 
 
 
The final PLS-DA model provided the following figures: R
2
 = 0.69, Q
2
 = 
0.65, misclassification error = 0.05 ± 0.04, AUROC = 0.92 ± 0.07. A 
good separation between the different groups is observed in the PLS-DA 
scores plot (Figure 3.38.A), with low overlap between the 95 % 
confidence interval Hotelling's ellipses drawn for each class. The model 
was further validated using a permutation test strategy with excellent 
results, as no overlap was obtained for values obtained using the 
permuted classes and the real values obtained with the actual PLS-DA for 
the misclassification error (Figure 3.38.B) and the AUROC (Figure 
3.38.C).  
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Figure 3.38. Summary of the results provided by the PLS-DA model built using 3 
LVs and the top-23 ranked variables based on the data obtained with the generic 
untargeted metabolomic analysis of livers of medaka treated with either non-
toxic or hepatotoxic compounds acting through different mechanism of 
hepatotoxicity. A) Scores plot. The lines denote 95 % confidence interval 
Hotelling's ellipse for each class. Green: non-toxic; blue: cholestasis; red: 
phospholipidosis; purple; steatosis. B) Permutation test for the misclassification 
error. C) Permutation test for the multiclass AUROC. In both cases the 
histograms represent the values obtained using the permuted classes. The actual 
value obtained with the real classes is indicated by the red dot.  
 
 
In summary, although the application of our experimental and 
analytical design to medaka was of limited utility in predicting 
hepatotoxicity in a generic sense, the good results provided by the 
model computing the different mechanisms of hepatotoxicity 
corroborate the trend obtained by the non-supervised analysis (Figure 
3.30). In a general sense, the results provided by the experiments 
performed in medaka were comparable both in terms of hepatotoxicity 
markers and predictive capabilities with those obtained in vitro using 
HepG2 cells, and represent an additional evidence to highlight the 
usefulness of medaka as animal model for the study of hepatotoxicity. 
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3.4.2 Differential metabolomic analysis of rats exposed to 
tetracycline and paracetamol 
 
As a final approximation to predict human hepatotoxicity, our 
metabolomic strategy was applied to the analysis of metabolomic 
changes in serum and liver tissue of rats exposed to hepatotoxic drugs. 
The main drawback of this experimental model is its limitation in the 
number of animals per study due to ethical, economical, space and 
handling restrictions. Therefore only two model hepatotoxins 
(tetracycline, representative of steatosis, and paracetamol, representative 
of OS) were selected as proof of principle of our analytical strategy. First, 
untargeted metabolomic analyses were performed using both liver and 
serum samples and finally targeted analyses of serum hepatotoxicity 
markers were performed. 
The clinical chemistry data obtained in rats treated with paracetamol 
and tetracycline are shown in Table 3.4. Both drugs induced the increase 
of total bilirubin in serum, indicative of hepatobiliary damage. On the 
other hand paracetamol, but not tetracycline provoked an increase in 
alanine aminotransferase (ALT).  
 
Table 3.4. Clinical laboratory analysis of serum samples from rats treated with 
hepatotoxic compounds. 
 
Parameter Control Paracetamol Tetracycline 
Glucose (mg/dL) 110 ± 40 n.d. 180 ± 60* 
TG (mg/dL) 65 ± 19 n.d. 40 ± 30 
Total cholesterol (mg/dL) 82 ± 11 n.d. 90 ± 40 
HDL cholesterol (mg/dL) 45 ± 9 n.d. 58 ± 18 
Total bilirrubin (mg/dL) 0.15 ± 0.03 0.24 ± 0.03 *** 0.4 ± 0.2 ** 
ALT (U/L) 53 ± 12 76 ± 11 ** 50 ± 20 
AST (U/L) 200 ± 80 260 ± 70 190 ± 50 
Data expressed as mean ± standard deviation. Comparisons performed using a 
Student t test. *: p value < 0.05; ** p value < 0.01; *** p value < 0.001. ALT: 
alanine aminotransferase; AST: aspartate aminotransferase; HDL: High density 
lipoprotein.  
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Untargeted metabolomic analysis 
 
First of all, the serum and liver samples from rats administered either 
vehicle, paracetamol or tetracycline were analyzed using an untargeted 
metabolomic strategy. The corresponding PCA scores plots are shown in 
Figure 3.39. In all the cases the non-supervised analysis was able to 
distinguish between samples from rats administered vehicle or 
hepatotoxic compounds. Therefore, following our pre-established data 
analysis workflow, the metabolomic data were explored in order to look 
for the alterations induced in the metabolome by each of the treatments. 
 
Figure 3.39. Scores plots corresponding to the PCA performed using the data 
obtained from the metabolomic analysis of liver (upper panels) and serum (lower 
panels) of rats dosed either vehicle (i.e. control, green) or model hepatotoxins 
(i.e. paracetamol, left panels, orange, and tetracycline, right panels, purple). The 
lines denote 95 % confidence interval Hotelling's ellipse drawn for each class. 
PCA models were developed using two principal components. 
Results & Discussion 
218 
Metabolomic changes associated to the treatment with tetracycline 
 
As previously observed using HepG2 cells and medaka, steatosis was 
the main mechanism involved in tetracycline hepatotoxicity. Although 
tetracycline treatment induced no or a very subtle hepatic damage (Table 
3.4), the PCA analysis showed a clear separation between tetracycline 
and vehicle-treated rats (Figure 3.39).  
As expected for a steatogenic drug, and following the tendency 
observed for the two experimental models used previously, the 
treatment with tetracycline induced an increase in the levels of hepatic 
TG and a decrease of FAs (Figure 3.40). These changes suggest an 
increased flux of FA to TG synthesis (Figure 3.40). However, the increase 
in intrahepatic levels of TG was not accompanied by TG increase in 
serum (Table 3.4), what can be related to a reduction in lipid export by 
the inhibition of microsomal TG transfer protein activity. Both 
mechanisms of steatosis have been previously associated to tetracycline 
(32, 88). Although the total amount of FA was diminished in the liver, 
increased levels of hydroxylated FA (i.e. FA(14:0)(OH) and FA(16:0)(OH)) 
were observed. Tetracycline is known to inhibit β-oxidation of FA (32, 
88), thus leading to extramitochondrial FA oxidation resulting in higher 
rates of ROS production and lipid peroxidation. Increased levels of 3-
hydroxyadipic acid (3-hydroxyhexanedioic acid) were also observed 
(Figure 3.42). This metabolite is derived from the ω-oxidation of 3-
hydroxy FA and the subsequent β-oxidation of longer chain 3-hydroxy 
dicarboxylic acids (367), which is consistent with the increased levels of 
FA(14:0)(OH) and FA(16:0)(OH) detected in the liver of rats administered 
tetracycline. Moreover, increased urinary levels of 3-hydroxyadipic acid 
and other 3-hydroxy-dicarboxilic acids have been also previously 
reported as a result of inhibition of FA oxidation (367).  
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Figure 3.40. Boxplots showing the most important changes associated to 
tetracycline treatment in the liver of rats. Analysis preformed following a generic 
untargeted metabolomics analysis strategy. Values are expressed as relative 
intensity. Boxes denote interquartile ranges, lines denote medians, and whiskers 
denote the 10th and 90th percentiles. 
 
 
Several changes in the levels of intrahepatic BA were also detected 
(Figure 3.40). Tetracycline-treatment induced an increase in taurine-
conjugated BAs (the main class of BAs in rat liver (207)), accompanied by 
increased levels of taurine, and a decrease in the levels of glycine-
conjugated BAs (a minor class in rat liver (207)). Interestingly, altered 
levels of BA were also detected in the serum of rats treated with 
tetracycline (Figure 3.41), with decreased levels of non-conjugated and 
glycine conjugated BAs and increased levels of taurine-conjugated BAs. 
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Previous reports have pointed out that rats administered tetracycline 
showed alterations in the BA pool in different samples (i.e. liver, serum 
and urine) (137, 140, 368).  
Increased levels of total acylcarnitines were also found (Figure 3.41). 
Similar results have been reported in the serum of rats treated with 
tetracycline (140) and in the serum of patients with steatosis (369). 
These data are coherent with the previously described inhibition of β-
oxidation of FA by tetracycline (32, 88). 
 
 
 
Figure 3.41. Boxplots showing the most important changes associated to 
tetracycline treatment in the serum of rats. Analysis preformed following a 
generic untargeted metabolomics analysis strategy. Values are expressed as 
relative intensity. Boxes denote interquartile ranges, lines denote medians, and 
whiskers denote the 10th and 90th percentiles. 
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Metabolomic changes associated to the treatment with paracetamol 
 
Paracetamol is normally detoxified by sulfation or glucuronidation 
(370). When administered at high doses, it is metabolized by different 
CYPs (i.e. CYP1A2, CYP2A6, CYP2E1 and CYP3A4) to generate the 
reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI) (371), 
which is further inactivated by conjugation with GSH before excretion. In 
absence of sufficient GSH, the reactive NAPQI can cause toxic and 
covalent protein modifications that lead to cell death and tissue injury 
(372). Proteomic and transcriptomic studies have shown that 
paracetamol can cause numerous changes in pathways related to cellular 
stress response, mitochondrial function, and metabolism, as well as in 
cell cycle, structural, signaling, and apoptotic proteins (373, 374). 
Paracetamol administration induced several changes in the hepatic 
metabolome of rats. The most altered pathways were related to FA 
oxidation, PL metabolism, OS and BA metabolism. Paracetamol treatment 
resulted in the alteration of several species of PL and intermediates in PL 
biosynthesis and degradation, such as choline, phosphocholine and 
glycerophosphoethanolamine (Figure 3.42), what can be related to 
NAPQI-mediated damage to intracellular membranes. More interesting is 
the detection of alterations that can be related to the β-oxidation of FA 
such a decrease in the levels of FA and an increase in the levels of 
acylcarnitines (Figure 3.42). These results are in concordance with a 
previous metabolomic study in the serum of paracetamol-treated 
Cyp2e1-null mice which revealed that the CYP2E1-mediated metabolic 
activation and OS following paracetamol treatment can cause irreversible 
inhibition of FA oxidation, potentially through suppression of PPARα-
regulated pathways (220). 
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Figure 3.42. Boxplots showing the most important changes associated to 
paracetamol treatment in the liver of rats. Analysis preformed following a generic 
untargeted metabolomics analysis strategy. Values are expressed as relative 
intensity. Boxes denote interquartile ranges, lines denote medians, and whiskers 
denote the 10th and 90th percentiles. 
 
 
Directly related to the oxidative insult and the GSH consumption 
provoked by NAPQI was the appearance of alterations of metabolites 
related to GSH metabolism and -glutamyl cycle (Figures 3.13, 3.14) such 
as ophthalmic acid and -glutamyl-aspartate (Figure 3.42). Besides these 
alterations, no changes in the levels of GSH, GSSG or GSH/GSSG were 
observed. In a previous study the kinetics of GSH and ophthalmic acid 
were analyzed in paracetamol-overdosed mice (138). The appearance of 
ophthalmic acid is an early event related to GSH decrease and, whereas 
the intrahepatic levels of GSH are rapidly recovered after the 
administration, the levels of ophthalmic acid require longer times to 
recover the pre-dose status (138). Alterations in the intrahepatic levels of 
ɣ-glutamyl-dipeptides and related compounds have been previously 
described as a result of paracetamol overdose in rat (140). Finally, it is 
interesting to point out that alterations in the levels of BAs were also 
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observed (Figure 3.42). Alterations in the hepatic BA pool as a result of 
paracetamol treatment have been previously described (140). 
The main alterations in the serum metabolome of rats administered 
paracetamol were related to BAs and -glutamyl-dipeptides and related 
compounds (see next section for detailed information). 
 
3.4.3 Targeted analysis of non-invasive serum markers of 
hepatotoxicity in rats 
 
As shown in the previous section, the untargeted metabolomic analysis 
of liver and serum samples from rats treated with either tetracycline or 
paracetamol revealed BAs and -glutamyl-dipeptides and related 
compounds as the most promising biomarker candidates. Yamazaki et al 
(140) analyzed the serum and hepatic metabolome of rats treated with 
different model hepatotoxins, including paracetamol and tetracycline, 
and pointed out that perturbation of BA homeostasis and OS are early 
events of DILI in rats. Moreover, a recent study concluded that drugs that 
impaired both mitochondrial energetics and BSEP functional activity 
produced more severe manifestations of DILI than drugs that only have a 
single liability factor (375).  
Based on these evidences we decided to develop targeted analysis 
methods for the evaluation of the serum levels of BAs and -glutamyl-
dipeptides and related compounds. 
 
Targeted analysis of BA 
 
BAs are major components of bile formed from cholesterol through 
various enzymatic reactions in hepatocytes. Before being excreted into 
bile canaliculi, primary BAs synthesized in the liver (i.e., CA and CDCA in 
humans plus αMCA and βMCA in rodents) (41, 42, 376-380) are mainly 
conjugated with taurine or glycine amino acids through the terminal 
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side-chain carboxylic group present in the BA structure (42). BAs are 
transported across the canalicular membrane of the hepatocytes into the 
bile and stored in the gallbladder before being released into the 
intestinal tract (381). In the intestine, primary BAs are deconjugated and 
converted into secondary BAs by microbiota through dehydroxylation 
and epimerization reactions (39, 42, 377, 382). Then, most BAs are 
reabsorbed back to the liver, conjugated by hepatocytes, and re-excreted 
into bile to complete enterohepatic circulation (41, 42, 381) (Figure 
3.43).  
In the past, BAs were considered to be mere detergents required for 
the solubilization and absorption of dietary fats. However, BAs are now 
recognized as regulatory molecules capable of activating specific 
receptors. BAs are physiological ligands for the farnesoid X receptor 
(FXR), an intracellular BA sensor that controls the expression of the 
genes involved in BA synthesis, metabolism, and transport in order to 
minimize the deleterious effects of their accumulation (39, 42). BAs are 
also able to bind other nuclear receptors (e.g. PXR or VDR) and the G-
protein coupled receptor TGR5 and can activate several cell signaling 
pathways (i.e., JNK, ERK, or AKT) (39, 40, 43, 44). By activating these 
receptors and signaling cascades, BAs regulate not only their own 
homeostasis but also FA, lipoprotein, glucose, and energy metabolism 
(39-41). The primary signaling function of BAs seems to be the 
regulation of metabolic flux in the liver and the gastrointestinal tract 
during the feed/fast cycle; however, they are also involved in the control 
of cell proliferation and inflammatory processes (39, 41). Alterations in 
the levels of BAs have been described in a series of pathological 
situations including hepatobiliary or drug-induced liver injury (140, 166, 
183, 368, 383). 
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Figure 3.43. Summary of BA metabolism and transport processes. Primary BAs 
are synthesized in the hepatocytes from cholesterol through various enzymatic 
reactions. BAs are mainly conjugated with taurine and glycine before being 
excreted into the bile canaliculi. In the intestine, primary BAs are deconjugated 
and converted into secondary BAs by microbiota. Most BAs are reabsorbed back 
to the liver to complete enterohepatic circulation. Although BAs recycling is a 
very efficient process, a little amount is excreted in the faeces. Moreover, a low 
percentage of reabsorbed BAs escape hepatic uptake and enter into the systemic 
circulation. Under cholestatic conditions urinary excretion might occur. At the 
basolateral membrane of hepatocytes, BA efflux is an important spillover route 
for BA and bilirubin (bili) that has accumulated during BA overload under 
cholestatic conditions.  
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BAs targeted analysis was performed using a validated LC-MS/MS 
method that allowed the simultaneous quantification of 31BAs including 
non-conjugated, taurine-conjugated and glycine-conjugated major and 
minor species (207, 384). The results are shown in Table 3.5 and Figure 
3.44. 
 
Table 3.5. BA concentration (expressed as nM) in the serum of rats as a result of 
the indicated treatments. 
 
Bile Acid Control Paracetamol Tetracycline 
CDCA 2100 ± 1500 2400 ± 1600 50 ± 50 ** 
DCA 900 ± 1000 2100 ± 900 * 1.6 ± 1.5 * 
UDCA 180 ± 120 220 ± 120 7 ± 5 ** 
HDCA 2000 ± 2000 1100 ± 500 35 ± 7 * 
CA 9000 ± 6000 28000 ± 7000 *** 160 ± 150 ** 
ωMCA 3000 ± 4000 15000 ± 9000 ** 17 ± 17 * 
αMCA 3000 ± 2000 8000 ± 5000 * 16 ± 18 * 
βMCA 1800 ± 1800 9000 ± 4000 *** 30 ± 30 * 
HCA 400 ± 500 1800 ± 1500 ** n.d. 
GCDCA 70 ± 70 90 ± 70 n.q. 
GDCA 200 ± 200 500 ± 600 n.q. 
GHDCA 100 ± 100 40 ± 30 n.d. 
GCA 700 ± 700 2800 ± 1700 ** 36 ± 19 * 
GHCA 10 ± 10 20 ± 20 n.d. 
TCDCA 45 ± 17 60 ± 40 140 ± 70 *** 
TDCA 60 ± 60 160 ± 60 ** 8 ± 4 * 
TUDCA 5 ± 2 10 ± 4 5 ± 3 
THDCA 170 ± 140 50 ± 30 3 ± 3 ** 
TCA 280 ± 130 2100 ± 1000 *** 1300 ± 600 *** 
TωMCA 40 ± 30 80 ± 40 * 16 ± 3 
TαMCA 190 ± 130 380 ± 130 * 330 ± 180 * 
TβMCA 80 ± 40 200 ± 200 * 170 ± 90 ** 
Non-conjugated 23000 ± 15000 70000 ± 30000 *** 300 ± 300 ** 
Glycine-conjugated 1100 ± 900 3000 ± 2000 ** 40 ± 20 ** 
Taurine-conjugated 900 ± 300 3100 ± 1200 *** 2000 ± 900 ** 
Total 25000 ± 16000 70000 ± 30000 *** 2400 ± 800 ** 
Data expressed as mean ± standard deviation. Comparisons between control and 
each treatment were performed using a Student t test, p values were adjusted for 
multiple comparisons using false discovery rate method. *: p value < 0.05; ** p 
value < 0.01; ** p value < 0.001. n.d. not detected; n.q. not quantified 
 
Results & Discussion 
227 
 
 
Figure 3.44. BA composition in the serum of rats as a result of the indicated 
treatments. Results expressed as percentage of the indicated group of BA (non-
conjugated, glycine-conjugated and taurine-conjugated) with respect the total 
pool of BA.  
 
 
With respect to tetracycline, a generic reduction in the levels of all the 
individual species was observed except for those taurine-conjugated 
species of primary BAs (i.e. TCA, TCDCA, TαMCA and TβMCA). Similar 
results have been reported by Yamazaki et al (140). Under normal 
circumstances the serum BA pool is dominated by non-conjugated BA 
(Table 3.5, Figure 3.44) (207). The changes induced by tetracycline 
result in a decrease of both non-conjugated and glycine-conjugated BAs, 
what, besides the increase in taurine-conjugated BAs, leads to a decrease 
in the total amount of BAs in the serum. Moreover, Figure 3.44 shows 
how the circulating BA pool of tetracycline-dosed rats is dominated by 
taurine-conjugated BAs. Tetracycline is a broad-spectrum antibiotic which 
can induce severe alterations in the microbiota, which in the end may be 
responsible of the changes observed in the BA pool (Figure 3.43). 
Therefore rather than a specific pattern of hepatic damage, changes in 
the BA pool might be the consequence of the damages in the 
gastrointestinal microbiota. Furthermore, these alterations in the BA pool 
can have severe consequences in the hepatic FA, lipoprotein, glucose 
and energy metabolism (39-42). 
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With respect to paracetamol, the induced changes in the serum levels 
of BAs were more quantitative than qualitative. While the proportion 
between non-conjugated, taurine-conjugated and glycine-conjugated BAs 
was maintained (Figure 3.44), the total amount of each group species 
was increased around 3-fold with contribution of both primary and 
secondary BAs (Table 3.5). 
These results, in conjunction with the extensive available literature of 
BAs alterations in hepatobiliary diseases and DILI (137, 140, 166, 183, 
368), reinforce the usefulness of BA profiling for the discovery of 
biomarkers of disease and toxicity (207, 384). 
 
Targeted analysis of -glutamyl dipeptides and related compounds 
 
-glutamyl dipeptides and ophthalmic acid have been previously 
described as markers of OS both as a result of different hepatobiliary 
diseases (246, 369) and as a result of DILI (138, 140). -glutamyl 
dipeptides can be synthesized in the liver via two different mechanisms 
(Figures 3.13, 3.14): i) via the ligation of glutamate with various amino 
acids and amines by GCS (246); ii) via the action of GGT over GSH. In 
both cases their appearance can be related to a (temporary or 
permanent) decrease in the intrahepatic levels of GSH due to an oxidative 
insult. Given the utility of -glutamyl dipeptides and related compounds 
(i.e. ophthalmic acid, GSH, GSSG, cysteinyl-glycine,...) as OS markers, a 
LC-MS/MS targeted analytical method was developed (Section 2.14). 
The targeted analysis of serum samples revealed that, as expected, 
several compounds were altered in paracetamol overdosed rats, while no 
significant alterations were produced as a result of the administration of 
tetracycline (Table 3.6).  
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Table 3.6. -Glutamyl dipeptides and related compounds concentration 
(expressed as nM) in the serum of rats as a result of the indicated treatments. 
 
Compound Control Paracetamol Tetracycline 
Pyroglutamate 8400 ± 1900 10600 ± 400 5700 ± 800 
Glutamine 360000 ± 60000 400000 ± 30000 330000 ± 70000 
Glutamate 123000 ± 16000 117000 ± 5000 110000 ± 10000 
-Glutamyl-Glycine 12000 ± 4000 13000 ± 1000 9000 ± 3000 
-Glutamyl-Alanine 3900 ± 1400 6500 ± 1700 * 4400 ± 800 
-Glutamyl- Serine 8000 ± 2000 13300 ± 1900 ** 7000 ± 2000 
-Glutamyl-Valine 1000 ± 300 1400 ± 300 900 ± 400 
-Glutamyl-Threonine 7100 ± 800 12000 ± 2000 *** 6000 ± 2000 
-Glutamyl-Taurine 1600 ± 400 1700 ± 300 1400 ± 100 
-Glutamyl-Leucine 2400 ± 700 3100 ± 400 1900 ± 500 
-Glutamyl-Isoleucine 290 ± 140 380 ± 140 180 ± 120 
-Glutamyl-Asparagine 2300 ± 700 3300 ± 300 2400 ± 600 
-Glutamyl-Glutamine 48000 ± 14000 55000 ± 19000 42000 ± 13000 
-Glutamyl-Lysine 11000 ± 5000 14000 ± 5000 10000 ± 2000 
-Glutamyl-Glutamate 1500 ± 500 3000 ± 500 ** 1170 ± 190 
-Glutamyl-Metthionine 1300 ± 400 1900 ± 1100 1280 ± 170 
-Glutamyl-Histidine 1700 ± 600 2700 ± 500 * 1900 ± 500 
Ophthalmate 1200 ± 600 10000 ± 4000 *** 1200 ± 300 
-Glutamyl-Phenylalanine 900 ± 300 1800 ± 300 ** 1200 ± 400 
-Glutamyl-Arginine 5900 ± 1400 10000 ± 2000 ** 4500 ± 1300 
-Glutamyl-Citrulline 4100 ± 1500 5000 ± 2000 1400 ± 400 * 
-Glutamyl-Tyrosine 2000 ± 400 3400 ± 700 ** 1500 ± 400 
-Glutamyl-Triptophan 270 ± 70 530 ± 150 ** 270 ± 50 
-Glutamyl-Cysteine 900 ± 400 1500 ± 600 700 ± 300 
GSH 2700 ± 1600 6000 ± 6000 2800 ± 1400 
GSSG 8000 ± 2000 16100 ± 1700 *** 8800 ± 1900 
Data expressed as mean ± standard deviation. Comparisons between control and 
each treatment were performed using a Student t test, p values were adjusted for 
multiple comparisons using false discovery rate method. *: p value < 0.05; ** p 
value < 0.01; ** p value < 0.001. 
 
 
We have previously observed alterations in the levels of ophthalmic 
acid in HepG2 cells treated with tetracycline (Figure 3.26), thus 
indicating that OS was a mechanism involved in the hepatotoxic effect. In 
contrast, no alterations in the levels of OS markers were detected in the 
serum of tetracycline-dosed rats. Similar results have been previously 
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reported by Yamazaki et al (140). Tetracycline can induce OS damage as 
a result of the mitochondrial disturbances induced by the inhibition of β-
oxidation of FA and their extramitochondrial catabolism (32, 88, 276). 
HepG2 cells are less efficient in preventing oxidative damage than 
hepatocytes within the physiological environment provided by the liver 
(5), which may explain the higher oxidative damage in HepG2 cells 
compared to the in the in vivo model. Moreover, OS markers (a decrease 
in the GSH/GSSG ratio) were also detected in the liver of medaka 
administered steatogenic drugs (Figure 3.40). As previously discussed, 
lipid metabolism in medaka favors the development of the drug-induced 
steatosis insult to an extent comparable to that observed in NASH, a 
clinical situation in which OS play an essential role (31, 246, 276, 369). 
Several metabolites related to GSH metabolism were altered in the 
serum of rats overdosed paracetamol (Table 3.6). These finding are in 
agreement with GSH depletion induced by NAPQI which results in 
increased GSH recycling via the -glutamyl cycle and GSH synthesis via 
the consecutive action of GCS and GS. No significant alterations in the 
levels of GSH were observed. These results are in concordance with a 
previously published study showing a rapid recovery of GSH levels after 
the oxidative insult (138). Upon OS, GSH/GSSG pair shift toward the 
oxidized state and then GSSG may either recycle to GSH or exit from the 
cells to prevent its intracellular accumulation (385). This could explain 
the high GSSG levels detected in the serum of rats overdosed 
paracetamol (Table 3.6). Overall, the increased levels of γ-glutamyl 
dipeptides were indicative of an OS state; however, the identification of 
specific patterns of altered γ-glutamyl and its potential utility to identify 
the mechanisms responsible of OS remain to be investigated. 
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4.1. Conclusions 
 
The work presented in this thesis can be divided into two different 
stages. First, our efforts were devoted to the development of the suitable 
protocols to apply LC-MS-based metabolomics to mammalian cells in 
culture. And in the second stage the developed protocols were applied to 
the metabolic profiling of different in vitro and in vivo models. Based on 
the work described in the present thesis, the following conclusions can 
be drawn: 
 
1. The use of IS and QC samples in conjunction with a carefully 
designed sample analysis define a quality assurance framework that 
allows to monitor the performance of the analytical platform before, 
during and after sample analysis. 
 
2. The combined used of uni- and multivariate data analyses represent 
a straightforward strategy for the identification of metabolomic 
alterations and the development of predictive/classificatory models. 
 
3. The use of bespoke metabolome extraction and analysis protocols 
based on the chemical properties of each metabolite class allows to 
expand the endometabolome coverage of HepG2 cells. 
 
4. The application of metabolomics to the study of DILI using HepG2 
represents a suitable tool to detect pre-lethal alterations associated 
to hepatotoxicity and thus it may be implemented as a sensitive 
tool in pre-clinical testing. 
 
4.1 Metabolomics revealed generic and mechanism-specific 
sensitive pre-lethal markers of hepatotoxicity in HepG2 cells 
that were coherent with the known in vivo alterations. 
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4.2 Predictive models aimed to distinguish between non-
hepatotoxic and hepatotoxic compounds or between non-
hepatotoxic compounds and those acting through specific 
mechanisms of hepatotoxicity (i.e. oxidative stress, steatosis 
and phospholipidosis) were satisfactorily developed. 
 
5. The combination of a lipid-focused metabolomics analysis in 
conjunction with HepG2 cells pre-loaded with fatty acids constitutes 
a suitable strategy for the fast development of drug-induced 
phospholipidosis and steatosis, the detection of sensitive 
mechanism-specific lipid markers and the development of 
predictive/classificatory models.  
 
6. Oxidative insult was revealed as a common event associated to 
hepatotoxicity and the development of a specific targeted analysis 
method allowed to quantify different markers of oxidative stress in 
HepG2 cells. 
 
7. Metabolomic alterations in medaka (Oryzias latipes) are in 
agreement with those observed in HepG2 cells and suggest this in 
vivo model as a suitable alternative for high throughput 
hepatotoxicity testing. 
 
8. Experiments in rats revealed that BAs and -glutamyl dipeptides are 
common serum markers associated to hepatotoxicity and could be 
good candidates as biomarkers of DILI in pre-clinical and clinical 
testing.  
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4.2. Outlook 
 
The first aim achieved within the framework herein defined was the 
development of a global sample preparation and analysis strategy for the 
determination of HepG2’s endometabolome. While the methodology 
developed here expands the metabolome coverage, it presents some 
limitations that are intrinsic to the employed analytical platform (i.e. LC-
MS). Thus, we are planning to evaluate whether the incorporation of GC-
MS into our analytical workflow could suppose a significant improvement 
in the detection and characterization of any group of metabolites of 
interest. 
The results obtained in the development of this thesis have allowed us 
to identify metabolomic alterations associated to specific mechanisms of 
hepatotoxicity using HepG2 cells as in vitro model. However, HepG2 cells 
present some limitations such as low biotransformation capabilities, low 
expression and activity of transporters relevant to hepatotoxicity and the 
lack of a cell polarity that resembles the in vivo phenotype. Different 
alternatives are available to circumvent these limitations, and among 
them, HepaRG cells are the most promising one. Moreover, we plan to 
evaluate a higher number of model hepatotoxins in order to select a well 
defined set of biomarkers with respect to the development of LC-MS/MS 
targeted quantitative analyses.  
The in vivo experiments in rats, allowed us to identify BAs and -
glutamyl dipeptides and related compounds as promising serum 
biomarkers of hepatotoxicity. Moreover, the development of targeted LC-
MS/MS analyses allowed us their quantification in a highly sensitive and 
specific way. Two different lines of experimentation could arise from 
these observations. On one hand, the increase in the number of model 
hepatotoxins tested in rodent models would allow us to identify patterns 
of BAs and -glutamyl dipeptides associated to hepatotoxicity in general 
or to specific mechanism of hepatotoxicity. On the other hand, the 
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analysis of serum samples from patients who have suffered a DILI event 
would allow us to determine whether those alterations and biomarkers 
identified in rodents are applicable to human hepatotoxicity. 
Resumen en Castellano 
237 
RESUMEN EN CASTELLANO 
 
El hígado es un órgano especialmente susceptible a sufrir toxicidad 
debido a su particular localización anatómica y a su papel en el 
metabolismo y detoxificación de xenobióticos en general y fármacos en 
particular. Múltiples mecanismos están implicados en el daño que un 
fármaco o sus metabolitos pueden producir en los hepatocitos. El modo 
en que los orgánulos, macromoléculas y/o funciones se ven afectadas 
define el patrón del daño hepático. En base a la manifestación clínica 
inicial provocada a raíz del daño hepático, cuatro mecanismos de 
toxicidad diferentes pueden tener lugar: i) Esteatosis, caracterizada por 
la acumulación de lípidos, principalmente triglicéridos, en el interior de 
los hepatocitos; ii) Fosfolipidosis, caracterizada por la excesiva 
acumulación de fosfolípidos en el interior de las células; iii) Colestasis, 
producida a raíz de un disminución en el flujo biliar que conduce a la 
acumulación de sales biliares con los consecuentes daños para el 
hepatocito; y iv) Estrés oxidativo, producido cuando la generación de 
especies oxidantes sobrepasa la capacidad antioxidante de las células. 
El daño hepático causado por fármacos es un problema de gran 
relevancia a nivel sanitario y económico y la hepatotoxicidad es la 
principal causa de finalización de ensayos clínicos y de retirada de 
fármacos tras su comercialización. Uno de los principales problemas 
asociados a la hepatotoxicidad es el fallo a la hora de detectar fármacos 
potencialmente hepatotóxicos durante el proceso de desarrollo de 
nuevos fármacos. Los ensayos pre-clínicos deberían ser capaces de 
detectar posibles hepatotoxinas en etapas tempranas del proceso de 
desarrollo con el fin de minimizar los riesgos sanitarios y las pérdidas 
económicas. Múltiples modelos celulares hepáticos in vitro han sido 
desarrollados para su uso en la investigación toxicológica con el fin de 
conseguir una mayor comprensión de los mecanismos de 
hepatotoxicidad y detectar el potencial de nuevas entidades químicas de 
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producir toxicidad a nivel hepático. Aunque no consiguen reproducir 
fielmente la fisiología de un organismo completo o la complejidad del 
hígado, su bajo coste, alta reproducibilidad y la posibilidad de disponer 
de modelos de origen humano hacen de ellas un buen complemento 
para los tradicionales estudios in vivo y especialmente útiles para la 
predicción de fenómenos tóxicos en etapas tempranas del desarrollo de 
fármacos. 
Los estudios toxicológicos basados en modelos celulares in vitro se 
han llevado a cabo tradicionalmente usando ensayos de citotoxicidad, 
basados en la estimación de la viabilidad celular y/o el estado 
metabólico o funcional de las células previamente expuestas al tóxico en 
estudio. No obstante, la utilidad de este tipo de estudios es limitada ya 
que monitorizan eventos que tienen lugar en etapas avanzadas del daño 
celular, cuando las células se encuentran cercanas a la muerte, y por 
tanto no se puede extraer información mecanística alguna. La aplicación 
de las nuevas tecnologías "ómicas" (transcriptómica, proteómica, 
citómica y metabonómica) permite la determinación simultánea de 
múltiples parámetros en una misma muestra biológica y representa una 
herramienta más sensible y potente para el estudio de eventos 
relacionados con la hepatotoxicidad. Entre ellas la metabonómica se 
dedica al estudio de los productos finales de la "cascada ómica" 
proporcionando de este modo una información que no está accesible a 
través de otras "ómicas", lo que representa una mayor proximidad al 
fenotipo que el estudio de los genes, los transcritos o las proteínas. 
En base a estas evidencias, decidimos evaluar si la metabonómica en 
combinación con modelos celulares in vitro y con modelos animales in 
vivo puede representar una alternativa útil para el estudio de 
mecanismos de hepatotoxicidad y el reconocimiento de patrones 
característicos asociados a estos. Los siguientes objetivos fueron 
definidos dentro del marco de trabajo de la presente tesis: 1) Puesta a 
punto de una estrategia analítica basada en LC-MS para el estudio del 
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metaboloma: desde el procesamiento y análisis de las muestras hasta el 
análisis de los datos y la validación de biomarcadores; 2) Identificación 
de biomarcadores y patrones metabonómicos específicos asociados a 
mecanismos de hepatotoxicidad usando HepG2 como modelo celular in 
vitro; 3) Comparación de los resultados obtenidos in vitro con modelos 
animales in vivo. 
En primer lugar definimos un marco de trabajo adecuado que, gracias 
a la combinación de un cuidadoso diseño del análisis de las muestras, en 
conjunción con la incorporación de diferentes patrones internos y 
controles de calidad, nos permitió llevar a cabo los análisis 
metabonómicos en un ambiente que aseguraba la calidad de los 
resultados obtenidos.  
A continuación optimizamos una estrategia de procesamiento y 
análisis de las muestras de interés que nos permitió la extracción y 
análisis diferenciado de un gran rango de metabolitos, desde altamente 
polares hasta muy apolares, lo que nos permitió maximizar la cobertura 
del metaboloma. Con respecto a la extracción del metaboloma esto se 
consiguió gracias a una extracción en múltiples pasos en la que la 
combinación de solventes con diferentes características hizo posible la 
extracción diferencial de los metabolitos en base a sus propiedades 
químicas. Con respecto al análisis, se consiguió gracias a la combinación 
de cromatografía en fase reversa e HILIC, lo que permite la separación y 
detección de las diferentes clases de metabolitos en condiciones 
óptimas, maximizando la cobertura y minimizando las interferencias. 
La aplicación de las herramientas previamente desarrolladas a células 
HepG2 previamente tratadas con hepatotoxinas modelo que actúan a 
través de diferentes mecanismos de hepatotoxicidad nos permitió la 
identificación de patrones metabonómicos específicos asociados a cada 
uno de los mecanismos de interés. Además, los metabolitos y rutas 
metabólicas alteradas fueron coherentes con los mecanismos de 
hepatotoxicidad previamente descritos en humanos. En base a los 
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resultados obtenidos, experimentos adicionales fueron llevados a cabo 
para lograr una mejor caracterización de las alteraciones provocadas a 
consecuencia de daños por estrés oxidativo o desórdenes relacionados 
con lípidos como son la esteatosis y la fosfolipidosis. 
La utilidad de la estrategia analítica fue confirmada mediante su 
aplicación a estudios in vivo con medaka (Oryzias latipes) y rata como 
modelos animales. Los resultados in vivo mostraron una gran 
concordancia con los obtenidos in vitro usando HepG2 como modelo. 
Además, el uso de rata como modelo animal nos permitió identificar 
marcadores comunes de hepatotoxicidad en sangre que podrían ser 
usados como marcadores en estudios preclínicos o incluso extrapolados 
a humanos.  
En base al trabajo presentado en esta tesis, las siguientes conclusiones 
pueden ser extraídas: 
 
1. El uso de patrones internos y muestras de control de calidad en 
conjunción con un cuidadoso diseño del análisis de las muestras 
supone un marco adecuado de control de calidad para la 
monitorización del funcionamiento de la plataforma analítica antes, 
durante y después del análisis de las muestras. 
2. El uso combinado de técnicas de análisis uni- y multivariante 
representa una estrategia adecuada de análisis de datos para la 
identificación de alteraciones metabolómicas y el desarrollo de 
modelos clasificatorios/predictivos. 
3. El uso de un protocolo de extracción y análisis del metabonoma 
adaptado a las propiedades químicas de las clases de metabolitos 
permite expandir la cobertura del endometaboloma en células 
HepG2. 
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4. La aplicación de la metabonómica al estudio del daño hepático 
inducido por fármacos en HepG2 representa una herramienta 
adecuada para la detección de alteraciones pre-letales asociadas a 
hepatotoxicidad y por tanto puede ser implementada como una 
herramienta sensible en ensayos preclínicos. 
4.1 Los estudios metabolómicos revelaron marcadores asociados 
con hepatotoxicidad genérica y asociada a mecanismos 
específicos de hepatotoxicidad en células HepG2 que además 
eran coherentes con las alteraciones in vivo previamente 
descritas. 
4.2 Se desarrollaron modelos predictivos dirigidos a la 
discriminación entre compuestos no tóxicos y compuestos 
hepatotoxicos y entre compuestos no tóxicos y compuestos 
que actúan a través de mecanismos de hepatotoxicidad 
específicos: estrés oxidativo, esteatosis y fosfolipidosis. 
5. La combinación de una aproximación lipidómica en conjunción con 
HepG2 precargardas con ácidos grasos representa una estrategia 
adecuada para el rápido desarrollo de esteatosis y fosfolipidosis 
inducidos por fármacos, la detección de marcadores lipídicos 
asociados a dichos mecanismos y el desarrollo de modelos 
clasificatorios/predictivos. 
6. El daño oxidativo fue revelado como un evento común asociado a 
hepatotoxicidad, el desarrollo de un análisis dirigido permitió la 
cuantificación de diferentes marcadores de estrés oxidativo en 
células HepG2. 
7. Las alteraciones metabolómicas detectadas en medaka (Oryzias 
latipes) fueron coherentes con las observadas en HepG2 lo que 
sugiere que medaka representa una alternativa válida como modelo 
in vivo de alto rendimiento para la predicción de hepatotoxicidad. 
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8. Experimentos en rata revelaron que las sales biliares y los -glutamil 
dipeptidos son marcadores séricos comunes asociados a 
hepatotoxicidad y pueden ser buenos candidatos a biomarcadores 
de daño hepático inducido por fármacos en ensayos tanto pre-
clínicos como clínicos. 
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